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Chapter 1 General introduction
An increasing number o f individuals are suffering 
from autoimmune diseases, especially in Western 
countries. Since most disorders eventually affect 
everyday tasks, it is o f great interest to elucidate 
the etiology and develop adequate therapy for the 
different autoimmune diseases. Intensive research 
in the last decades revealed that both genetic 
and environmental factors are involved in the 
development o f autoimmunity. Most autoimmune 
diseases are characterized by the presence of 
autoantibodies directed against a variety of ‘self'- 
molecules, so-called autoantigens, in patients' 
sera. Some o f the autoantibodies, which frequently 
are produced already early in the disease, are 
specifically associated with a particular autoimmune 
disease and therefore can be applied as a diagnostic 
biomarker. Also for myositis, a rare autoimmune 
disease in which skeletal muscle tissue is chronically 
inflamed, a number of biomarkers that are helpful in 
diagnosis and prognosis have been described. The 
first two chapters of this thesis summarize our current 
knowledge on the processes that are associated with 
the development of myositis and provide an overview 
o f autoantibody-autoantigen systems associated with 
this disease and autoantibody detection techniques.
Myositis / Idiopathic inflammatory 
myopathies (IIM)
Autoimmune diseases are characterized by the inability 
o f an individual's immune system to discriminate 
between ‘self' and ‘non-self' molecules. This may 
lead to an attack on self tissues or cells. To date 
many autoimmune disorders have been described 
with known or unknown etiology. Connective tissue 
diseases such as systemic sclerosis (SSc), systemic 
lupus erythematosus (SLE), Sjogren's syndrome 
(SjS), mixed connective tissue disease (MCTD), and 
myositis (idiopathic inflammatory myopathies or IIM) 
have no known cause, but they all are characterized 
by the presence of autoantibodies.
Myositis is characterized by progressive skeletal 
muscle weakness, elevated serum levels o f muscle 
enzymes (e.g. creatine kinase, aldolase, lactate 
dehydrogenase) and distinct inflammatory features. 
Further clinical, immunological and pathohistological 
characteristics are used to distinguish between the 
different myositis subtypes which are polymyositis 
(PM), dermatomyositis (DM) and inclusion-body 
myositis (IBM) [1-3]. Depending on the study, 
incidence numbers o f myositis patients vary from 1.0 
to 6.3 per 100,000 persons [4]. The development of 
DM and PM can start in childhood and between 30 
and 50 years, whereas IBM most frequently occurs
in individuals of over 50 years. IBM occurs more 
often in elderly males (3:1), whereas DM and PM 
are more commonly found in females compared to 
males (2:1). Diagnostic factors in PM patients are 
characterized by a subacute onset of symmetrical 
proximal muscle weakness accompanied by CD8+
T cells and macrophages that invade muscle fibers 
which express high levels o f MHC class I molecules
[5]. IBM patients develop slow and progressively 
distinct asymmetric proximal muscle weakness 
together with the infiltration o f MHC class I expressing 
muscle fibers by CD8+ T cells, similarly as seen in PM
[6]. Moreover, in IBM myodegenerative processes 
are detected that are associated with vacuolisation 
o f muscle fibers and accumulation o f proteins, like 
amyloid-related proteins, p-amyloid precursor protein 
(APP), phosphorylated tau, and proteins involved 
in oxidative stress [7]. Individuals with DM contain 
different immunological factors, such as CD4+ T 
cells, B cells and dendritic cells (DCs) in perivascular 
muscle infiltrates. Additionally, characteristic skin 
manifestations, such as Gottron's papules (60 -  80% 
o f patients), heliotropic rash (50% of patients), ‘shawl' 
sign and so-called ‘mechanic hands' can also be 
detected in DM patients [8,9]. However, increasing 
knowledge about myositis heterogeneity may lead 
to a further subclassification of this disease, such 
as cancer-associated myositis, clinical amyopathic 
myositis, myositis overlap, necrotizing myositis, and 
childhood myositis. 3
Etiology of myositis
The current ideas on the development of autoimmune 
diseases emphasize a multifactorial background in 
the breaking o f immunological tolerance. Several 
environmental factors, like smoking [10] and UV-light 
[11], as well as genetic factors [12] were shown to be 
involved in disease onset or progression. Additionally, 
in up to 80% of myositis patients so-called myositis- 
associated autoantibodies (MAA) or myositis-specific 
autoantibodies (MSA) directed to a variety of cellular 
components can be found [13,14]. MAA, such as anti- 
Ro52, anti-Ku and polymyositis-scleroderma overlap 
autoantibody (anti-PM/Scl) are not specific for 
myositis and also found in other rheumatic disorders.
The MSA are highly specific for myositis and include 
anti-aminoacyl-tRNA synthetases (e.g. Jo-1, PL-7), 
anti-Mi-2 and anti-signal recognition particle (anti- 
SRP) antibodies (reviewed by [15]). Insight into 
the autoantibody repertoire o f myositis patients is 
important to predict progression and outcome of the 
disease.
Muscle fiber necrosis in IIM is associated with
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Inclusion-body myositis
\
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Fig . 1 Factors involved in the  deve lopm ent of myositis.
C lin ica l m anifesta tions o f skeleta l m uscle, skin , and lung tissue  are often found in individuals suffering from  m yositis. The deve lopm ent o f this 
d isease is believed to  result from  im m une- or non-im m une-m ediated m echanism s and lead to  skeleta l m uscle damage. A bbrevia tions: ER , 
endoplasm ic reticulum ; UPR, unfolded protein response; N F-kB, nuclear factor-KB; MHC, major h istocom patib ility  complex. Adapted from  [17]
mononuclear inflammatory cell infiltrates in skeletal 
muscle tissue. However, these inflammatory 
processes do not always correlate with the severity of 
disease. The mononuclear infiltrates mainly consist of 
B cells and T cells, although also macrophages, DCs 
and natural killer cells are found in inflamed muscle 
tissue [16]. Together with a diverse expression profile 
o f cytokines and chemokines, a complex inflammatory 
milieu is commonly found in affected tissues of 
myositis patients. The inflammatory environment can 
stimulate cell death to occur locally. Indeed, loci of 
extensive necrotic cell death have been detected 
in myositis patients and CD8+ T cells are found to 
surround non-necrotic muscle fibers (reviewed by [5]). 
Cell death has been associated with autoimmunity for 
many years. During cell death many (bio)chemical 
processes occur that post-translationally modify 
endogenous proteins. The protein modifications 
might be involved in breaking immunological 
tolerance and/or promote inflammation. Furthermore, 
many environmental factors (e.g. viruses, UV-light, 
smoking) as well as secreted molecules (e.g. perforin,
granzyme B, nitric oxide (NO^)) have been described 
to stimulate cell death. In addition to the immune 
mediated responses mentioned above, evidence 
accumulates that also non-immune processes play 
a role in the pathogenesis of myositis. An excellent 
review by Henriques-Pons and Nagaraju discusses 
the endoplasmic reticulum (ER) stress response, 
nuclear factor-KB (NF-kB) signaling and autophagy 
as possible non-immune pathways by which muscle 
damage or autoimmunity might develop in myositis 
patients [17]. In addition, NF-kB is thought to connect 
both immunological and non-immunological pathways 
to muscle damage. How the combination o f structural, 
immunological and environmental alterations relates 
to pathological processes involved in IIM remains, 
however, elusive (Fig. 1).
Cell death and autoimmunity
Cell death may occur as a response to physiological 
or pathological triggers encountered by a tissue or a 
cell. The criteria o f the different types of cell death
4
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Fig . 2  S chem atic representation o f apoptotic and necrotic cell death.
Apoptosis: A fter the  induction o f apoptosis cells sh rink and chrom atin condenses, followed by contro lled degradation o f cell organelles and 
relocalization. Small am ounts o f ce llu lar content, confined by a membrane, are  released from  the  apoptotic cell (“budding”). The cells d isintegrate 
to  apoptotic bodies, which normally are cleared by neighbouring phagocytic cells w ithou t inducing in flam m atory processes. Necrosis: Ce lls take in 
extrace llu lar flu id and swell, which results in the  loss of m em brane integrity, leakage of ce llu lar content and blebbing. Finally, ce llu lar and nuclear 
lysis occurs. In addition, the release o f its ce llu lar content m ay trigger inflam mation. Adapted from  [75].
are often defined by morphological changes and 
the involvement o f specific enzyme systems such 
as proteases and nucleases. There are two major 
mechanisms o f cell death: apoptosis and necrosis. 
These two forms and their potential relationship with 
myositis will be introduced below (Fig. 2).
Apoptosis and myositis
Apoptosis, also called programmed cell death (PCD), 
is a well studied phenomenon and associated with 
many physiological processes, such as embryonic 
development, immune system regulation (induction of 
tolerance) and anti-cancer mechanisms [18-20]. This 
ATP-dependent mechanism of cell death results in 
the controlled degradation o f the cellular organization, 
which is a prerequisite for the appropriate clearance 
o f the dying cell by surrounding cells and phagocytes. 
Apoptosis is an energy-consuming process that leads 
to the well-defined compartmentalization of cellular 
structures found during the dying process. Cell 
shrinkage, loss of membrane asymmetry, chromatin 
condensation, DNA fragmentation, and membrane 
blebbing are distinct changes that occur when cells 
undergo apoptosis. The apoptotic blebs/bodies 
contain many cellular proteins that might stimulate 
the autoreactive T cells and/or B cells when they 
are released from these vesicles. However, these
confined structures are normally cleared efficiently by 
neighbouring phagocytic cells.
Two main apoptotic pathways, the extrinsic and 5  
intrinsic pathways, regulate the induction of PCD, 
both with slightly different activation modes. The FasL 
and TNF-a related apoptosis-inducing ligand (TRAIL) 
stimulate cell surface receptors of the TNF receptor 
(TNFR) family, like TNFR, Fas and TRAIL-R, which 
initiates the extrinsic pathway. Activation of these 
receptors can result in various cellular responses, 
such as proliferation, differentiation and cell death.
The formation o f a death-inducing signaling complex 
(DISC) induces apoptosis by the recruitment and 
activation o f initiator caspase-8 and caspase-10, 
which further downstream activate executioner 
caspases that are also involved in the intrinsic 
pathway [21].
DNA damage and cytotoxic insults activate the 
intrinsic pathway by antagonizing the anti-apoptotic 
Bcl-2 family members (e.g. Bcl-2, Bcl-Xl, and 
Bcl-w) that maintain mitochondrial integrity [22]. As 
a result, the pro-apoptotic Bcl-2-like proteins (e.g.
Bax, Bak, Bad, and Bim) release cytochrome c 
from the mitochondria. Cytochrome c is needed for 
the formation of the apoptosome that activates the 
initiator caspase-9. Finally, caspase-9 will cleave pro- 
caspases-3, -6, and -7, which are responsible for the
Table 1. Reactive oxygen and reactive nitrogen species
Reactive oxygen species (ROS) Reactive nitrogen species (RNS)
Superoxide anion (O.;-) 
Hydroxyl radical (OH^) 
Peroxyl radical (ROO^) 
Hydrogen peroxide (H2O2) 
Hypochlorous acid (HOCl)
Nitric oxide (NO^)
Nitric dioxide (NO./) 
Peroxynitrite (ONOO-) 
Peroxynitrous acid (ONOOH) 
Alkylperoxynitrite (ROONO)
substrate cleavage typical for apoptotic cell death 
[23,24]. Post-translational modifications, such as the 
cleavage of proteins, are essential for the induction of 
apoptosis, but may also be involved in the initiation of 
pathological events, such as autoimmunity.
Both pro-apoptotic and anti-apoptotic Bcl-2 proteins 
appear to be associated with the development of 
or protection against rheumatoid arthritis (RA). 
Anti-apoptotic Mcl-1 expression was increased 
in RA synovial macrophages and fibroblasts and 
correlated with the degree o f inflammation [25,26]. 
The increased Mcl-1 levels reduced apoptotic cell 
death in the synovium, which suggests that it is 
a critical molecule for cell survival and a potential 
therapeutic target in RA. In addition, Bim and Bid, 
potent initiators o f apoptosis in multiple cell types, 
have been shown to be involved in joint cellularity 
and local inflammation o f RA patients by maintaining 
apoptotic homeostasis [27]. Altered levels of these 
6  pro-apoptotic and anti-apoptotic molecules are also 
found in other autoimmune disorders, like myositis. 
The high incidence of cytotoxic T lymphocytes (CTLs), 
which are capable of inducing apoptosis, suggest 
an important role for PCD in myositis. In addition, 
Sugiura and colleagues describe fiber apoptosis as a 
result o f the binding of mononuclear cells, expressing 
FasL, to Fas-containing muscle fibers [28]. However, 
several other groups were unable to confirm these 
findings [29-32]. These contradictory results might 
be explained by the upregulated expression o f anti- 
apoptotic proteins that counteract these pro-apoptotic 
signals. Recently, Kondo et al. emphasized the pro- 
inflammatory cytokine microenvironment to promote 
muscle fiber apoptosis after Fas/FasL interaction
[33]. Indeed, many cytokines and chemokines are 
found to be upregulated in IIM patients (reviewed 
by [16]). One candidate might be the DNA-binding 
protein high mobility group box protein 1 (HMGB1), 
which under physiological conditions is involved in 
transcription, but also can act as a pro-inflammatory 
molecule when released during cell death. HMGB1 
is actively released from macrophages/monocytes in 
PM/DM patients and induces the expression o f TNF-a 
and IL-1, which are both pro-inflammatory cytokines
[34]. Moreover, HMGB1 has been shown to induce 
the expression of MHC class I molecules in murine 
muscle fibers and was suggested to be involved in 
muscle dysfunction during the first stages of IIM [35]. 
In addition, recently elevated numbers of so-called 
micro-particles, which are involved in intercellular 
communication, were found in autoimmune disorders 
such as PM/DM [36,37]. However, the actual role of 
these particles, whether it is induction, amplification 
or counteracting the autoimmune response, is not 
clear yet.
Besides immunological triggers, environmental 
factors are also known to play an important role in the 
development of autoimmunity. Rosen et al. reported 
that UV-B irradiated keratinocytes develop apoptotic 
manifestions leading to distinct subcellular localization 
o f several autoantigenic proteins, including Jo-1, 
Mi-2, Ro52, and Ku [38]. Cytoplasmic or nuclear 
antigens eventually can be found in apoptotic blebs 
or bodies of the dying cell. UV-B exposure is known to 
increase the formation o f intracellular reactive oxygen 
species (ROS), which are able to oxidatively damage 
a (selective) number of biomolecules and can result 
in the loss o f cell function and/or death [39,40]. 
Moreover, D'Emilio and colleagues demonstrated the 
occurrence of apoptotic changes in UV-B irradiated 
cultured myoblasts and myotubes due to elevated 
ROS levels [41]. The overproduction of ROS in 
skeletal muscle cells might correlate with immune 
responses against muscle fibers found in myositis. 
How ROS and derivates might be implicated in the 
development o f myositis will be discussed later. In 
addition, smoking has been suggested to stimulate 
apoptosis in inflammatory rheumatic disorders [10]. It 
should, however, be noted that indisputable evidence 
for the association of apoptotic muscle fibers with the 
development o f myositis has not been produced yet. 
Andrade and colleagues detected a caspase- 
independent ability of granzyme B (GrB) to cleave 
several downstream death substrates [42]. Further 
studies expanded the number o f GrB substrates 
and revealed unique fragments from autoantigenic 
proteins that are not found in other forms o f cell death
[43]. A putative substrate for GrB is the histidyl-tRNA
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synthetase (HisRS), also designated Jo-1 protein, 
which is the major autoantigen in PM/DM patients
[44]. The resulting N-terminal part o f Jo-1, but also 
full-length Jo-1, stimulated primary CD4+ T cells, or 
CD8+ lymphocytes, as well as immature dendritic 
cells, which may perpetuate the development of 
myositis [45,46].
Necrosis and myositis
Necrotic cell death was considered an uncontrolled 
form of cell death for years. This might be true after 
severe physical damage, but increasing evidence 
supports the existence o f a regulated caspase- 
independent pathway as well [47]. Furthermore, the 
release o f intracellular proteins to the extracellular 
environment was thought to elicit pro-inflammatory 
stimuli that could attract destructive inflammatory cells 
to the site o f tissue damage or activate local antigen- 
presenting cells. However, it is clear that these cells 
are not only involved in tissue destruction but also 
are needed to battle potential infections, to remove 
cellular debris and/or to participate in the regeneration 
o f damaged tissue. Infiltrating macrophages appear 
to be involved in the activation of satellite cells that 
are needed to regenerate injured muscle tissue 
[48-51]. Necrosis-induced morphological changes 
are distinct from the structures found in apoptotic 
cells and include cell and organelle swelling, with 
subsequent loss o f cell membrane integrity and 
release of the cellular content into the surrounding 
extracellular environment. Several proteins/enzymes 
under distinct conditions have been shown to play 
a role in the initiation o f necrosis, such as TNFR1, 
RIP1, TRADD and TLRs [21]. These molecules work 
on downstream factors such as ceramide, reactive 
oxygen species (ROS), phospholipases, and calpains 
that may lead to necrotic cell death. However, a lot of 
mechanisms and players in this process remain as 
yet unknown.
There is only little experimental evidence concerning 
the contribution o f necrosis to the development of 
autoimmune disorders. However, necrotic loci and 
the infiltration o f immune cells into non-necrotic 
sites are important parameters for the diagnosis of 
myositis. Autoaggressive CD8+-cytotoxic T cells are 
found to invade MHC class I expressing muscle fibers 
in PM and IBM patients. These T cells are thought 
to release perforin granules, which result in muscle 
fiber necrosis rather than apoptosis, possibly by the 
overexpression o f anti-apoptotic molecules described 
in the previous section. Complement deposits induce 
capillary necrosis, perivascular inflammation, and 
muscle fiber destruction in DM patients (reviewed 
by [5]). The tissue damage, as a consequence of
necrosis, results in the development o f muscle atrophy 
and to a decreased number o f blood vessels leading 
to tissue ischemia in myositis patients. Whether these 
clinical manifestations are cause or consequence of 
the disease has yet to be established.
Oxidative stress and autoimmunity
Reactive oxygen species are chemically-reactive 
molecules containing oxygen, such as oxygen 
ions and peroxides. ROS can be generated in 
the mitochondria as a by-product o f the electron 
transport chain, which is mediated by complexes 
that are involved in the cellular energy metabolism, 
generating energy-rich molecules such as ATP,
NADH, and FADH2. ROS can also be generated by 
NADPH oxidase, a plasmamembrane-bound enzyme 
complex that catalyzes the electron transfer across the 
membrane from NADPH to O2 within the extracellular 
space or within specialized compartments (e.g. 
phagosomes). This mainly results in the production 
o f superoxide anion (O ^-) and hydrogen peroxide 
(H2O2). Both molecules are implicated in physiological 
responses, such as defense mechanisms against 
pathogens (e.g. respiratory burst by macrophages) 
or cell signaling (reviewed by [52]). In addition, 
several other enzymes in many different cell types 
are able to produce ROS, including xanthine oxidase, 
cyclo-oxygenases, myeloperoxidases, as well as 
cytochrome P450-based enzymes. The free radicals 7  
produced by these enzymes are O ^- , hydroxyl 
radicals (OH^) and peroxyl radicals (ROO^), whereas 
non-free radicals include H2O2 and hypochlorous acid 
(HOCl). Besides ROS also several intermediates 
o f reactive nitrogen species (RNS) are generated 
and contribute to physiological functions, such as 
vasorelaxation and neurotransmission [53]. These 
intermediates are derived from nitric oxide (NO^) 
that is synthesized during the conversion o f free 
L-arginine to L-citrulline by nitric oxide synthetases 
(NOS) [54]. The RNS comprise free radical nitric 
dioxide (NO./), NO^ and various non-free radicals 
such as peroxynitrite (ONOO-) and protonated 
forms including peroxynitrous acid (ONOOH), and 
alkylperoxynitrite (ROONO) (Table 1).
The radicals most often found participating in 
physiological processes are O ^- , H2O2 and NOv In 
order to maintain the cellular redox balance and to 
prevent cell damage, various anti-oxidant systems, 
such as glutathione (GSH), vitamins and enzymes 
(e.g. catalase, peroxidases, and superoxide 
dismutases), continuously remove or neutralize 
ROS/RNS [55]. The low physiological concentrations 
o f free radicals are sufficient to exert their function.
However, next to cellular processes also xenobiotics, 
drugs, cytokines and environmental factors (such 
as UV-light, and smoking) can increase ROS/RNS 
production. Under pathophysiological conditions 
ROS/RNS production might exceed the endogenous 
detoxification and/or utilization capacity which may 
result in oxidative or nitrosative stress depending on 
its chemical composition or environment.
This suggests a dual role for ROS/RNS: 1) 
physiological (protective) functions that are 
summarized above, and 2) harmful (destructive) 
effects resulting from oxidative or nitrosative stress 
[56]. The stress responses describe conditions in 
which radicals mediate negative effects in vivo. Both 
ROS and RNS are able to modify biomolecules 
such as DNA, proteins, lipids and carbohydrates 
when produced at non-physiological levels and 
such modifications may lead to loss o f cell function 
and apoptotic or necrotic cell death [57-60]. Certain 
radical-induced modifications are associated with 
specific radical -  biomolecule interactions and are 
highly dependent on the differences in ROS/RNS 
half-life, reactivity, and chemical composition. The 
destructive nature o f ROS/RNS has been emphasized 
to play a role in the aging process, in carcinogenesis 
and in several pathologies including cardiovascular 
disorders, neurodegenerative disorders, RA, and 
SLE [61-63].
The main target tissue of the immune system in 
8  myositis, the skeletal muscle fibers, is o f particular 
interest with respect to oxidative and nitrosative 
stress effects because of its continuous exposure to 
ROS/RNS. Skeletal muscle fibers consume relatively 
high amounts of ATP to perform their function 
and therefore are depending on a well performing 
oxidative metabolism and anaerobic metabolism. 
During in vitro exercise studies, skeletal muscles 
show increased levels of free oxygen radicals 
that contribute to oxidative stress and stimulate 
peroxynitrite formation with NO^ [64,65]. Studies with 
cultured skeletal myoblasts and T-cells also led to the 
detection o f cell death upon treatment with low doses 
o f H2O2 [66,67]. Abnormal cytochrome c oxidase 
activities are emphasized to result in mitochondrial 
abnormalities, muscle weakness and wasting that are 
found in muscle fibers of DM and IBM patients [68,69]. 
Moreover, studies o f de Paepe et al. showed elevated 
expression levels o f inducible NOS in PM and IBM 
patients in comparison with healthy controls [70]. In 
addition, markers of NO^ production were shown to 
be elevated in IIM patients compared to controls, 
which suggests increased NOS activity in these 
patients [71]. Recently, He and colleagues reported 
the activation of the ER stress response upon the
accumulation o f ROS in the ER of retinal pigment 
epithelial cells [72]. A similar process might be 
responsible for the activation of ER stress response 
and increased chaperone expression in myositis 
patients [73,74]. Taken together, the results of all of 
these studies are consistent with a role of ROS/RNS 
in the pathophysiology of myositis. However, further 
studies will be required to clarify whether ROS/RNS 
directly contribute to the development of myositis, 
or whether the elevated levels of ROS/RNS are an 
epiphenomenon resulting from the cellular infiltrates 
found in IIM patient muscle tissue.
Outline of this thesis
The studies described in this thesis were initiated to 
obtain more insight into ROS/RNS-induced protein 
modification o f myositis autoantigens and their 
association with the autoimmunological features of 
this disease. As described above, ROS/RNS have 
many physiological and pathological functions and 
are capable of activating cell death mechanisms 
as well as modifying biomolecules such as DNA, 
lipids, carbohydrates, and proteins via (in)direct 
mechanisms. The results of these studies were 
expected to provide clues for the contribution o f ROS/ 
RNS to post-translational modification-mediated loss 
o f immunological tolerance against myositis-specific 
autoantigens.
In Chapter 2 the diagnostic and research 
methodologies that are currently used to identify 
and detect myositis-specific biomarkers, which are 
essential for an adequate diagnosis, prognosis, 
and treatment, are introduced. In addition, the 
established and recently identified myositis-specific 
autoantibodies and their targets are discussed, 
as well as their importance for the classification of 
myositis subtypes and/or pathogenesis.
The modification o f several autoantigenic proteins 
under oxidative stress conditions is presented in 
Chapter 3. The direct and indirect effects and nature 
o f oxidative stress-associated free radicals were 
addressed in cells and recombinant proteins, and 
also the identity of the most relevant ROS species 
are presented using specific generators of ROS. 
Chapter 4 describes novel oxidative stress-induced 
post-translational modifications of the major myositis 
autoantigen Jo-1 (HisRS), which were identified by 
immunoblotting assays and characterized by mass 
spectrometry-based methods. The effects o f the ROS- 
induced post-translational modifications on the tRNA 
aminoacylation activity o f Jo-1 and its recognition 
by anti-Jo-1 antibodies in patient sera are described 
as well. In the studies presented in Chapter 5 the
Chapter 1 General introduction
redox-sensitive dimerization o f the Jo-1 molecule is 
documented. The modifications involved in HisRS 
homodimerization, both in vitro and in living cells, and 
their effects on its enzymatic activity are elucidated 
by mass spectrometry, computational modeling, 
and functional analysis. The studies described in 
Chapter 6 allowed the identification of a distinct Jo-1 
modification that was observed to occur in RNS- 
stressed cells. Under these conditions, endogenous 
Jo-1 as well as the ectopically expressed wild-type 
Jo-1 protein appeared to form covalent dimers, not 
mediated by disulfide bridges. The effects of amino 
acid substitution mutants on dimerization, the 
enzymatic activity and autoantigenicity were studied 
as well.
In Chapter 7 the identification and characterization 
o f the first IBM-specific autoantibody biomarker is 
reported. This was only possible because human 
skeletal muscle extracts were used as a source of 
potential autoantibody targets. The methods used to 
identify these IBM-specific autoantibodies emphasize 
the importance o f the source material used in studies 
aimed at new biomarkers in autoimmunity.
Finally, in Chapter 8 the experimental results of the 
studies described in this thesis are discussed in a 
more general context.
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Abstract
In recent years, the detection and characterization of (novel) autoantibodies is becoming increasingly important 
for the early diagnosis o f autoimmune diseases. The idiopathic inflammatory myopathies (IIM, also indicated 
with myositis) are a group o f systemic autoimmune disorders that involve inflammation and weakness of 
skeletal muscles. One o f the hallmarks is the infiltration of inflammatory cells in muscle tissues. A number of 
myositis-specific autoantibodies have been identified and these may be associated with distinct IIM subclasses 
and clinical symptoms. Here, we review all myositis-specific autoantibodies identified today as well as their 
target proteins, together with their clinical associations in IIM patients. Post-translational modifications that 
might be associated with the generation o f autoantibodies and the development o f the disease are discussed 
as well. In addition, we describe well established autoantibody detection techniques that are currently 
being used in diagnostic laboratories, as well as novel multiplexed methods. The latter techniques provide 
great opportunities for the simultaneous detection of distinct autoantibodies, but may also contribute to the 
identification o f novel autoantibody profiles, which may have additional diagnostic and prognostic value. The 
ongoing characterization of novel autoantibody specificities emphasizes the complexity of processes involved 
in the development of such autoimmune diseases.
C hapter 2 MSA: Detection and Clinical Association
Autoantibodies in idiopathic 
inflammatory myopathies
Autoantibodies directed against a variety of 
autoantigens are strongly associated with systemic 
autoimmune diseases. Within the heterogeneous 
group of connective tissue diseases (CTD) a wide 
range of nuclear and cytoplasmic autoantigenic 
targets have been described. However, it is still 
unclear why autoantibodies directed against these 
autoantigens are formed and whether they participate 
in pathological processes during disease development 
and/or progression. Post-translational modifications 
(PTMs) have been hypothesized to generate novel 
epitopes in antigenic proteins. The cross-presentation 
o f these post-translationally modified epitopes might 
break immunological tolerance and initiate the 
development of an autoimmune response resulting in 
autoantibody formation.
The idiopathic inflammatory myopathies (IIM) are a 
group of disorders characterized by inflammation and 
weakness mainly of the muscles closest to the trunk 
of the body (proximal muscles). These disorders 
include polymyositis (PM), dermatomyositis (DM) and 
inclusion body myositis (IBM). IIM may be associated 
with inflammation in other organs, including the 
joints, heart, lungs, intestines and skin. In IIM, like 
in other systemic autoimmune diseases, distinct 
clinical phenotypes can be correlated with specific 
autoantibody targets in patients, which emphasizes 
the clinical relevance o f these biomarkers [1]. 
Autoantibodies found in IIM patients can be divided 
into myositis-associated autoantibodies (MAA), 
which are not specific for the disease and are also 
found in other rheumatic disorders, and myositis- 
specific autoantibodies (MSA) which are found 
primarily in patients with IIM. Tables 1 and 2 show 
a comprehensive overview o f the autoantigens 
recognized by MSA and MAA together with their 
function. In this review we will describe the most 
prevalent MSA in more detail, their detection and the 
clinical manifestations associated with them.
Autoantibody detection assays
The development o f less invasive and more advanced 
imaging tools in order to discriminate between 
the clinical characteristics o f various inflammatory 
myopathy subtypes, contributed greatly to the often 
difficult diagnosis of these diseases. The application 
o f advanced techniques such as magnetic resonance 
imaging (MRI), X-ray computed tomography 
(CT), positron emission tomography (PET), and 
ultrasonography can also increase the sensitivity of
detecting IIM prior to muscle biopsy [2]. In addition, 
several serological markers in IIM which can be 
specific for certain IIM subtypes or be helpful in 
evaluating disease progression have been detected 
in the last decades. These biomarkers mostly are 
autoantibodies directed to one or more cellular 
components. The fact that only a limited number 
of proteins appear to be targets of autoantibodies 
suggests that distinct processes are involved in their 
generation.
A variety o f techniques are available to detect 
the various autoantibodies for research or routine 
diagnostics, all with their distinct sensitivity and 
specificity traits. Conventional methods such as 
indirect immunofluorescence, immunoprecipitation, 
immunodiffusion andcounterimmuno-electrophoresis, 
or immunoassays such as the enzyme-linked 
immunosorbent assay (ELISA) and immunoblotting 
are already in use for many years. In most cases 
these techniques are suitable for the detection of 
a single autoantibody specificity. In contrast, a new 
generation of assays (so-called multiplexed analysis 
techniques) allows the simultaneous detection of 
several autoantibody specificities [3, 4]. The latter 
techniques probably will dominate serological profiling 
in diagnostic laboratories in the future, provided that 
validation and reproducibility are ensured.
Immunofluorescence
Several antinuclear antibodies (ANA) are still being 1 5  
detected by indirect immunofluorescence on HEp-2 
cells or tissue substrates. Some ANA-positive IIM sera 
may show a particular staining pattern that can be 
correlated with a distinct autoantigen. However, this 
technique is laborious and needs specific technical 
skills to perform. It is therefore less convenient for 
present day diagnostic analyses.
Immunoprecipitation, ELISA and immunoblotting  
The most unambiguous way to determine the presence 
o f autoantibodies against a particular autoantigen 
is the detection o f an autoantibody by virtue of its 
binding to the antigen in its fully native state. Although 
the immunoprecipitation (IP) method is the most 
obvious choice, this technique is not widely applied 
because it is laborious, expensive and requires 
specific technical skills. Radiolabeled cell extracts 
are often used as substrates for immunoprecipitation 
assays and subsequent mass-spectrometry analysis 
can characterize the specific targets [5, 6] (Fig.
1). However, the antigen to be detected may be 
associated with other (non-antigenic) proteins and 
as a consequence the IP procedure often leads to 
a complex pattern of precipitated proteins of which
Table 1. Myositis-specific autoantibodies and their functional activities
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Autoantibody Autoantigen Molecular 
Mass (kDa)
Function of autoantigen
Myositis-specific autoantibodies (MSA)
Anti-aaRS
Anti-Jo-1/PL1 HisRS 54 Aminoacylation o f tRNAs
Anti-PL7 ThrRS 80
Anti-PL12 AlaRS 106
Anti-EJ GlyRS 75
Anti-OJ IleRS 150
Anti-KS AsnRS 65
Anti-Ha TyrRS 58
Anti-Zo PheRS 57/66
Anti-tRNA tRNAHis Translation
tRNAAla
Anti-Mi-2 Mi-2a 220 Transcription regulator & nucleosome remodelling
Mi-2ß 218
Anti-SRP SRP54 54 Protein translocation to the ER
SRP68 68
SRP72 72
Anti-p155/140 Tif1-Y 155 Ubiquitination
unknown 140 n.d.
Anti-CADM-140 MDA5 117 Innate immunity (RNA sensor)
Anti-SAE SAE1 38 Sumolytion
SAE2 72
Anti-p140 NXP-2 107 RNA binding & nuclear transcription
not determ ined: n.d.
only one or a few proteins are truly autoantigenic. 
Nevertheless, detection o f autoantigenic biomarkers 
in IIM by immunoprecipitation techniques is still 
w idely used.
The first high-throughput assays such as ELISA 
increased the number of patient sera that could be 
analysed compared to the previously mentioned 
conventional assays. However, purification of the 
antigen and use o f the correct reagents has to be 
monitored to warrant an optimal specificity [7, 8]. 
In addition, at least some conformational epitopes 
might be lost, because the antigen is bound to 
the ELISA plate. Immunoblotting (IB) analysis, in 
addition to ELISA, may increase the specificity of 
the signal detected in the immune assays. However, 
IB may allow the detection of autoantibodies only to 
linear epitopes, because the antigen is completely 
denatured during preparation of the blot. This might 
decrease sensitivity of the IB method as compared 
to IP and ELISA. As a consequence only the ELISA
method is widely used in routine laboratories where 
large numbers o f sera have to be tested.
Multiplex assays
A number of multiplex-based assays have 
been developed during the years, with distinct 
methodological differences. In this review we will 
discuss the high-throughput-based micro-array 
format, described in this paragraph, and a macroscopic 
assay that has been developed for the simultaneous 
detection o f multiple autoantibodies in IIM sera, the 
line-blot, which is described separately in the next 
paragraph. Multiplex assays are able to screen a 
single sample o f blood or other biological fluid for an 
array of autoantibody specificities simultaneously. In 
this way a patient-specific autoantibody profile can be 
made. Future prospects suggest that antigen/patient- 
specific therapies might be developed from these 
patient-specific autoantibody profiles, which might 
prevent disease progression, remission or relapse
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Table 2. Myositis-associated autoantibodies and their functional activities
Autoantibody Autoantigen Molecular 
Mass (kDa)
Function of autoantigen
Myositis-associated autoantibodies (MAA)
Anti-PM/Scl PM/Scl-75 75 RNA processing & degradation
PM/Scl-100 100
Anti-Mas Serine-tRNASec 48 Selenocysteine incorporation
protein complex
Anti-Ro/SS-A
Anti-Ro52 Ro52 52
Anti-SS-A Ro60 60 RNA quality control
Anti-La/SS-B La 48 RNA binding & Pol III transcription
Anti-RNP U1A 34 Pre-mRNA splicing
U1C 22
U1-70k 70
Anti-Wa Peptide 46 unknown
Anti-PMS a.o. PMS1, n.d. DNA binding protein complex involved in DNA
PMS2 repair
Anti-Ku Ku70 70 DNA dependent protein phosphorylation
Ku80 80
Anti-Fer eEF1 Translation
Anti-KJ Peptide 30/34 Translation factor
Anti-56k Nuclear RNP 56 unknown
polym yositis, scleroderm a overlap (PM/Scl), ribonucleoprotein (RNP), postm eiotic segregation (PMS), eukaryotic elongation facto r (eEF1), not
determ ined: n.d. 17
over time. The basic principles of two main types of 
micro-array-based multiplex assays will be discussed 
below.
Solid surface-based autoantigen microarrays 
contain immobilized proteins or other biomolecules 
in predetermined positions on a solid surface. 
Interactions between the immobilized antigens and 
molecules in the serum sample such as (labeled) 
antibodies can be detected by fluorescence- 
based procedures [4, 9]. Such antigen arrays have 
already been used to screen the autoantibody 
profiles in autoimmune diseases, IgE reactivity in 
allergy, and the immune response to infections, 
vaccination, and cancer reviewed by [4]. However, 
this technique is based on commercialized or home­
made microarrays that depend on specific technical 
expertise and equipment (Fig. 2). In order to simplify 
technical aspects as much as possible so-called 
addressable-bead autoantigen microarrays have 
been developed [10, 11]. Individual antigens of 
interest are chemically coupled to beads of different 
colours. Subsequently, sera or other biological fluids 
can be analyzed in a m icrotiter well containing a
bead mixture as described by [3, 12]. One laser will 
measure the colour of the specific antigen-coupled 
bead, whereas a second laser determines the 
presence and quantity o f a fluorochrome-coupled 
secondary antibody bound to the bead (Fig. 3). Both 
autoantigen microarray techniques have advantages 
over the conventional techniques in terms o f reduced 
sample volumes, enhanced sensitivity, automation 
and increased numbers of samples that can be 
tested. The sometimes imperfect specificity and 
reproducibility o f these methods can be obstacles for 
their implementation in routine diagnostics.
Line-blot assay
The line-blot assays, or so-called line immunoassays 
(LIAs), are based on immunoblotting procedures that 
spot purified antigens on protein binding membranes 
without the need of gel electrophoresis (Fig. 4). The 
laborious purification procedure of native antigens is 
being replaced by the more reproducible production 
o f highly purified recombinant antigens or synthetic 
peptides. These developments contribute to the 
increased sensitivity and specificity o f commercially
IPP sera NS Jo-1 PL-12 PL-7 EJ KS OJ Zo SRP Mi-2 SAE p155 p140
n 40
F ig . 1 I m m unoprecip itation assay w ith m yositis-specific  autoantibodies. 
P olypeptides im m unoprecip itated from  35S-m ethion ine-labe lled K562 
cell extracts by antibodies from  patient sera were separated by SDS- 
polyacrylam ide gele lectrophoresis and visualized by autoradiography. 
Sera used fo r im m unoprecip itation included serum from  a healthy 
individual (NS), anti-Jo-1, anti-PL-12, anti-PL-7, anti-EJ, anti-KS, anti- 
OJ, anti-Zo, anti-SRP, anti-M i-2, anti-SAE, anti-p155/140, anti-p140 
(reproduced from  [6], by perm ission o f The British Society for 
Rheumatology).
available line-blots. Several LIAs o f different 
manufacturers have recently been clinically validated 
in multicenter studies, and the results indicate that 
LIAs are becoming a suitable alternative to the more 
costly and complex techniques sometimes used in 
diagnostic laboratories reviewed by [13, 14].
Myositis-specific autoantibodies
Aminoacyl-tRNA synthetases
Function
An efficient and reliable transcription and translation 
of the genetic code is essential for cell survival. Genes 
are transcribed into messenger RNA (mRNA), which 
contains a string of nucleotide triplets, called codons. 
During translation every codon is translated into one 
particular amino acid (aa) with the help o f transfer 
RNAs (tRNAs) (Fig. 5). The mRNA sequence is thus 
converted into a chain of amino acids that makes 
up a functional polypeptide. The tRNAs involved 
are specific for both the amino acid and the mRNA 
codon. The amino acids are coupled to their cognate 
tRNA via an esterification reaction that is catalyzed 
by specific aminoacyl tRNA synthetases (aaRSs) in a 
two-step reaction:
aaRS + aa + ATP <  > ■ aaRS*aa~AMP + PPi 
aaRS*aa~AMP + tR N A ^-> -aa R S  + aa-tRNA + AMP
Most of the twenty canonical amino acids are 
recognized by a single aaRS, with the exception of
F ig . 2 Schem atic representation o f the so lid  su rface-based autoantigen  
array.
A utoantigen ic m olecules are im m obilized at defined positions on a solid 
surface. Binding o f autoantibod ies in patient sera to the  im mobilized 
autoantigens can be detected v ia  fluorescently labelled secondary 
antibodies.
GluRS and ProRS in higher eukaryotes [15, 16]. The 
aminoacylated-tRNA, or so-called charged tRNA, is 
used by the ribosome to incorporate the appropriate 
amino acid into the growing peptide chain.
In addition to the well-known function of aaRSs 
described above, a diverse array of other biological 
functions has been described as well. These include 
amino acid biosynthesis, DNA replication, RNA 
splicing, cell cycle control, and apoptosis (reviewed 
by [17, 18]).
Depending on highly conserved sequence motifs and 
aminoacylation acitivities, the aaRSs can be divided 
into two classes, Class I and Class II, and three sub­
classes a, b, and c (Fig. 6). The catalytic domain of 
Class I aaRSs consists of a typical Rossmann fold 
(nucleotide binding domain) and two highly conserved 
sequence motifs whereas the Class II aaRSs are 
characterized by an anti-parallel U-strand surrounded 
by a-helices, and three conserved sequence motifs 
[19]. Additionally, Class I aaRSs mainly exist as 
monomeric or dimeric complexes and aminoacylate 
the 2'-hydroxyl group of the terminal ribose o f tRNA. 
Class II aaRSs usually are dimeric or tetrameric 
structures and aminoacylate the 3'-hydroxyl group of 
the terminal ribose. The only exception is the PheRS 
that belongs to the Class II aaRSs but nevertheless 
aminoacylates the 2'-OH of the ribose. Higher 
eukaryotic cells have been shown to contain a high 
molecular mass multi-synthetase complex (MSC), 
which contains nine aaRSs and three accessory 
proteins (Fig. 6). The MSC is thought to promote 
protein synthesis, proofreading activity, and serve as 
a reservoir o f regulatory molecules that are involved 
in functions other than aminoacylation [20, 21].
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laser 1
laser 2
antigen 
autoantibody 
labeled antibody
detector 1
Fig. 3 Schem atic representation o f a addressab le -bead  autoantigen  
immunoassay.
Purified autoantigens are coupled to d iffe rentia lly  labelled m icrobeads 
that can be  detected  by  illum ination w ith a laser. P atien t sera can 
be incubated w ith m ixtures o f beads each coated w ith a d iffe rent 
autoantigen. One laser is used to  identify the specific antigen coupled 
to each bead based upon the fluorescent properties o f the bead, and 
a second laser is used to determ ine the b ind ing  o f autoantibod ies to 
the beads a fte r incubation w ith secondary antibod ies conjugated to a 
d istinct fluorophore.
Potentially disease-related PTMs 
Three aaRSs (HisRS, AlaRS, and IleRS) have been 
described as substrates for the serine protease 
Granzyme B (GrB), which is present in granules 
of cytotoxic T-lymphocytes (CTLs) or natural 
killer (NK) cells and plays an important role in 
granule exocytosis-induced cytotoxicity [22, 23]. 
The exposure to GrB leads to unique fragments of 
autoantigens, which are not detected during other 
forms of cell death [24]. Indeed, almost all IIM 
autoantigens (except SSA/Ro52) can be cleaved 
by GrB, in contrast to non-autoantigenic proteins, 
which are either not cleaved or cleaved at sites also 
used by caspases [24]. The fragments generated by 
GrB, which are believed to contain new and unique 
epitopes, may help in breaking tolerance against 
the autoantigens when they are encountered by 
the immune system. The cleavage products as well 
as the full length autoantigenic HisRS and AsnRS 
have been described to exert chemotactic properties 
through their interaction with the chemokine receptors 
CCR3 or CCR5, in contrast to the non-autoantigenic 
AspRS and LysRS [25, 26]. Levine and colleagues 
found a proteolytically sensitive HisRS conformation 
in normal lungs compared to muscle tissue and 
proposed the lung as a target site where initiation 
and propagation against HisRS may take place [27]. 
However, the GrB-induced aaRS fragmentation and 
the subsequent dendritic cell-driven autoreactive 
CD4+ T cell activation have not been demonstrated 
in IIM patients yet.
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F ig . 4 L ine-b lo t fo r autoantibody detection in IIM sera.
S trips (vertical) containing a series o f recom binant IIM-related 
autoantigens were  incubated w ith seven IIM patient sera (1-7) and a 
contro l serum  (8). A ntibody binding w as visualized using the  protocol 
provided by the  manufacturer. The strips were incubated w ith sera 
conta ining the fo llow ing autoantibod ies (1) anti-PL12, (2) anti-EJ, (3) 
anti-PL7, (4) anti-SRP and anti-M i-2, (5) anti-Jo-1, (6) anti-PM -Scl75 
and anti-PM -Scl100, (7) anti-Ku.
An additional cleavage product o f HisRS has been 
described by Ramirez-Sandoval and colleagues 
upon the induction of apoptosis in HEp-2 cells 
by camptothecin [28]. Also TyrRS, and its close 
homologue TrpRS, are both described to stimulate 
chemotactic activities as well as angiogenesis in vitro 
upon cleavage [29, 30]. The exposure to reactive 
oxygen and/or nitrogen species (ROS/RNS) may also 
lead to post-translationally modified biomolecules 
and result in the loss o f immunological tolerance.
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Fig . 5 Am inoacyla tion of tR N A  by h istidyl-tRNA synthetase.
The HisRS, as well as other aaRSs, cata lyze the  A TP-dependent esterif ¡cation reaction tha t is needed to  couple  an am ino acid to  its cognate tRNA. 
Subsequently, the  am inoacyla ted-tRNA can be used in translation. A M P : adenosine m onophosphate, ATP: adenosine triphosphate, PPi: inorganic 
phosphate.
Interestingly, increased levels o f ROS/RNS have been 
reported to be present in inflammatory autoimmune 
diseases [31, 32]. We have observed selective 
oxidative modifications in HisRS, but the significance 
o f these for IIM remains to be established (Van 
Dooren et al., manuscript submitted for publication).
Antibodies to aaRSs and their clinical associations 
Autoantibodies directed to aminoacyl-tRNA 
synthetases are the most commonly detected MSA 
in adult IIM patients. They can be found in about 40% 
o f individuals with IIM and in lower frequencies in 
juvenile IIM patients [33]. In addition, autoantibodies 
against the cognate tRNAs have been found [34, 35]. 
Most anti-aminoacyl-tRNA synthetase antibodies 
(anti-aaRS) are directed against the Class II aaRSs, 
including PL1/Jo-1 (HisRS), PL7 (ThrRS), PL12 
(AlaRS), EJ (GlyRS), KS (AsnRS), and Zo (PheRS). 
Only two Class I aaRS autoantibody targets, namely 
OJ (IleRS) and Ha (TyrRS) have been described so 
far [6]. Most IIM patients with anti-aaRS produce 
autoantibodies against a single aaRS, although 
in rare cases antibodies may occur directed to two 
aaRSs [36].
The anti-Jo-1 (or anti-HisRS) is the most frequently 
occurring autoantibody in PM/DM patients, its 
presence nearly excludes one of the three IIM, being 
inclusion-body myositis [37-39]. Different clinical 
and immunological features are associated with the 
presence o f anti-Jo-1 antibodies, but whether the 
autoantibodies are a cause or a consequence of 
the development o f the disease remains unknown, 
despite the fact that a correlation between the titer 
o f anti-Jo-1 antibody and disease activity has been 
observed [40].
The major epitope of the Jo-1 molecule has been
defined as a coiled-coil structure within the protein 
[41], although antibodies directed to other parts o f the 
Jo-1 protein can be detected as well [42, 43]. Class 
switching, affinity maturation, species-specificity, and 
spectrotype broadening during the Jo-1 antibody 
response have been detected, which suggests a T 
cell-dependent and antigen-driven response in IIM 
patients [41, 43-45]. These processes also suggest 
that epitope spreading during the course o f the 
disease may occur. Most studies that investigate the 
autoepitopes on the Jo-1 protein report activities that 
recognize multiple, both linear and conformation- 
dependent Jo-1 epitopes.
Myositis-specific autoantibody profiles are often 
associated with distinct clinical features [46]. Indeed, 
anti-aaRS antibodies are associated with a unique 
clinical syndrome, the so-called anti-synthetase 
syndrome. Characteristics of the anti-synthetase 
syndrome include myositis, Raynaud's phenomenon, 
arthralgia, fever, skin changes and interstitial lung 
disease, although clinical features may differ between 
patients with the anti-synthetase syndrome [47, 48]. 
The interstitial lung disease is important as it may 
negatively affect prognosis [49].
A number of studies investigated the genetic 
background of IIM patients and tried to 
correlate phenotypic characteristics with genetic 
predispositions. Besides associations with the human 
leukocyte antigen (HLA) 8.1 ancestral haplotype 
(HLA-DRB1*03 - DQA1*05 - DQB1*02), significant 
correlations were found between the presence of 
anti-Jo-1 antibody and HLA-DRB1*0301 and/or HLA- 
DPB1*0101 (reviewed by [50]). There are also data 
supporting the idea that candidate IIM autoantigens 
can be involved in the induction and propagation of 
the autoimmune response. The expression of the
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Class I Class II
accessory prote ins
CysRS
ArgRS
IleRS
LeuRS
ValRS
MetRS
G lnRS
G luRS
TrpRS
TyrRS
p43
p38
p18
SerRS
ProRS
HisRS
ThrRS
AlaRS
GlyRS
LysRS
AsnRS
AspRS
PheRS IIc
F ig . 6 C lassifica tion o f am inoacyl-tRN A synthetases.
A aR Ss are (sub)classified according to the  chem ical specific ity o f the 
reaction they cata lyze and on the  presence o f conserved dom ains in 
the ir am ino acid sequences (C lass I and II, and subclasses a, b, and c). 
The aaRS tha t are associated w ith the m ultisynthetase com plex (M SC ) 
are connected to  the  three MSC accessory prote ins (p43, p38, and 
p18) v ia  bold lines.
Jo-1 antigen was found to be elevated in regenerating 
muscle o f IIM patients compared to normal muscle 
[51, 52]. However, clear pathologic relevance of 
these antibodies in IIM has not been found yet.
How to assay for anti-aaRS antibodies 
Commercially based LIAs can be used to test for 
several anti-aaRS antibodies, including anti-Jo-1, 
anti-PL7, and anti-PL12 see Fig. 4 and [13, 14, 53]. 
However, reaction conditions (e.g. temperature) have 
to be standardized, because they can have profound 
effects on the experimental outcome [13]. Recently, 
LIA strips have been developed that also detect anti- 
EJ and anti-OJ reactivities. Other less frequently 
found anti-aaRS reactivities such as anti-KS, anti-Ha, 
and anti-Zo are not commercially exploited yet. The 
latter anti-aaRSs are still being detected by the more 
conventional immunoblot and immunoprecipitation- 
based techniques.
involves covalent modification o f nucleosomes 
such as methylation of DNA and (de-)acetylation 
o f lysine residues in the core histones. The second 
mechanism involves dynamic changes of the histone- 
DNA interactions within the nucleosome in an ATP- 
dependent manner, which results in an increased or 
decreased accessibility of nucleosomal DNA (Fig. 
7). The major remodeling enzymes involved can be 
categorized based on their ATPase subunits. These 
include the ISWI/SNF2L-type ATPases and the 
chromodomain helicase DNA-binding (CHD) protein 
family.
The Mi-2 protein was first identified as a DM-specific 
autoantigen and later shown to be a subunit o f the 
nucleosome remodeling and deacetylation (NuRD) 
complex [56, 57]. The core subunits of the Mi-2/ 
NuRD complexes are classified into the CHD protein 
family and are found to occur in different subunit 
compositions, depending on their functional activity 
reviewed by [58]. The components include histone 
de-acetylases (HDAC1 and HDAC2), retinoblastoma 
associated proteins (RbAp), metastasis-associated 
protein (MTA), a methyl-CpG-binding domain 
containing protein (MBD), and either one o f the highly 
related Mi-2a (CHD3) and Mi-2p (CHD4) proteins [58­
60]. The NuRD complexes are unique transcriptional 
regulators since they combine three enzymatic 
activities, namely histone deacetylation, histone 
demethylation, and ATP-dependent chromatin 
remodeling activities.
Potentially disease-related PTMs 
The Mi-2/NuRD complex or Mi-2 protein complex 
has been described to be a substrate for modifying 
enzymes such as enzymes conjugating the small 
ubiquitin-related modifier (SUMO) and GrB [24, 61]. 
However, a direct relation between modified protein 
and IIM pathogenesis has not been demonstrated 
yet.
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Function
The chromatin in the nucleus of eukaryotic cells 
consists of a densely packed complex o f DNA and 
proteins. The basic structure is the nucleosome, each 
o f which contains an octamer o f four core histones 
(H2A, H2B, H3, and H4) and a piece of approximately 
150 basepairs DNA tightly wrapped around it. To allow 
gene transcription and chromosome replication, the 
chromatin is dynamically and orderly unfolded and, 
after replication or transcription repression, reformed. 
Chromatin structure remodeling is mainly regulated 
via two mechanisms reviewed by [54, 55]. The first
Antibodies to Mi-2 and their clinical associations 
Reichlin and coworkers were the first to describe anti- 
Mi-2 antibodies in IIM patients and to date the anti-Mi-2 
antibody can be detected in up to 20% of DM patients 
[62, 63]. The anti-Mi-2 positive patient sera are able to 
immunoprecipitate a major protein of approximately 
240 kDa, together with up to 8 other components of 
the Mi-2 complex (200, 150, 72, 65, 63, 50, and 34 
kDa) [56, 64](Fig. 1). Subsequently, two highly related 
Mi-2 proteins, Mi-2a and Mi-2p (calculated molecular 
masses are 220 and 218 kDa, respectively), which 
both contain epitopes that are recognized by anti- 
Mi-2 antibodies, have been identified as antigens in 
patients [57, 65]. Although anti-Mi-2 antibodies seem
closed chromatin 3! tfDAC
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Fig . 7 Predicted model o f chrom atin remodeling by the M i-2/NuRD 
complex.
The core subunits o f the M i-2/NuRD com plex are suggested to be 
involved in modifying the chrom atin s tructu re , which can resu lt in the 
initiation and/or m aintenance o f gene repression.
to be more tightly associated with DM, in several 
studies anti-Mi-2 positive PM and IBM patients have 
been detected as well [8, 66]. Therefore, cutaneous 
characteristics such as Gottron's papules, heliotrope 
rash, cuticular overgrowth and so-called V- and shawl 
sign, in combination with autoantibody profiles are 
considered to be the most reliable diagnostic features 
for DM [1]. Anti-Mi-2 positive patients tend to respond 
well to steroid therapy and thus have a relatively good 
prognostic profile [67].
Recent studies have found elevated Mi-2 expression 
levels in (regenerating) DM muscle biopsies and 
in certain tumors associated with autoimmune IIM 
[51, 68]. Additionally, Kashiwagi et al. described 
a crucial role o f Mi-2 in the development and 
repair o f the basal epidermis which may support a 
pathophysiological role for Mi-2 in the development of 
DM [69]. Moreover, latitudinal differences have been 
demonstrated to affect the occurrence o f DM. These 
studies suggest an important role o f environmental 
factors such as UV-light in the development o f DM 
and anti-Mi-2 formation [70-73]. Anti-Mi-2 antibodies 
were detected in juvenile DM as well as adult 
DM, although autoantibody frequency may vary 
between the different DM subtypes [74-76]. Genetic 
predispositions in different HLA genes o f (non-) 
Caucasians, but also protein tyrosine phosphatase 
and pro-inflammatory cytokine genes have been 
shown to be involved in the development o f IIM 
reviewed by [50]. The HLA-DRB1*0302 and HLA- 
DRB1*0701 alleles have been described as risk 
factors for the generation o f anti-Mi-2 antibodies in 
African-American and Caucasian individuals [50, 
77].
How to assay for anti-Mi-2 antibodies 
Several diagnostic assays have been used over 
the years to detect anti-Mi-2 antibody reactivities 
in patient sera. To date home-made tests are still 
more accurate, however, due to an enhanced 
reproducibility, sensitivity, and specificity, line-blot 
techniques will probably be preferred over the more 
conventional ELISA and IP assays in the future [53].
Signal Recognition Particle (SRP)
Function
Proteins that are involved in intercellular signaling are 
either being secreted or transported to the plasma 
membrane. The intracellular translocation of such 
proteins, from translational site to functional site, is 
regulated by a specialized secretory pathway. First, 
newly synthesized proteins have to be directed to 
the endoplasmic reticulum (ER), which is a signal 
peptide sequence driven process. This sequence is 
located at the N-terminus o f the protein, and protein 
translocation can occur post-translationally or co- 
translationally. Co-translational translocation involves 
the so-called signal recognition particle (SRP), which 
is a ribonucleoprotein (RNP) complex that consists of 
six proteins (9, 14, 19, 54, 68, and 72 kDa) and a RNA 
molecule o f approximately 300 nucleotides, termed 
7SL RNA [78]. In the SRP complex two distinct 
RNP domains can be distinguished (Fig. 8) [79-81]. 
The S-domain consists o f SRP19, SRP54, SRP68, 
SRP72, and a forked 7SL RNA moiety. It recognizes 
the signal peptide on the growing peptide chain and 
targets the complex to the ER membrane. The Alu­
domain is formed by SRP9, SRP14 at the opposite 
end o f the 7SL RNA and probably causes a transient 
translational arrest until the ribosome/nascent 
chain complex has docked to the ER. The SRP 
particle has a high affinity for ribosomes containing 
a protruding signal peptide. After binding, the SRP- 
ribosome complex binds the SRP receptor (SR) on 
the ER membrane via GTP-dependent interactions. 
Subsequently, the ribosome can dock onto the 
translocon and the binding between signal sequence 
and SRP complex is broken, allowing translation to 
resume. Finally, after GTP hydrolysis, SRP and the 
SR dissociate and the SRP complex is recycled for 
a following round o f translocation reviewed by [82].
Potentially disease-related PTMs 
Casciola-Rosen et al. described SRP72 as a 
substrate for GrB and suggested a pathogenic role 
for the unique fragments generated in this way [24].
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Fig . 8 SRP m ediates translocation o f nascent, signal peptide-contain ing proteins.
(A) Schem atic structure o f S R P  (B) M echanism  of protein translocation mediated by S R P  First, SRP b inds to  the  N-term inal signal peptide o f the 
grow ing peptide chain which results in elongation arrest (1). Subsequently, the  ribosom e/SRP com plex is targeted to  the  SRP receptor (S R ) at 
the  ER m em brane by specific  sequences in the  SRP prote ins (2). Docking o f the  com plex to  the  mem brane bound translocon re leases the  signal 
peptide from  the  SRP com plex and enables translation to  continue (3). The SRP dissociates and is recycled fo r additional translocation events (4).
Antibodies to SRP and their clinical associations 
Reeves and colleagues were the first to describe 
the SRP as an autoantigen in IIM patients [83]. 
Autoantibodies directed to SRP54 are most frequently 
found, although anti-SRP72, anti-SRP68, and anti- 
7SL RNA reactivities have been reported as well [84­
86]. Patients that generate anti-SRP antibodies (up 
to 5% of patients with IIM) appear to form a distinct 
clinical and histopathological subset within the IIM 
[84, 87]. The so-called necrotizing myopathy seen 
in anti-SRP positive patients, include necrotic and 
regenerating myofibers. Muscle enzyme elevations 
as well as lower numbers o f infiltrating lymphocytes 
are found in muscle biopsies compared to PM. In 
addition, patients with anti-SRP antibodies frequently 
reveal an unusually severe weakness, acute onset, 
rapid disease progression, and resistance to 
treatment [84, 87, 88]. These distinct characteristics 
emphasize that anti-SRP antibodies can be used as a 
biomarker for a distinct subgroup of IIM patients. Anti- 
SRP antibodies are rarely detected in juvenile IIM [6].
How to assay for anti-SRP antibodies 
Anti-SRP antibodies, sim ilar to anti-aaRS, anti-Mi-2, 
and several anti-MAA, can be detected via commercial 
LIAs. However, Ronnelid and colleagues found 
discrepancies in the autoantibody reactivities when 
commercial LIAs were used at different temperatures. 
This temperature sensitivity is most pronounced for
weakly positive and negative samples, which may 
result in false positive or false negative diagnoses 
[13]. This emphasizes the importance o f further 
evaluation and development of commercial LIAs, in 
order to ensure that specificity and sensitivity are 
warranted.
CADM-140
Function
The innate immune system utilizes a specific group of 
receptors, the so-called pattern recognition receptors 
(PRRs), to detect specific pathogenic components 
[89]. Three major classes o f PRRs have been 
identified, including Toll-like receptors (TLRs), retinoic 
acid-inducible gene I (RIG-I)-like helicases (RLHs) 
and nucleotide-oligomerization domain (NOD)-like 
receptors (NLRs). The melanoma differentiation- 
associated gene 5 (MDA5), or CADM-140 autoantigen, 
together with RIG-I and LGP2 (laboratory o f genetics 
and physiology 2) are members of the RLH helicase 
family. Both RIG-I and MDA5 contain N-terminal 
caspase-recruitment domains (CARDs) followed by a 
DExD/H box RNA helicase domain, whereas LGP2 
has a similar helicase domain but lacks a CARD 
domain. LGP2 has been suggested to function as a 
negative regulator of RIG-I/MDA5 signaling [90-92]. 
The TLRs and RLHs are able to sense viral RNA and 
DNA components and downstream signaling results
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in the activation of cells to produce type I interferons 
(IFNs) and pro-inflammatory cytokines. These factors 
stimulate the immune system by activating natural 
killer (NK) and T cells, and promote the induction of 
apoptosis o f virus-infected cells and the cellular anti­
viral response that interferes with cellular and viral 
processes.
the recombinant CADM-140 protein as antigen, 
was used to test for anti-CADM-140 antibodies 
with a fairly high sensitivity and specificity [98]. The 
recombinant CADM-140 antigen might be suitable for 
the development of a commercial test.
p155/140
Potentially disease-related PTMs 
Barral and colleagues describe MDA5/CADM-140 
degradation products, both in puromycin-induced 
apoptotic HeLa cells and poliovirus-infected cells, 
which is suggested to antagonize the type I IFN- 
induced anti-viral response [93]. Disease-associated 
MDA5/CADM-140 modifications have not been 
described yet.
Antibodies to CADM-140 and their clinical 
associations
The IIM classification criteria enable clinicians to 
categorize several distinct IIM populations. Some 
individuals, the so-called amyopathic DM patients, 
exert typical skin manifestations of DM but little or no 
evidence o f clinical IIM. When patients do not develop 
clinical symptoms of IIM for at least 2 years after the 
onset of skin manifestations they will be classified 
as clinically-amyopathic DM (CADM) [94]. Japanese 
patients with CADM develop a rapidly progressive 
interstitial lung disease (ILD), which frequently 
24 appears to be resistant to treatment and which may 
lead to early death [95, 96]. Sato and colleagues were 
the first to describe a novel antibody (anti-CADM-140) 
that immunoprecipitated a 140-kDa protein in 53% 
o f the CADM patients, whereas no such antibodies 
were detected in any of the PM or DM patients [97] 
(Fig. 1). Recently, it was shown that this 140-kDa 
protein is identical to MDA5 [98]. It is intriguing that 
anti-CADM-140 antibodies are only reported to 
occur in Japanese patients so far. Nakashima and 
colleagues confirmed the anti-CADM-140 antibody to 
be specific for CADM, although a few positive patients 
showed symptoms o f IIM (DM according to criteria)
[99]. A recent report from Hoshino et al., suggested 
that anti-CADM140/MDA5 autoantibodies could be 
used as a novel serological marker to distinguish 
between different DM subsets and associated clinical 
complications [100].
How to assay for anti-CADM-140 antibodies 
No commercial assay is available yet for the detection 
o f the anti-CADM-140 antibody. Sato and colleagues 
used immunoprecipitation, immunoblotting and 
indirect immunofluorescence techniques to detect 
this specificity [97]. In addition, an ELISA, containing
Function
The Tif1-g, or p155/140 protein has been characterized 
as a member of the transcriptional intermediary factor 
1 (Tif1) gene family [101-103]. Similar to the other Tif1 
members, Tif1-a and Tif1-p, Tif1-g contains several 
specific protein domains, including a RING finger, 
B-boxes, a coiled-coil domain, a PHD/TTC domain, 
and a bromodomain involved in protein-protein 
interactions. Several possible functions of the Tif1-g 
protein have been described, including regulation of 
transcription and maintenance of tissue homeostasis 
[104, 105].
While the antigenic p155 protein (one of the two 
antigenic proteins) has been identified as Tif1-g, the 
identity of the p140 protein remains elusive [103].
Potentially disease-related PTMs
No modifications have been associated with disease.
Antibodies to p155/140 and their clinical associations 
Several studies indicated that anti-p155/140 
antibodies appear to be associated with adult and 
juvenile DM (JDM) patients [106]. Up to 23% o f DM 
patients seem to contain autoantibodies reactive with 
a 155/140-kDa protein doublet (Fig. 1). The positive 
adult DM patients often have more severe cutaneous 
involvement and an increased risk for malignancies 
(particularly adenocarcinomas) [106-109]. Follow- 
up studies confirmed the cancer-associated DM 
(C-ADM) subset specificity of the anti-p155/140 
antibody [100]. The anti-p155/140 antibody is 
detected in JDM sera with a similar frequency as in 
adult DM, although the association with malignancy 
in JDM was not observed [110].
How to assay fo r anti-p155/140 antibodies 
Anti-p155/140 was first identified using an 
immunoprecipitation procedure with C-ADM 
patient sera and radiolabeled K562 cell extracts 
and immunoblotting [106]. Recently, the 
immunoprecipitation o f biotinylated recombinant 
Tif1-g was used to evaluate the clinical features 
associated with anti-p155/140 in DM patients
[100]. The availability o f such recombinant proteins 
might encourage the development of a commercial 
diagnostic test.
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Small ubiquitin-like modifier activating enzyme 
(SAE)
Function
Many enzymes are involved in post-translational 
protein modifications, and thereby regulate protein 
activity, subcellular localization, stability and protein­
protein interactions. These protein modifications can 
be a response to environmental triggers or depend 
on the cellular state. The SUMO protein family is 
structurally related to ubiquitin, and, like ubiquitin, 
can be post-translationally conjugated to other 
proteins by a similar mechanism. SUMO needs to 
be activated before post-translational conjugation 
can occur. This process is regulated by the SUMO- 
activating enzyme (E1) and involves the small 
ubiquitin-like modifier activating enzyme (SAE), 
which consists o f a heterodimer o f SAE1 and SAE2. 
Sumoylation is found to be involved in a variety of 
processes such as nuclear protein transport, DNA 
replication and repair, and cell division [111]. In 
addition, the number o f substrates is increasing and 
emphasizes the diverse roles of SUMO modification 
in many cellular processes [112]. Although several 
SUMO family members have been shown to play 
role in the sumoylation of proteins, information about 
the consequences of sumoylation on the functions of 
these proteins is rather scarce.
Potentially disease-related PTMs
No disease-associated modifications have been
documented.
Antibodies to SAE and their clinical associations 
Betteridge and colleagues reported a novel 
autoantibody in adult DM patients that 
immunoprecipitated two uncharacterized bands at 
40 and 90 kDa [113]. Further proteomic analysis 
identified the autoantigenic targets as small ubiquitin- 
like modifier activating enzyme (SAE) subunits. A 
large scale autoantibody screening by IP identified 
anti-SAE antibodies in 8.4% of DM patients. These 
results suggest that anti-SAE may identify a new 
serological IIM subset that present initially CADM 
and progress to develop IIM with a high frequency of 
systemic features except interstitial pneumonia.
How to assay for anti-SAE antibodies 
Anti-SAE antibodies can be detected by 
immunoprecipitation and show a diffuse, coarse, 
speckled, nucleolar-sparing pattern in indirect 
immunofluorescence analysis [113, 114].
p140
Function
The NXP-2 protein is a recently identified nuclear 
matrix associated protein. Ectopically expressed 
NXP-2 mutants and structure prediction programs 
allowed the identification o f several functional domains 
for NXP-2, including RNA-binding, nuclear matrix- 
binding, and coiled-coil domains [115]. Northern blot 
analysis showed NXP-2 to be expressed in specific 
tissues and at different levels. Moreover, RNA-binding 
and nuclear-binding capacities of NXP-2 suggest 
a similar role in the control o f posttranscriptional 
processes as are described for other nuclear 
matrix proteins that contain similar domains [116]. 
Rosendorff and coworkers reported a transcriptional 
repressor activity for the NXP-2 in vitro, which may 
be mediated by SUMO modification [117]. These 
results suggest that NXP-2 may be involved in tissue- 
specific RNA metabolism and maintenance of nuclear 
structure rather than being a constitutive factor in 
nuclear functions.
Potentially disease-related PTMs 
NXP-2 was recently described to be a candidate 
substrate for SUMO modification, which might result 
in the down-regulation o f transcription [112, 117].
However, whether this results in the initiation of 
pathogenic mechanisms leading to immunological 
dysregulation is not known yet. 25
Antibodies to p140 and their clinical associations 
Oddis and colleagues described autoantibodies 
directed against a 140-kDa target (anti-MJ) in a cohort 
o f juvenile IIM patients [118]. Later, Gunawardena and 
co-workers identified antibodies to a 140-kDa protein 
in 23% o f juvenile IIM sera that form a distinct JDM 
subset [119]. The p140 autoantigen targeted by these 
antibodies is different from the p155/140 antigen 
described above. Immunodepletion experiments with 
reference anti-p140-positive sera and anti-NXP-2 
monoclonal antibodies suggested that the p140 
protein is identical to the MJ autoantigen. Recent 
studies o f Targoff‘s group characterized the p140/
MJ antigen and described the p140 protein as the 
nuclear matrix protein (NXP-2) [120].
The presence of this anti-p140 antibody is associated 
with calcinosis, which defines a different clinical 
phenotypic JDM subset.
How to assay fo r anti-p140 antibodies 
Radiolabeled immunoprecipitation assays have been 
used to identify the presence of this antibody activity 
[119].
Novel MSAs
Christopher-Stine and colleagues recently described 
a novel autoantibody in a subset of individuals 
suffering from necrotizing myopathy, which previously 
were considered to be autoantibody negative [121]. 
They studied 255 patients with myopathies and found 
38 muscle biopsies with necrotizing myopathies. 
Twenty-six patients were diagnosed as autoantibody 
negative, whereas in the remaining 12 sera anti-SRP 
or anti-aaRS activities were detected. Screening of 
the 26 negative sera for putative novel autoantibody 
reactivities by immunoprecipitation resulted in the 
detection of two antigenic proteins with molecular 
weights o f approximately 200 kDa and 100 kDa in 
62% o f these patients. The evaluation o f clinical data 
suggested that patients with anti-200/100 antibodies 
form a separate group o f necrotizing myopathies that 
are associated with the exposure to statin medication 
and are responsive to immunosuppression. Further 
characterization o f the anti-200/100 target might 
contribute to the understanding how this particular 
subset can develop.
Concluding remarks and perspectives
The characterization of MSA and the development 
o f methods to detect these autoantibodies in patient 
sera for diagnostic purposes represent an active 
26 field of research. A series o f novel MSA have been 
identified during the last decade and new technologies 
have been developed for their identification and 
detection, especially using multiplex assays. The 
application o f multiplex assays will not only facilitate 
the simultaneous detection o f multiple autoantibody 
reactivities, MSA as well as MAA, but may also allow 
the identification o f autoantibody profiles that might 
have additional diagnostic or prognostic value. 
Although the prevalence o f MSAs in IIM patients is 
generally relatively low (< 20%), for a number of them 
clinical associations have indeed been identified. 
Several reports indicate that MSAs are able to 
discriminate between distinct disease entities and/or 
can be correlated to disease severity, which suggests 
that MSAs might help define IIM subtypes and predict 
disease progression, and/or treatment. The number 
o f MSA is steadily growing and the diverse functions 
and subcellular localizations o f the associated 
autoantigenic targets suggest selective mechanisms 
in the development of these autoantibodies. Whether 
autoantibodies directly contribute to the development 
and/or progression of IIM, however, remains elusive. 
All MSA that have been characterized up to now are 
associated with PM and/or DM. An intriguing question
is whether MSA are also produced by patients with 
the third major type of IIM, IBM.
The detection o f novel autoantibody targets in the 
different immune-mediated myopathies emphasizes 
the complexity of the mechanisms that define the 
development o f these autoimmune diseases. Further 
studies that elucidate structure and function of 
autoantigenic targets will be essential in understanding 
the underlying pathological mechanisms in IIM.
Acknowledgements
We would like to thank B. van Engelen (UMCN, The 
Netherlands) for critically reading the manuscript 
as well as EUROIMMUN who generously provided 
line-blots free-of-charge. This work was financially 
supported by the European Union Sixth Framework 
Programme (project Autocure; LSH-018661).
C hapter 2 MSA: Detection and Clinical Association
References
[1] Mammen,A.L. Dermatomyositis and polymyositis: [17] 
Clinical presentation, autoantibodies, and 
pathogenesis. Ann. N. Y. Acad. Sci. 1184:134-53;
2010.
[2] Walker, U.A. Imaging tools for the clinical [18] 
assessment of idiopathic inflammatory myositis.
Curr. Opin. Rheumatol. 20:656-661; 2008.
[3] Tozzoli, R. Recent advances in diagnostic 
technologies and their impact in autoimmune [19] 
diseases. Autoimmun. Rev. 6:334-340; 2007.
[4] Sharp, V.; Utz, PJ. Technology insight: can [20] 
autoantibody profiling improve clinical practice?
Nat. Clin. Pract. Rheumatol. 3:96-103; 2007.
[5] Betteridge, Z.; Gunawardena, H.; North, J. et al. 
Anti-synthetase syndrome: a new autoantibody [21] 
to phenylalanyl transfer RNA synthetase (anti-
Zo) associated with polymyositis and interstitial 
pneumonia. Rheumatology. (Oxford). 46:1005­
1008; 2007. [221
[6] Gunawardena, H.; Betteridge, Z.E.; McHugh, N.J. 
Myositis-specific autoantibodies: their clinical and 
pathogenic significance in disease expression. 
Rheumatology. (Oxford). 48:607-612; 2009.
[7] Tan, E.M.; Smolen, J.S.; McDougal, J.S. et al. [23] 
A critical evaluation of enzyme immunoassays
for detection of antinuclear autoantibodies of 
defined specificities. I. Precision, sensitivity, and 
specificity. Arthritis Rheum. 42:455-464; 1999.
[8] Brouwer, R.; Hengstman, G.J.; Vree, E.W. et al. [24] 
Autoantibody profiles in the sera of European 
patients with myositis. Ann. Rheum. Dis. 60:116­
123; 2001.
[9] Robinson, W.H.; DiGennaro, C.; Hueber, W. [25] 
et al. Autoantigen microarrays for multiplex 
characterization of autoantibody responses. Nat.
Med. 8:295-301; 2002.
[10] Bizzaro, N.; Bonelli, F.; Tonutti, E. et al. New 
coupled-particle light-scattering assay for 
detection of Ro/SSA (52 and 60 kilodaltons) [26] 
and La/SSB autoantibodies in connective tissue 
diseases. Clin. Diagn. Lab Immunol. 8:922-925;
2001.
[11] Fulton, R.J.; McDade, R.L.; Smith, P.L. et [27] 
al. Advanced multiplexed analysis with the 
FlowMetrix system. Clin. Chem. 43:1749-1756;
1997.
[12] Fritzler, M.J. Advances and applications
of multiplexed diagnostic technologies in [28] 
autoimmune diseases. Lupus. 15:422-427; 2006.
[13] Ronnelid, J.; Barbasso, H.S.; Storfors, H. et 
al. Use of a commercial line blot assay as a 
screening test for autoantibodies in inflammatory 
myopathies. Autoimmun. Rev. 9:58-61; 2009. [29]
[14] Ghirardello, A.; Bendo, R.; Rampudda, M.E. et 
al. Commercial blot assays in the diagnosis of 
systemic rheumatic diseases. Autoimmun. Rev. 
8:645-649; 2009. [30]
[15] Ting, S.M.; Bogner, P.; Dignam, J.D. Isolation of 
prolyl-tRNA synthetase as a free form and as a 
form associated with glutamyl-tRNA synthetase.
J. Biol. Chem. 267:17701-17709; 1992. [31]
[16] Quevillon, S.; Robinson, J.C.; Berthonneau, E. et 
al. Macromolecular assemblage of aminoacyl- 
tRNA synthetases: identification of protein-
protein interactions and characterization of a core 
protein. J. Mol. Biol. 285:183-195; 1999. 
Hausmann, C.D.; Ibba, M. Aminoacyl-tRNA 
synthetase complexes: molecular multitasking 
revealed. FEMS Microbiol. Rev. 32:705-721; 
2008.
Guo, M.; Yang, X.L.; Schimmel, P. New functions 
of aminoacyl-tRNA synthetases beyond 
translation. Nat. Rev. Mol. Cell Biol. 11:668-674;
2010.
Cusack, S. Aminoacyl-tRNA synthetases. Curr. 
Opin. Struct. Biol. 7:881-889; 1997.
Kyriacou, S.V.; Deutscher, M.P. An important role 
for the multienzyme aminoacyl-tRNA synthetase 
complex in mammalian translation and cell 
growth. Mol. Cell. 29:419-427; 2008.
Ray, P.S.; Arif, A.; Fox, P.L. Macromolecular 
complexes as depots for releasable regulatory 
proteins. Trends Biochem. Sci. 32:158-164;
2007.
Heusel, J.W.; Wesselschmidt, R.L.; Shresta, S. 
et al. Cytotoxic lymphocytes require granzyme B 
for the rapid induction of DNA fragmentation and 
apoptosis in allogeneic target cells. Cell. 76:977­
987; 1994.
Shresta, S.; MacIvor, D.M.; Heusel, J.W. et al. 
Natural killer and lymphokine-activated killer cells 
require granzyme B for the rapid induction of 
apoptosis in susceptible target cells. Proc. Natl. 
Acad. Sci. U. S. A. 92:5679-5683; 1995. 
Casciola-Rosen, L.; Andrade, F.; Ulanet, D. et al. 
Cleavage by granzyme B is strongly predictive of 
autoantigen status: implications for initiation of 
autoimmunity. J. Exp. Med. 190:815-826; 1999. 
Howard, O.M.; Dong, H.F.; Yang, D. et al. 
Histidyl-tRNA synthetase and asparaginyl-tRNA 
synthetase, autoantigens in myositis, activate 
chemokine receptors on T lymphocytes and 
immature dendritic cells. J. Exp. Med. 196:781- 
791;2002.
Oppenheim, J.J.; Dong, H.F.; Plotz, P. et 
al. Autoantigens act as tissue-specific 
chemoattractants. J. Leukoc. Biol. 77:854-861; 
2005.
Levine, S.M.; Raben, N.; Xie, D. et al. Novel 
conformation of histidyl-transfer RNA synthetase 
in the lung: the target tissue in Jo-1 autoantibody- 
associated myositis. Arthritis Rheum. 56:2729­
2739; 2007.
Ramirez-Sandoval, R.; Sanchez-Rodriguez, 
S.H.; Herrera-van, O.D. et al. Antinuclear 
antibodies recognize cellular autoantigens driven 
by apoptosis. Joint Bone Spine. 70:187-194; 
2003.
Wakasugi, K.; Schimmel, P. Highly differentiated 
motifs responsible for two cytokine activities of 
a split human tRNA synthetase. J. Biol. Chem. 
274:23155-23159; 1999.
Wakasugi, K.; Slike, B.M.; Hood, J. et al. A human 
aminoacyl-tRNA synthetase as a regulator of 
angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 
99:173-177; 2002.
Henrotin, Y.E.; Bruckner, P.; Pujol, J.P. The role 
of reactive oxygen species in homeostasis and 
degradation of cartilage. Osteoarthritis. Cartilage. 
11:747-755; 2003.
27
28
[32] Sakurai, H.; Kohsaka, H.; Liu, M.F. et al. Nitric [46] 
oxide production and inducible nitric oxide 
synthase expression in inflammatory arthritides.
J. Clin. Invest. 96:2357-2363; 1995.
[33] Wedderburn, L.R.; McHugh, N.J.; Chinoy, H.
et al. HLA class II haplotype and autoantibody [47] 
associations in children with juvenile 
dermatomyositis and juvenile dermatomyositis- 
scleroderma overlap. Rheumatology. (Oxford). 
46:1786-1791; 2007. [48]
[34] Brouwer, R.; Vree, E.W.; Jongen, P.H. et 
al. Frequent occurrence of anti-tRNA(His) 
autoantibodies that recognize a conformational 
epitope in sera of patients with myositis. Arthritis [49] 
Rheum. 41:1428-1437; 1998.
[35] Bunn, C.C.; Bernstein, R.M.; Mathews, M.B. 
Autoantibodies against alanyl-tRNA synthetase [50] 
and tRNAAla coexist and are associated with 
myositis. J. Exp. Med. 163:1281-1291; 1986.
[36] Gelpi, C.; Kanterewicz, E.; Gratacos, J. et al. 
Coexistence of two antisynthetases in a patient
with the antisynthetase syndrome. Arthritis [51] 
Rheum. 39:692-697; 1996.
[37] Nishikai, M.; Reichlin, M. Heterogeneity of 
precipitating antibodies in polymyositis and 
dermatomyositis. Characterization of the Jo-1 [52] 
antibody system. Arthritis Rheum. 23:881-888;
1980.
[38] Mimori, T.; Imura, Y.; Nakashima, R. et al. 
Autoantibodies in idiopathic inflammatory [53] 
myopathy: an update on clinical and 
pathophysiological significance. Curr. Opin. 
Rheumatol. 19:523-529; 2007.
[39] Hengstman, G.J.; van Engelen, B.G.; Badrising,
U.A. et al. Presence of the anti-Jo-1 autoantibody [54] 
excludes inclusion body myositis. Ann. Neurol.
44:423; 1998.
[40] Stone, K.B.; Oddis, C.V.; Fertig, N. et al. Anti-Jo-1 [55] 
antibody levels correlate with disease activity
in idiopathic inflammatory myopathy. Arthritis 
Rheum. 56:3125-3131; 2007. [56]
[41] Raben, N.; Nichols, R.; Dohlman, J. et al. A 
motif in human histidyl-tRNA synthetase which 
is shared among several aminoacyl-tRNA 
synthetases is a coiled-coil that is essential [57] 
for enzymatic activity and contains the major 
autoantigenic epitope. J. Biol. Chem. 269:24277­
24283; 1994.
[42] Dohlman, J.G.; Lupas, A.; Carson, M.
Long charge-rich alpha-helices in systemic [58] 
autoantigens. Biochem. Biophys. Res. Commun. 
195:686-696; 1993.
[43] Martin, A.; Shulman, M.J.; Tsui, F.W. Epitope 
studies indicate that histidyl-tRNA synthetase is a [59] 
stimulating antigen in idiopathic myositis. FASEB
J. 9:1226-1233; 1995.
[44] Miller, F.W.; Waite, K.A.; Biswas, T. et al. The role [60] 
of an autoantigen, histidyl-tRNA synthetase, in
the induction and maintenance of autoimmunity.
Proc. Natl. Acad. Sci. U. S. A. 87:9933-9937; [61] 
1990.
[45] Katsumata, Y.; Ridgway, W.M.; Oriss, T. et al. 
Species-specific immune responses generated
by histidyl-tRNA synthetase immunization are [62] 
associated with muscle and lung inflammation. J. 
Autoimmun. 29:174-186; 2007.
Hengstman, G.J.; van Engelen, B.G.; van 
Venrooij, W.J. Myositis specific autoantibodies: 
changing insights in pathophysiology and clinical 
associations. Curr. Opin. Rheumatol. 16:692- 
699;2004.
Kalluri, M.; Sahn, S.A.; Oddis, C.V. et al. Clinical 
profile of anti-PL-12 autoantibody. Cohort study 
and review of the literature. Chest. 135:1550­
1556; 2009.
Marguerie, C.; Bunn, C.C.; Beynon, H.L. 
et al. Polymyositis, pulmonary fibrosis and 
autoantibodies to aminoacyl-tRNA synthetase 
enzymes. Q. J. Med. 77:1019-1038; 1990.
Marie, I.; Hachulla, E.; Cherin, P. et al. Interstitial 
lung disease in polymyositis and dermatomyositis. 
Arthritis Rheum. 47:614-622; 2002.
Chinoy, H.; Lamb, J.A.; Ollier, W.E. et 
al. An update on the immunogenetics of 
idiopathic inflammatory myopathies: major 
histocompatibility complex and beyond. Curr. 
Opin. Rheumatol. 21:588-593; 2009. 
Casciola-Rosen, L.; Nagaraju, K.; Plotz, P. et al. 
Enhanced autoantigen expression in regenerating 
muscle cells in idiopathic inflammatory myopathy. 
J. Exp. Med. 201:591-601; 2005.
Zampieri, S.; Biral, D.; Adami, N. et al. Expression 
of myositis specific autoantigens during post­
natal myogenesis. Neurol. Res. 30:145-148;
2008.
Ghirardello, A.; Rampudda, M.; Ekholm, L. et 
al. Diagnostic performance and validation of 
autoantibody testing in myositis by a commercial 
line blot assay. Rheumatology. (Oxford). 49:2370­
2374; 2010.
Becker, P.B.; Horz, W. ATP-dependent 
nucleosome remodeling. Annu. Rev. Biochem. 
71:247-73; 2002.
Ehrenhofer-Murray, A.E. Chromatin dynamics at 
DNA replication, transcription and repair. Eur. J. 
Biochem. 271:2335-2349; 2004.
Ge, Q.; Nilasena, D.S.; O'Brien, C.A. et al. 
Molecular analysis of a major antigenic region of 
the 240-kD protein of Mi-2 autoantigen. J. Clin. 
Invest. 96:1730-1737; 1995.
Seelig, H.P.; Moosbrugger, I.; Ehrfeld, H. et 
al. The major dermatomyositis-specific Mi-2 
autoantigen is a presumed helicase involved 
in transcriptional activation. Arthritis Rheum. 
38:1389-1399; 1995.
Ramirez, J.; Hagman, J. The Mi-2/NuRD 
complex: a critical epigenetic regulator of 
hematopoietic development, differentiation and 
cancer. Epigenetics. 4:532-536; 2009.
Bowen, N.J.; Fujita, N.; Kajita, M. et al. Mi-2/ 
NuRD: multiple complexes for many purposes. 
Biochim. Biophys. Acta. 1677:52-57; 2004. 
Denslow, S.A.; Wade, P.A. The human Mi-2/ 
NuRD complex and gene regulation. Oncogene. 
26:5433-5438; 2007.
Gong, Z.; Brackertz, M.; Renkawitz, R. 
SUMO modification enhances p66-mediated 
transcriptional repression of the Mi-2/NuRD 
complex. Mol. Cell Biol. 26:4519-4528; 2006. 
Reichlin, M.; Mattioli, M. Description of a 
serological reaction characteristic of polymyositis. 
Clin. Immunol. Immunopathol. 5:12-20; 1976.
C hapter 2 MSA: Detection and Clinical Association
[63] Targoff, I.N.; Reichlin, M. The association 
between Mi-2 antibodies and dermatomyositis. 
Arthritis Rheum. 28:796-803; 1985.
[64] Nilasena, D.S.; Trieu, E.P.; Targoff, I.N. Analysis
of the Mi-2 autoantigen of dermatomyositis. [78] 
Arthritis Rheum. 38:123-128; 1995.
[65] Seelig, H.P.; Renz, M.; Targoff, I.N. et al. Two 
forms of the major antigenic protein of the 
dermatomyositis-specific Mi-2 autoantigen. 
Arthritis Rheum. 39:1769-1771; 1996. [79]
[66] Hengstman, G.J.; Vree Egberts, W.T.; Seelig,
H.P. et al. Clinical characteristics of patients 
with myositis and autoantibodies to different 
fragments of the Mi-2 beta antigen. Ann. Rheum. [80] 
Dis. 65:242-245; 2006.
[67] Love, L.A.; Leff, R.L.; Fraser, D.D. et al. A 
new approach to the classification of idiopathic 
inflammatory myopathy: myositis-specific [81] 
autoantibodies define useful homogeneous 
patient groups. Medicine (Baltimore). 70:360­
374; 1991. [82]
[68] Mammen, A.L.; Casciola-Rosen, L.A.; Hall,
J.C. et al. Expression of the dermatomyositis 
autoantigen Mi-2 in regenerating muscle. Arthritis 
Rheum. 60:3784-3793; 2009. [83]
[69] Kashiwagi, M.; Morgan, B.A.; Georgopoulos, K.
The chromatin remodeler Mi-2beta is required for 
establishment of the basal epidermis and normal 
differentiation of its progeny. Development. [84] 
134:1571-1582; 2007.
[70] Hengstman, G.J.; van Venrooij, W.J.; 
Vencovsky, J. et al. The relative prevalence of [85] 
dermatomyositis and polymyositis in Europe 
exhibits a latitudinal gradient. Ann. Rheum. Dis. 
59:141-142; 2000.
[71] Okada, S.; Weatherhead, E.; Targoff, I.N. et al.
Global surface ultraviolet radiation intensity may [86] 
modulate the clinical and immunologic expression
of autoimmune muscle disease. Arthritis Rheum. 
48:2285-2293; 2003.
[72] Love, L.A.; Weinberg, C.R.; McConnaughey, [87] 
D.R. et al. Ultraviolet radiation intensity predicts
the relative distribution of dermatomyositis and 
anti-Mi-2 autoantibodies in women. Arthritis 
Rheum. 60:2499-2504; 2009. [88]
[73] Burd, C.J.; Kinyamu, H.K.; Miller, F.W. et 
al. UV radiation regulates Mi-2 through 
protein translation and stability. J. Biol. Chem. 
283:34976-34982; 2008. [89]
[74] Rider, L.G.; Miller, F.W.; Targoff, I.N. et al. A 
broadened spectrum of juvenile myositis. 
Myositis-specific autoantibodies in children. [90] 
Arthritis Rheum. 37:1534-1538; 1994.
[75] Feldman, B.M.; Reichlin, M.; Laxer, R.M. et al.
Clinical significance of specific autoantibodies 
in juvenile dermatomyositis. J. Rheumatol. 
23:1794-1797; 1996. [91]
[76] Shamim, E.A.; Rider, L.G.; Pandey, J.P. et 
al. Differences in idiopathic inflammatory 
myopathy phenotypes and genotypes between 
Mesoamerican Mestizos and North American 
Caucasians: ethnogeographic influences in the [92] 
genetics and clinical expression of myositis. 
Arthritis Rheum. 46:1885-1893; 2002.
[77] O'Hanlon, T.P.; Rider, L.G.; Mamyrova, G. et
al. HLA polymorphisms in African Americans [93]
with idiopathic inflammatory myopathy: allelic 
profiles distinguish patients with different clinical 
phenotypes and myositis autoantibodies. Arthritis 
Rheum. 54:3670-3681; 2006.
Walter, P.; Blobel, G. Purification of a membrane- 
associated protein complex required for protein 
translocation across the endoplasmic reticulum. 
Proc. Natl. Acad. Sci. U. S. A. 77:7112-7116; 
1980.
Gundelfinger, E.D.; Krause, E.; Melli, M. et al. 
The organization of the 7SL RNA in the signal 
recognition particle. Nucleic Acids Res. 11:7363­
7374; 1983.
Walter, P.; Johnson, A.E. Signal sequence 
recognition and protein targeting to the 
endoplasmic reticulum membrane. Annu. Rev. 
Cell Biol. 10:87-119; 1994.
Siegel, V.; Walter, P. Functional dissection of the 
signal recognition particle. Trends Biochem. Sci. 
13:314-316; 1988.
Egea, P.F.; Stroud, R.M.; Walter, P. Targeting 
proteins to membranes: structure of the signal 
recognition particle. Curr. Opin. Struct. Biol. 
15:213-220; 2005.
Reeves, W.H.; Nigam, S.K.; Blobel, G. Human 
autoantibodies reactive with the signal- 
recognition particle. Proc. Natl. Acad. Sci. U. S. 
A. 83:9507-9511; 1986.
Targoff, I.N.; Johnson, A.E.; Miller, F.W. Antibody 
to signal recognition particle in polymyositis. 
Arthritis Rheum. 33:1361-1370; 1990.
Okada, N.; Mimori, T.; Mukai, R. et al. 
Characterization of human autoantibodies that 
selectively precipitate the 7SL RNA component 
of the signal recognition particle. J. Immunol. 
138:3219-3223; 1987.
Satoh, T.; Okano, T.; Matsui, T. et al. Novel 
autoantibodies against 7SL RNA in patients with 
polymyositis/dermatomyositis. J. Rheumatol. 
32:1727-1733; 2005.
Hengstman, G.J.; ter Laak, H.J.; Vree Egberts, 
W.T. et al. Anti-signal recognition particle 
autoantibodies: marker of a necrotising myopathy. 
Ann. Rheum. Dis. 65:1635-1638; 2006.
Miller, T.; Al-Lozi, M.T.; Lopate, G. et al. Myopathy 
with antibodies to the signal recognition particle: 
clinical and pathological features. J. Neurol. 
Neurosurg. Psychiatry. 73:420-428; 2002. 
Meylan, E.; Tschopp, J.; Karin, M. Intracellular 
pattern recognition receptors in the host 
response. Nature. 442:39-44; 2006.
Yoneyama, M.; Kikuchi, M.; Matsumoto, K. et al. 
Shared and unique functions of the DExD/H-box 
helicases RIG-I, MDA5, and LGP2 in antiviral 
innate immunity. J. Immunol. 175:2851-2858;
2005.
Rothenfusser, S.; Goutagny, N.; DiPerna, G. et al. 
The RNA helicase Lgp2 inhibits TLR-independent 
sensing of viral replication by retinoic acid- 
inducible gene-I. J. Immunol. 175:5260-5268;
2005.
Saito, T.; Hirai, R.; Loo, Y.M. et al. Regulation 
of innate antiviral defenses through a shared 
repressor domain in RIG-I and LGP2. Proc. Natl. 
Acad. Sci. U. S. A. 104:582-587; 2007.
Barral, P.M.; Morrison, J.M.; Drahos, J. et al.
29
30
MDA-5 is cleaved in poliovirus-infected cells. J.
Virol. 81:3677-3684; 2007. [108]
[94] Sontheimer, R.D. Dermatomyositis: an overview 
of recent progress with emphasis on dermatologie 
aspects. Dermatol. Clin. 20:387-408; 2002.
[95] Tokiyama, K.; Tagawa, H.; Yokota, E. et al. [Two [109] 
cases of amyopathic dermatomyositis with fatal 
rapidly progressive interstitial pneumonitis]. 
Ryumachi. 30:204-209; 1990.
[96] Fujikawa, K.; Kawakami, A.; Kaji, K. et al. 
Association of distinct clinical subsets with [110] 
myositis-specific autoantibodies towards 
anti-155/140-kDa polypeptides, anti-140-
kDa polypeptides, and anti-aminoacyl tRNA 
synthetases in Japanese patients with 
dermatomyositis: a single-centre, cross-sectional [111] 
study. Scand. J. Rheumatol. 38:263-267; 2009.
[97] Sato, S.; Hirakata, M.; Kuwana, M. et al. [112] 
Autoantibodies to a 140-kd polypeptide, 
CADM-140, in Japanese patients with clinically 
amyopathic dermatomyositis. Arthritis Rheum. 
52:1571-1576; 2005. [113]
[98] Sato, S.; Hoshino, K.; Satoh, T. et al. RNA helicase 
encoded by melanoma differentiation-associated 
gene 5 is a major autoantigen in patients 
with clinically amyopathic dermatomyositis: 
association with rapidly progressive interstitial [114] 
lung disease. Arthritis Rheum. 60:2193-2200;
2009.
[99] Nakashima, R.; Imura, Y.; Kobayashi, S. et 
al. The RIG-I-like receptor IFIH1/MDA5 is a 
dermatomyositis-specific autoantigen identified 
by the anti-CADM-140 antibody. Rheumatology.
(Oxford). 49:433-440; 2010. [115]
[100] Hoshino, K.; Muro, Y.; Sugiura, K. et al. Anti-MDA5 
and anti-TIF1-gamma antibodies have clinical 
significance for patients with dermatomyositis. 
Rheumatology. (Oxford). 49:1726-1733; 2010.
[101] Venturini, L.; You, J.; Stadler, M. et [116] 
al. TIF1gamma, a novel member of the 
transcriptional intermediary factor 1 family. 
Oncogene. 18:1209-1217; 1999.
[102] Reymond, A.; Meroni, G.; Fantozzi, A. et al. The [117] 
tripartite motif family identifies cell compartments.
EMBO J. 20:2140-2151; 2001.
[103] Targoff, I.N.; Trieu, E.P.; Levy-Neto, M. et al. 
Autoantibodies to transcriptional intermediary [118] 
factor-1 gamma (TIF-1g) in dermatomyositis 
[abstract]. Arthritis Rheum. 54:S518; 2006.
[104] He, W.; Dorn, D.C.; Erdjument-Bromage, H. et al. 
Hematopoiesis controlled by distinct TIF1gamma [119] 
and Smad4 branches of the TGFbeta pathway.
Cell. 125:929-941; 2006.
[105] Bai, X.; Kim, J.; Yang, Z. et al. TIF1gamma 
controls erythroid cell fate by regulating [120] 
transcription elongation. Cell. 142:133-143;
2010.
[106] Targoff, I.N.; Mamyrova, G.; Trieu, E.P. et al. [121] 
A novel autoantibody to a 155-kd protein is 
associated with dermatomyositis. Arthritis 
Rheum. 54:3682-3689; 2006.
[107] Kaji, K.; Fujimoto, M.; Hasegawa, M. et al. 
Identification of a novel autoantibody reactive 
with 155 and 140 kDa nuclear proteins in patients 
with dermatomyositis: an association with 
malignancy. Rheumatology. (Oxford). 46:25-28;
2007.
Chinoy, H.; Fertig, N.; Oddis, C.V. et al. The 
diagnostic utility of myositis autoantibody testing 
for predicting the risk of cancer-associated 
myositis. Ann. Rheum. Dis. 66:1345-1349; 2007. 
Trallero-Araguas, E.; Labrador-Horrillo, M.; 
Selva-O'Callaghan, A. et al. Cancer-associated 
myositis and anti-p155 autoantibody in a series 
of 85 patients with idiopathic inflammatory 
myopathy. Medicine (Baltimore). 89:47-52; 2010. 
Gunawardena, H.; Wedderburn, L.R.; North, 
J. et al. Clinical associations of autoantibodies 
to a p155/140 kDa doublet protein in juvenile 
dermatomyositis. Rheumatology. (Oxford). 
47:324-328; 2008.
Dohmen, R.J. SUMO protein modification. 
Biochim. Biophys. Acta. 1695:113-131; 2004. 
Zhao, Y.; Kwon, S.W.; Anselmo, A. et al. Broad 
spectrum identification of cellular small ubiquitin- 
related modifier (SUMO) substrate proteins. J. 
Biol. Chem. 279:20999-21002; 2004.
Betteridge, Z.; Gunawardena, H.; North, J. et al. 
Identification of a novel autoantibody directed 
against small ubiquitin-like modifier activating 
enzyme in dermatomyositis. Arthritis Rheum. 
56:3132-3137; 2007.
Betteridge, Z.E.; Gunawardena, H.; Chinoy, 
H. et al. Clinical and human leucocyte antigen 
class II haplotype associations of autoantibodies 
to small ubiquitin-like modifier enzyme, a 
dermatomyositis-specific autoantigen target, 
in UK Caucasian adult-onset myositis. Ann. 
Rheum. Dis. 68:1621-1625; 2009.
Kimura, Y.; Sakai, F.; Nakano, O. et al. The 
newly identified human nuclear protein NXP-2 
possesses three distinct domains, the nuclear 
matrix-binding, RNA-binding, and coiled-coil 
domains. J. Biol. Chem. 277:20611-20617; 2002. 
Swanson, M.S.; Dreyfuss, G. Classification and 
purification of proteins of heterogeneous nuclear 
ribonucleoprotein particles by RNA-binding 
specificities. Mol. Cell Biol. 8:2237-2241; 1988. 
Rosendorff, A.; Sakakibara, S.; Lu, S. et al. NXP- 
2 association with SUMO-2 depends on lysines 
required for transcriptional repression. Proc. Natl. 
Acad. Sci. U. S. A. 103:5308-5313; 2006.
Oddis, C.V.; Fertig, N.; Goel, A. et al. Clinical 
and serological characterization of the anti-MJ 
antibody in childhood myositis [abstract]. Arthritis 
Rheum. 40:S139; 1997.
Gunawardena, H.; Wedderburn, L.R.; Chinoy, 
H. et al. Autoantibodies to a 140-kd protein in 
juvenile dermatomyositis are associated with 
calcinosis. Arthritis Rheum. 60:1807-1814; 2009. 
Targoff, I.N.; Trieu, E.P.; Levy-Neto, M. et al. 
Sera with autoantibodies to the MJ antigen react 
with NXP2. Arthritis Rheum. 56:S787; 2007. 
Christopher-Stine, L.; Casciola-Rosen, L.A.; 
Hong, G. et al. A novel autoantibody recognizing 
200-kd and 100-kd proteins is associated with an 
immune-mediated necrotizing myopathy. Arthritis 
Rheum. 62:2757-2766; 2010.
Chapter 3
Modification of autoantigenic proteins in 
oxidatively stressed Jurkat cells
Sander H.J. van Dooren*, Angelique M.C. Lokate*, Maarten Keijsers, Thijs Koorman, Dania Liembrug-Apers, 
Ger J.M. Pruijn, Helma Pluk
Department of Biomolecular Chemistry, Institute for Molecules and Materials, Nijmegen Centre for Molecular 
Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands.
* equally contributing authors
Manuscript in preparation
Abstract
Autoimmune diseases are believed to develop due to a loss of immunological tolerance, which may result in the 
formation o f autoantibodies and/or the destruction o f tissue. Post-translational modifications of autoantigens 
have been proposed to play a role in the generation o f autoantibodies. In addition to apoptosis- or necrosis- 
induced modifications, oxidative stress-induced modifications are also believed to play a role in the generation 
o f such neo-epitopes. To investigate whether oxidative stress leads to the modification of autoantigenic 
proteins in SLE, PM/Scl overlap syndrome and myositis, we analyzed these proteins from oxidatively stressed 
Jurkat cells as well as their purified recombinant equivalents by SDS-PAGE and immunoblotting. A time and 
H2O2-concentration dependent retarded electrophoretic mobility was observed for all analyzed proteins. In 
vitro oxidized recombinant U1A and Jo-1 proteins resulted in mobility shifts that were comparable with those 
observed with H2O2-treated Jurkat cells. The retarded migration o f U1A, Rrp40, Rrp41, Ro60, La, and Jo-1 
in SDS-PAGE can result from the oxidative modification of these proteins upon H2O2 treatment. Hydroxyl 
radicals are suggested to be involved in the oxidative modification, because we observed similar results with 
hypochlorite treated Jurkat cells and recombinant proteins. These modifications may result in the increased 
autoantigenicity of the protein to which the immune response in the respective autoimmune diseases is 
directed.
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Introduction
Neo-epitopes generated by modification o f self­
proteins may trigger the loss of immunological 
tolerance in autoimmune diseases. Since this 
hypothesis was formulated, researchers have 
focused on finding processes which may cause such 
alterations in self-proteins. Cell death is a process often 
accompanied by post-translational modifications. 
Both apoptotic and necrotic modifications have been 
reported to occur in a variety o f autoantigens [1,2]. 
Reactive oxygen species (ROS)-mediated reactions, 
which can be associated with necrosis, may also be of 
importance for the modification o f self-proteins. One of 
the mechanisms that are used by the innate immune 
system to destroy foreign pathogens is the rapid 
release of ROS, a process which is called oxygen- or 
respiratory burst. ROS are oxygen-based molecules 
which are highly reactive and include superoxide 
(O2"), hydroxyl radicals (OH^) and hydrogen peroxide 
(H2O2). ROS can be formed intracellularly, in for 
example the mitochondria, as a natural byproduct of 
oxygen metabolism. Under stress conditions ROS 
levels can increase dramatically and damage cellular 
structures, including DNA, proteins and lipids [3-5]. 
Cell damage often results in apoptosis or necrosis. 
Antigens in a variety o f autoimmune diseases, 
including systemic lupus erythematosus (SLE), 
type 1 diabetes (T1D), and rheumatoid arthritis 
(RA) have been shown to be oxidatively modified 
[6,7]. The observed oxidative modifications o f the 
antigens targeted in these diseases can be diverse. 
For example, Ro60, a 60 kDa antigenic target for 
antibodies present in a subset of SLE patients, can 
be modified by lipid oxidation products resulting in the 
formation o f aldehydes, mainly 4-hydroxy-2-alkenals. 
In addition, during inflammation non-enzymatic 
reactions can result in the production o f so-called 
“advanced glycation end” products (AGE), which 
can be associated with proteins [8]. AGE-modified 
antibodies are found amongst others in rheumatoid 
arthritis patients and are believed to be the result 
o f inflammation and/or oxidative stress [9]. The 
generation o f anti-IgG-AGE appears to be specific 
for a subset o f RA patients suggesting that the 
modification o f distinct proteins can result in different 
clinical phenotypes [10].
To further investigate whether oxidative stress 
conditions are able to cause distinct post-translational 
modifications (PTM) of autoantigenic proteins, we 
studied the effects o f ROS-inducing compounds on 
intracellular proteins.
Materials and Methods
Cell lines
Jurkat (human T cell lymphoma) cells were cultured in 
RPMI 1640 GlutaMAXTMI (Gibco-BRL) supplemented 
with 10% heat-inactivated fetal ca lf serum (Gibco- 
BRL), 25 mM Hepes-KOH, pH 8.0, 1 mM penicillin,
1 mM streptomycin, and 1 mM sodium pyruvate.
The cells were grown in a humidified 37 °C incubator 
containing 5% CO2 and maintained at a cell density of 
0.5 to 1.2 x 106 cells/ml.
Induction o f oxidative stress and cell extract 
preparation
Oxidative stress was generally induced by incubation 
o f Jurkat cells in culture medium supplemented with 
48 mM H2O2 (Acros Organics; Geel, Belgium) for 5 
hours, or as indicated. Alternatively, Jurkat cells were 
subjected for the indicated periods of time to 15 mM 
NaOCl in culture medium. Cells were harvested by 
centrifugation and resuspended in sonication buffer 
(20 mM Hepes-KOH, pH 7.4, 100 mM KCl, 0.5 mM 
PMSF, 0.1% NP-40, 2 mM EDTA, 1 mM DTE) at a 
concentration of 108 cells/ml and lysed by sonication 
on ice. Cell debris was removed by centrifugation for 
15 min at 16,000xg and supernatants were stored at 
-20 °C until use.
In vitro oxidative modification
Recombinant U1A and Jo-1 proteins were purified 3 3  
as described below, after which the buffer was 
exchanged with KRB-buffer (20 mM Hepes-KOH, pH 
7.4, 127 mM NaCl, 5.5 mM KCl, 10 mM glucose, 1 mM 
CaCl2, and 2 mM MgSO4) using over night dialysis at 
4 °C in 10 kDa cut-off Spectra/Por® 6 tubes (VWR). 
Recombinant proteins were subjected to oxidative 
conditions generated by the Fenton reaction by 
incubation with 100 pM Fe(SO4) and 1.7 mM ascorbic 
acid in KRB-buffer with or without 13 mM H2O2 for 
30 minutes. The reaction was stopped by adding 10 
mM EDTA. Alternatively, recombinant U1A and Jo-1 
protein was subjected for up to 30 minutes to 1.5 mM 
NaOCl in KRB-buffer.
Gel electrophoresis and immunoblotting 
Extracts from normal or oxidized Jurkat cells and 
material from mock or in vitro oxidized recombinant 
proteins were separated by electrophoresis in 
polyacrylamide gels and stained with colloidal 
Coomassie Brilliant Blue (CBB; 0.08% CBB G250,
1.6% ortho-phosphoric acid, 8% ammonium sulfate 
and 20% methanol) or transferred to nitrocellulose 
membranes by electroblotting. Membranes were 
blocked with 5% non-fat dried milk in PBS containing
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Fig. 1 Hydrogen peroxide-induced autoantigen m odification in Ju rka t cells.
(A) Extracts o f Jurkat cells which were treated fo r 5 hours w ith  0.15%  H2O 2 (H2O 2) or extracts o f non-treated Jurkat cells (Ctrl) were analyzed by 
im m unoblotting. W estern b lots conta ining the  respective extracts w ere  incubated w ith  patient sera containing antibody reactivities aga inst U1A or 
Jo-1, mouse monoclonal antibod ies reactive w ith Ro60 and La or w ith rabbit antibod ies directed to  the  exosom e prote ins Rrp40 and Rrp41. The 
positions o f the modified prote ins are indicated w ith asterisks. (B) Ju rka t cells w ere  cultured fo r 0 -  360 min after the  addition o f H2O 2 to  a final 
concentration o f 0.15% . Cell extracts w ere  separated by SDS-PAG E and stained w ith  Coom assie  B rilliant Blue.
0.05% Tween-20 (MPBST). Mouse monoclonal 
antibodies (anti-U1A, 9A9, anti-Ro60, 1D11, and anti­
La, SW5), rabbit polyclonal antibodies (anti-Rrp40, 
H70, anti-Rrp41, H71) and human patient sera (anti- 
Jo-1, anti-U1-70k and anti-topoisomerase I) were 
diluted in MPBST prior to the detection of proteins 
on western blot. As secondary antibody, horseradish 
peroxidase-conjugated rabbit-anti mouse IgG, 
swine anti-rabbit IgG or rabbit-anti human IgG 
(Dako Immunoglobulins) were used, respectively, 
in MPBST. Bound antibodies were visualized by 
chemiluminescence.
Recombinant protein production and purification 
The recombinant U1A and Jo-1 proteins were 
expressed in E. coli and purified as described 
previously [11,12]. The purified proteins were pooled 
and stored at -80 °C until use.
Results
Autoantigens are modified in oxidatively stressed 
Jurkat cells
Reactive oxygen species such as O H \ O2", and H2O2 
are able to induce cell death. Saito and colleagues 
describe apoptotic and necrotic phenotypes in Jurkat 
cells that were exposed to low or high concentrations 
o f H2O2, respectively [13]. The radicals generated 
during oxidative stress may lead to distinct cleavage 
products (Hof et al. unpublished results) or oxidation 
specific modifications in biomolecules that trigger
an immune response. Jurkat cells were subjected 
to similar levels o f oxidative stress as described 
by Casiano et al., by adding 48 mM H2O2 to the 
medium followed by culturing for 5 hours [1]. Cell 
lysates were prepared and analyzed by SDS- 
PAGE and immunoblotting. For all autoantigenic 
proteins analyzed (Ro60, La, Jo-1, U1A) a retarded 
electrophoretic mobility was observed (Fig. 1A). In 
addition, a mobility shift was observed for two human 
exosome core proteins, Rrp40 and Rrp41 (lanes 8, 
10). Interestingly, in the case o f Rrp41 two retarded 
species were observed. For the Ro60 antigen and 
possibly the La protein, not all molecules appeared 
to be modified after 5 hours in the presence of H2O2, 
since a signal similar to the non-modified sample 
could be detected as well (lanes 2, 6). Because the 
migration o f all proteins analyzed by immunoblotting 
appeared to be affected, cells were subjected to 
H2O2-induced oxidative stress for various periods 
o f time and the migration o f all proteins detectable 
by total protein staining o f the SDS-PAGE gels was 
examined. A highly sim ilar staining pattern was 
observed up to 180 min, after which several changes 
became apparent (Fig. 1B). These data indicate that 
after several hours o f oxidative stress many proteins 
undergo changes that affect their electrophoretic 
mobility in SDS-PAGE.
To investigate the rate o f modification of the 
autoantigenic proteins, their electrophoretic mobility 
was determined after different incubation times with 
48 mM H2O2. The results revealed strong differences
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Fig. 2 K inetics of autoantigen modification in oxidative ly stressed 
Jurkat cells.
Jurkat cells were treated w ith 0.15% H 2O 2 fo r the  indicated periods of 
time. Cell extracts w ere separated by SDS-PAG E and specific  proteins 
were visualized by im munoblotting using a patient serum containing 
antibod ies d irected against Jo-1, mouse monoclonal antibod ies to 
the U1A and Ro60 proteins, and a rabbit polyclonal antibody against 
Rrp41. The anti-U1A  monoclonal antibody cross-reacts with the U2B’: 
protein. Modified prote ins are indicated w ith asterisks.
between the rates by which the different proteins 
were modified. At 180 minutes the Ro60 antigen 
shows a transition o f the non-modified to the oxidized 
protein (Fig. 2), and after 240 minutes the conversion 
is virtually complete. The Jo-1 and U1A proteins 
were completely modified after 120 and 180 min, 
respectively. Rrp41 was shifted completely after 120 
min, whereas the second retarded Rrp41 species 
appeared only after 180 min. The monoclonal 
antibody that was used for the detection o f U1A is 
cross-reactive with the U2B’’ protein [14]. Also U2B” 
appeared to be shifted, which was already detectable 
after 15 minutes and became complete after 60 
min. It should be noted that the signal intensities 
obtained with material from cells exposed for more 
than 180 minutes to H2O2 tended to decrease, which 
may result from the loss o f membrane integrity and 
intracellular content or from the disruption o f the 
epitopes recognized by the antibodies used (Fig. 2).
modificationConcentration-dependent 
autoantigens
To investigate whether similar oxidative modifications 
were observed at milder conditions, Jurkat cells were 
treated with different concentrations o f H2O2, ranging 
from 0.03 mM to 48 mM, for 5 hours. Only at the higher 
concentrations, 32 mM and 48 mM H2O2, a mobility 
shift for the U1A protein was observed (Fig. 3). The 
migration of U2B” was also affected at the higher 
H2O2 concentrations, although this did not seem to 
be as pronounced as that o f U1A. The relatively high
of
F ig. 3 Hydrogen peroxide concentration-dependent autoantigen 
modification.
Jurkat cells were cultured in the presence of various concentrations 
o f H2O 2 fo r 5 hours, after which cell extracts were analyzed by 
im munoblotting (lanes 4-11). W estern blots containing extracts of 
untreated (Ctrl) and treated cells were incubated w ith patient sera 
containing autoantibod ies aga inst DNA topo isom erase I (Topo I) or U1- 
70k. U1A w as detected with a monoclonal antibody tha t cross-reacts 
with the U2B ’’ protein (top panel). The modified protein s igna ls are 
indicated w ith asterisks. As add itiona l controls, cells were treated with 
0.15% H2O 2 for 5 hours to induce necrosis (lane 2), or 8 hours with 40 
^.M anisom ycin to induce apoptosis (lane 3). The induction of necrosis 
was m onitored by the appearance of the 45 kDa cleavage product of 
Topo I, Topo I CL (m iddle panel), whereas the induction o f apoptosis 
was m onitored by the appearance of the 40 kDa cleavage product of 
U1-70k, U1-70k CL (bottom panel). Note tha t Topo I in apoptotic cells is 
cleaved into a 70 kDa product (arrowhead), in agreem ent w ith previous 
observations.
concentrations of H2O2 may induce cell death and 
therefore the migration alterations observed may be 
associated with cell death. Hydrogen peroxide has 
been reported to induce necrosis [1], and therefore 
the induction of necrosis was monitored by the 
cleavage o f topoisomerase I (Topo I), which leads 
to a characteristic 45 kDa cleavage product. Indeed, 
the Jurkat cells appeared to become necrotic after 
exposure to the H2O2 concentrations that led to 
U1A and U2B” modification (Fig. 3) [1]. In contrast, 
relatively low H2O2-concentrations (0.03 mM -  0.3 
mM) induced apoptosis, as demonstrated by the 
specific fragmentation o f U1-70 kDa (Fig. 3). These 
concentrations did not result in a detectable mobility 
shift o f the U1A and U2B’’ proteins. Jurkat cells 
rendered apoptotic by anisomycin treatment were 
analyzed in parallel as a reference. Note that, as 
reported previously [1], also the Topo I protein was 
cleaved in apoptotic cells, resulting in a cleavage
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Fig . 4 In vitro oxidation o f recom binant Jo-1 and U1A.
Recom binant Jo-1 (recJo-1) and U1A (recU IA ) prote ins (Ctrl) were 
incubated under oxidative conditions generated by the  Fenton reaction. 
Material from  reactions supplem ented w ith H2O 2 is indicated w ith + 
(lane 2), w hereas material from  reactions w ithou t H2O 2 is labeled - 
(lane 3). Prote ins were v isualized using a patient serum  containing anti- 
Jo-1 or a m onoclonal anti-U1A  antibody. The positions o f the  retarded 
pro te ins (lane 2) are indicated with asterisks.
product that is different from that in necrotic cells. 
These data suggest that the observed oxidative 
modification o f antigens is primarily associated with 
H2O2 concentrations that induce necrosis.
In vitro oxidation of purified recombinant autoantigenic 
proteins
The exposure of Jurkat cells to H2O2 results in the 
elevation o f both extracellular and intracellular ROS 
levels. To investigate whether hydroxyl radicals, 
which are the main direct ROS emerging from H2O2, 
are involved in the modification reactions, purified 
recombinant autoantigenic proteins were exposed to 
hydroxyl radicals generated by the Fenton reaction 
3 6  [15-18]. In this reaction ferrous iron (Fe2+) is oxidized 
by H2O2 to yield ferric iron (Fe3+), a hydroxyl anion 
(OH-) and a hydroxyl radical (OH^). Both U1A and 
Jo-1 were oxidized in vitro, after which the proteins 
were analyzed by immunoblotting using a mouse 
monoclonal anti-U1A antibody and a anti-Jo-1 positive 
patient serum. The recombinant proteins were 
incubated under conditions generated by the Fenton 
reaction either in the presence o f or the absence of 
H2O2 (Fig. 4). After incubation in the presence of 
H2O2 the migration of both U1A and Jo-1 in SDS- 
PAGE appeared to be retarded, very similar to what 
was observed for these proteins from H2O2 treated 
Jurkat cells. The mobility shift was not observed when 
the proteins were incubated without H2O2. The results 
suggest that the observed protein modifications are a 
direct effect o f H2O2 or its products generated in the 
Fenton reaction.
Oxidative stress-induced protein modification is O f  
independent
To obtain more insight into the ROS species that 
are responsible for the detected modifications in 
Jurkat cells, we incubated these cells with two other 
ROS generators, menadione and paraquat, which
Fig. 5  The effect o f superoxide-induced oxidative  stress on 
autoantigen ic proteins.
Jurkat cells were treated fo r 2 hours w ith va rious concentrations of 
m enadione (A) or 24 hours w ith va rious concentrations o f paraquat 
(B). Cell extracts were separated by SDS-PAGE and analyzed 
by im m unoblotting using an anti-Jo-1 positive patient serum  or a 
monoclonal anti-U1A /anti-U 2B” antibody
generate O2'- inside the cell [19,20]. Jurkat cells 
treated with up to 0.4 mM menadione (Fig. 5A) or 
up to 0.4 mM paraquat (Fig. 5B) were lysed and 
analyzed by immunoblotting and FACS analysis. 
After treatment intracellular superoxide anion levels 
were monitored in Jurkat cells using FACS analysis 
and the fluorescent hydroethidine probe (data not 
shown). Although both menadione and paraquat 
treatment did result in an increase in the intracellular 
superoxide anion concentration, neither menadione 
nor paraquat led to the detectable modification o f the 
U1A and Jo-1 proteins.
Hypochlorous acid-induced autoantigen modification 
Since H2O2 may lead to the production o f OH' in cells, 
it is possible that H2O2-derived OH' plays a role in the 
observed modification of proteins. Neutrophils and 
monocytes express the enzyme myeloperoxidase 
(MPO), which plays a pivotal role in the destruction 
o f pathogens. MPO produces hypochlorous acid 
(HOCl), which can react with many biomolecules, 
e.g. oxidize thiols, damage side-chains, or induce 
the fragmentation or aggregation of proteins [21]. 
However, through its reaction with O2'- or Fe2+, HOCl 
also is a potent generator of the highly reactive OH' 
radical [22]. To investigate whether OH' is involved 
in electrophoretic mobility shifts o f proteins as have 
been observed after exposure to H2O2, Jurkat cells 
or recombinant proteins were subjected to the 
alternative OH' generator, HOCl. Subsequent to
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Fig . 6 The e ffect o f hypochlorous acid on Jo-1 and U1A.
(A) Ju rka t ce lls w ere treated with 0.1%  NaOCl fo r the  indicated periods 
o f tim e (m inutes; lanes 2-4), after which cell extracts w ere  prepared and 
analyzed by im munoblotting using m onospecific anti-Jo-1 or anti-U1A 
antibodies. In lane 1 material from  untreated cells w as loaded (Ctrl). 
Lane 5 conta ins extract o f Jurkat cells tha t were treated for 2 hours 
w ith 0.15%  H2O 2. The positions o f modified prote ins are m arked with 
asterisks. (B) R ecom binant Jo-1 (recJo-1) and U1A (recU1A) proteins 
were treated e ither fo r 5 or 30 min w ith 0.01%  NaOCl and visualized by 
im m unoblotting as in panel A. The  positions o f recJo-1 and recU1A in 
treated sam ples are indicated w ith asterisks.
0.1% or 0.01% NaOCl treatment o f Jurkat cells or 
recombinant proteins, respectively, samples were 
analyzed via immunoblotting. Both Jo-1 and U1A 
proteins from Jurkat cells showed a mobility shift 
already 30 min after the addition of NaOCl, which 
resulted in a similar electrophoretic mobility as 
observed after H2O2 exposure (Fig. 6A). RecJo-1 and 
recU1A became modified upon NaOCl treatment as 
well (Fig. 6B). A migration shift that was comparable 
to that upon H2O2, exposure was already detected 
after a 5 minute incubation in the presence o f NaOCl. 
Since mobility shifts in NaOCl treated samples 
were highly similar to those observed under H2O2 
conditions and the chemical nature o f radicals after 
H2O2 and NaOCl decomposition resemble each other, 
suggest that OH' radicals are responsible for the 
observed electrophoretic differences.
Discussion
The post-translational modification o f proteins 
can generate neo-epitopes, which in predisposed 
individuals can initiate an immune response and 
eventually lead to the loss o f immunological tolerance 
and autoimmunity. Here we report that autoantigenic 
proteins associated with various autoimmune 
diseases are modified upon their exposure to OH'. 
Oxidative modifications can have a variety o f effects on 
the affected biomolecule, e.g. loss or gain of function. 
In rabbits that have been immunized with oxidized 
Ro60 an accelerated disease process was reported,
in contrast to their non-oxidized counterparts [23]. A 
similar mechanism might be involved in the loss of 
immunological tolerance in autoimmune patients.
The altered electrophoretic mobility o f Jo-1 is in 
agreement with the results o f our previous studies 
on the oxidative modification o f Jo-1 in H2O2-treated 
Jurkat cells (Van Dooren et al., manuscript submitted 
for publication). The effects of H2O2 treatment were 
less pronounced for the Rrp40 and La proteins, 
which may be explained by differences in the number 
or m icroenvironment o f amino acids that can be 
oxidized. In addition, oxidative modification o f one 
residue could result in a conformational change of the 
protein and a concomitant increased susceptibility to 
oxidation o f other amino acids. This could explain the 
step-wise modification as observed for Rrp41.
The total protein analysis of the H2O2-treated Jurkat 
cell extracts revealed that particularly after three 
hours of oxidative stress important changes were 
observed, which at least in part will be due to the 
induction o f necrosis as indicated by the appearance 
o f the specific topoisomerase I cleavage product, 
but to oxidative protein modifications as well, as is 
evident from the western blot analyses. The number 
o f proteins that appear to become modified upon H2O2 
exposure implies that oxidative modification is not a 
unique feature of autoantigenic proteins. Remarkably, 
the modifications o f Ro60, Jo-1, Rrp41, and U1A did 
not occur simultaneously, and, although differences in 
the rate by which these proteins are oxidized clearly 
exist, all autoantigenic proteins analyzed appeared to 
be modified prior to the initiation of the major changes 
affecting the total protein pattern. It will be interesting 
to investigate whether autoantigenic proteins tend 
to be modified relatively fast (Fig. 2). Importantly, 
only concentrations o f H2O2 that are able to induce 
necrosis result in oxidatively modified proteins, 
which implies that the modifications may also be 
caused by necrosis-associated activities. Another 
open question is whether the oxidatively modified 
autoantigenic proteins, in contrast to other proteins, 
are exposed to the immune system and lead to a 
modification-dependent immune response. For such 
studies, techniques that allow the specific detection 
o f modified epitope targeting autoantibodies are 
needed.
Since H2O2-induced necrosis might be involved in the 
observed modifications, the possibility existed that 
intracellular ROS (e.g. from mitochondria) played 
a role. However, none o f the alternative necrosis 
induction methods (e.g. the exposure to ethanol, 
HgCl2 or heat) [24-26], which are associated with 
mitochondrial damage, nor generators o f intracellular 
superoxide radicals [19,20] led to modifications with
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a similar retarded electrophoretic mobility (data not 
shown and Fig. 5). Because the alternative necrosis 
induction methods, through mitochondrial damage, 
also mainly generate intracellular superoxide anion 
radicals, we conclude that superoxide radicals do 
not play a major role in the oxidative modification 
o f the autoantigenic proteins. The hydroxyl radical, 
O H \ on the other hand, appears to be strongly 
involved in the oxidative modification o f the proteins 
studied here, since both the in vitro oxidation of 
recombinant proteins and the treatment of Jurkat 
cells or recombinant proteins with NaOCl resulted in 
a mobility shift similar to that observed in H2O2 treated 
material (Fig. 4 & 6). The exact chemical nature of 
the modifications caused by the exposure to hydroxyl 
radicals requires further investigation, e.g. by the 
isolation of modified proteins and their analysis by 
mass spectrometry.
Taken together, our data show that the exposure to 
hydroxyl radicals leads to rapid oxidative modifications 
o f autoantigenic proteins, which can be monitored via 
their altered electrophoretic mobility in SDS-PAGE 
gels. These modifications are probably not unique 
for autoantigenic proteins, although differences in the 
rate of modification may exist. The questions whether 
autoantigenic proteins are generally modified faster 
than non-autoantigenic proteins and whether the 
oxidative modifications lead to the formation o f neo­
epitopes, require further investigations.
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Abstract
The aminoacyl-tRNA synthetases (aaRS) are ubiquitously expressed enzymes that catalyze the esterification of 
amino acids to their cognate tRNAs. Autoantibodies against several aaRS are found in autoimmune polymyositis 
and dermatomyositis patients. Because necrosis is often found in skeletal muscle biopsies of these patients, 
we hypothesized that cell death-induced protein modifications may help in breaking immunological tolerance. 
Since cell death is associated with oxidative stress, the effect o f oxidative stress on the main myositis-specific 
autoantibody target Jo-1 (histidyl-tRNA synthetase; HisRS) was studied in detail. The exposure o f Jurkat cells 
to hydrogen peroxide resulted in the detection of several oxidized methionines and one oxidized tryptophan 
residue in the HisRS protein, as demonstrated by mass spectrometry. Unexpectedly, the tRNA aminoacylation 
activity o f HisRS appeared to be increased upon oxidative modification. The analysis of myositis patient sera 
did not lead to the detection of autoantibodies that are specifically reactive with the modified HisRS protein. 
The results o f this study demonstrate that the Jo-1/HisRS autoantigen is modified under oxidative stress 
conditions. The consequences of these modifications for the function of HisRS and its autoantigenicity are 
discussed.
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Introduction
Aminoacylation of tRNAs plays a crucial role in the 
translation of genetic information in polypeptide 
chains. The generation o f aminoacylated-tRNAs 
depends on the ubiquitously expressed aminoacyl- 
tRNA synthetases (aaRS), which conjugate amino 
acids to their cognate tRNAs via an esterification 
reaction. In patients with idiopathic inflammatory 
myopathies (IIM / myositis), particularly polymyositis 
(PM) and dermatomyositis (DM), autoantibodies 
against several aaRS are found [1,2]. The IIM are 
a group of systemic autoimmune disorders that are 
associated with inflammation of skeletal muscles [3­
5].
Autoantibodies directed to intracellular proteins, which 
can be divided into myositis-specific autoantibodies 
(MSA) and myositis-associated autoantibodies 
(MAA), are found in up to 80% o f patients with PM 
or DM [6]. MAA are also found in other rheumatic 
disorders. MSA include autoantibodies directed 
against a component o f the nucleosome remodeling 
and deacetylase complex, Mi-2, the signal recognition 
particle (SRP) and several aaRS [7,8]. The most 
prevalent MSA is directed against the histidyl-tRNA 
synthetase, HisRS (the so-called anti-Jo-1 antibody), 
and can be detected in approximately 20% o f PM/ 
DM patients. Autoantibodies directed to other tRNA 
synthetases collectively are found in about 20% of 
myositis patients [9,10]. Environmental, genetic, 
and hormonal factors, together with the loss of 
immunological tolerance, play an important role. 
Inflammatory processes have been suggested to 
deregulate the maintenance of tissue homeostasis 
and immunological tolerance. Slight aberrations in 
apoptotic clearance mechanisms, like in systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA) 
have a great impact on the physiological processes of 
the immune system [11-13]. An increasing number of 
studies show that post-translational modifications of 
nuclear and cytoplasmic components can be involved 
in the breaking o f immunological tolerance. Specific 
polypeptide cleavages and/or unusual amino acid 
modifications occur during apoptotic or necrotic cell 
death, and have been suggested to be involved in the 
generation of neo-epitopes that are presented to the 
immune system [13-15]. In view of the autoimmunity 
associated with myositis, the infiltration o f inflammatory 
cells in the affected muscles, and the degeneration 
of muscle fibers, it is of great interest to investigate 
cell death-induced autoantigen modifications. 
Here, we studied apoptosis and necrosis-induced 
modifications of the major autoantigen in myositis, 
histidyl-tRNA synthetase (Jo-1). We focused on
post-translational modifications possibly occurring 
in the pathophysiological m icroenvironment found 
in myositis patients [16]. It has been shown that 
massive production of oxidizing agents occurs upon 
myocyte damage, suggesting an important role of 
reactive oxygen species (ROS) during muscle trauma
[17]. Both mechanical damage and T-lymphocytes 
are able to induce muscle trauma. Because human 
skeletal muscle cell lines were not readily available 
and because the induction of cell death in cultured 
mouse myoblasts and myotubes did not proceed in 
a very coordinated fashion, we decided to use Jurkat 
cells (a human T lymphoblastoid cell line), to study 
modifications of HisRS under oxidative conditions.
An increased oxidation status of the HisRS protein in 
oxidatively stressed Jurkat cells was observed, which 
unexpectedly increased its aminoacylation activity.
The potential relevance of these modifications for the 
generation of anti-Jo-1 antibodies is discussed.
Materials and methods
Cell lines
Jurkat (human T cell leukemia) cells were grown in 
RPMI 1640 GlutamaxTM-I medium supplemented 
with 1 mM sodium pyruvate, 1 mM penicillin, 1 mM 
streptomycin (Gibco) and 10% heat-inactivated fetal 
ca lf serum (PAA Laboratories GmbH). HEp-2 cells 
were grown to 80% confluency in DMEM+ (Gibco) 
containing 1 mM penicillin, 1 mM streptomycin and 43  
10% heat-inactivated fetal ca lf serum. Cells were 
cultured in a humidified incubator at 37 °C with 5%
CO2.
Induction of cell death and cell extract preparation 
Jurkat cells were maintained at a concentration of 106 
cells/ml. Induction of apoptosis was accomplished 
by the addition o f 40 pM anisomycin or various 
concentrations o f camptothecin as indicated (Sigma- 
Aldrich), followed by 8 hours incubation at 37 °C.
For the induction of necrosis, cells were exposed 
to 0.1% H2O2 and incubated for various time points 
at 37 °C. Cells were harvested by centrifugation at
1,000 g for 5 min, and washed with PBS to remove 
residual medium. Cell pellets were resuspended in 
ice-cold lysis buffer containing 50 mM Tris-HCl, pH
7.4, 100 mM KCl, 1 mM EDTA, 1 mM DTT and 1% 
Nonidet-P40 (NP-40) and lysed by sonication on ice. 
Subsequently, cell suspensions were cleared from 
insoluble material by centrifugation at 16,000 g for 30 
min at 4 °C. Cell lysates were stored at -20 °C.
Patient sera and antibodies
Patients were diagnosed with PM or DM at the
Department o f Neurology o f the University Medical 
Centre Nijmegen (The Netherlands) according to 
standard criteria [18,19]. The PM/DM patient sera 
were obtained with informed consent o f all participants 
and stored at -70 °C until use. Myositis patient sera 
with reactivity against the alanyl- (PL12) and threonyl- 
tRNA syntethase (PL7) were a kind gift o f Prof. Dr. 
N. McHugh (Royal National Hospital for Rheumatic 
Diseases, University o f Bath, UK). Polyclonal anti- 
glutamyl-prolyl-tRNA synthetase and monoclonal 
anti-methionyl-tRNA synthetase antibodies were 
purchased from Abcam (Cambridge, UK). The single 
chain monoclonal antibody (scFv) directed to HisRS 
has been described previously [20]. The monoclonal 
anti-eIF2a antibody has been described before [21] 
and the anti-IJ-actin antibody was purchased from 
Sigma-Aldrich.
SDS-polyacrylamide gel electrophoresis and 
immunoblotting
Sample buffer, containing 62.5 mM Tris-HCl, pH 
6.8, 2% SDS, 5% p-mercapto-ethanol, 10% glycerol 
and 0.005% Bromophenol Blue, was added to an 
equal volume o f cell lysate. After heating at 95 °C 
for 5 min material from 0.5*106 Jurkat cells per lane 
was loaded on 10% SDS-polyacrylamide gels and 
after electrophoresis transferred to nitrocellulose 
membranes by semi-dry western blotting. Protein 
transfer was checked by Ponceau S (Sigma-Aldrich) 
4 4  staining of the membrane. All further immunoblotting 
steps were performed under agitation at room 
temperature. Membranes were blocked with 3% non­
fat dried milk in PBS containing 0.05% Tween-20 
(Fluka BioChemika; MPBST). Patient serum in a
2,500-fold dilution or the anti-HisRS scFv (10-fold 
diluted) in MPBST was added and bound antibodies 
were detected with IRDye800-labeled goat anti-human 
or goat anti-mouse antibodies (LI-COR), 2,500-fold 
diluted in MPBST, followed by near-infrared detection 
and quantification with Odyssey 2.1 software and 
equipment.
Affinity purification
Anti-Jo-1 autoantibodies were isolated from patient 
sera by affinity chromatography using immobilized 
recombinant human HisRS protein expressed in 
E. coli (BL21) [22]. The isolated antibodies were 
covalently coupled to CNBr-activated Sepharose 4B 
(Amersham Bioscience) and used for the purification 
o f the HisRS protein from healthy and necrotic 
Jurkat cells. Anti-Jo-1-Sepharose was equilibrated 
with IPP150 (150 mM NaCl, 10 mM Tris-HCl, pH 
8.0, 0.1% Tween-20, 1 mM DTT and 0.1% NP-40). 
Cleared cell lysates, centrifuged at 16,000 g for 15
min at 4 °C, were added and incubated for 4 h in an 
end-over-end rotor at 4 °C. To minimize non-specific 
adsorption, a high salt elution step with IPP1000 (1 
M NaCl, 10 mM Tris-HCl, pH 8.0, 0.1% Tween-20,
1 mM DTT and 0.1% NP-40) was included prior to 
the elution of the bound HisRS protein by a pH shock 
(0.1 M glycine-HCl, pH 2.5). Eluted material was 
neutralized immediately with Tris-base. The purified 
HisRS preparations were stored at -20 °C until use.
Depletion of anti-Jo-1 reactivity to recombinant 
human HisRS
Anti-Jo-1 reactivity in patient sera against the 
bacterially expressed recombinant human HisRS 
protein was removed by pre-incubating the anti-Jo-1 
sera with 0.1, 1, 10, or 100 ng purified recombinant 
HisRS in 100 pl o f 400- to 50,000-fold diluted serum in 
PBS. After incubation for 30 min at room temperature, 
sera were centrifuged at 16,000 g for 30 min at 4 °C. 
The anti-Jo-1 depleted and the untreated control anti- 
Jo-1 sera were used for immunoblotting as described 
above.
Analysis of HisRS oxidation by LC-MS/MS 
Recombinant human HisRS was oxidized in vitro by 
incubation in a solution containing 1.7 mM ascorbic 
acid (Fluka BioChemika), 0.1 mM Fe(II)SO4 (Merck) 
and 0.18% H2O2 for 10 min at room temperature. The 
reaction was stopped by the addition o f 1 mM EDTA 
(final concentration). Recombinant HisRS and in 
vitro oxidized HisRS, as well as HisRS isolated from 
healthy Jurkat cells and from oxidatively stressed 
Jurkat cells (see above) were separated by 10% 
SDS-PAGE and stained using colloidal Coomassie 
Brilliant Blue (CBB; 0.08% CBB G250, 1.6% ortho- 
phosphoric acid, 8% ammonium sulfate and 20% 
methanol). The bands corresponding to HisRS 
were excised from the gel and washed with water. 
Prior to in-gel digestion, proteins were reduced 
with 1,4-dithiothreitol (6.5 mM) and alkylated with 
iodoacetamide (54 mM). After thorough washing, 
pieces were rehydrated in trypsin solution (10 ng/pl) 
on ice. After addition of 30 pl o f NH4HCO3 (50 mM, 
pH 8.5), samples were digested for 16 h at 37 °C. 
The supernatant o f the digest was collected and the 
gel pieces were washed for 15 min in 5% formic acid 
at room temperature, after which the supernatant 
was combined with the earlier fraction and stored 
at -2 0  °C. All LC-MS/MS analyses were performed 
on a LTQ-FTICR mass spectrometer (Thermo, San 
Jose, CA) connected to an Agilent 1100 series nano- 
LC system. Peptides were separated on C18 with 
a multi-step gradient o f 0.6% acetic acid (HAc) and 
0.6% HAc/80% acetonitrile. The mass spectrometer
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Fig . 1 A nalysis o f the  H isRS autoantigen in apoptotic cells.
Jurkat or HEp-2 ce lls w ere  treated w ith anisom ycin or cam ptothecin, and cell lysates were analyzed by im m unoblotting. C leavage of the  U1-70k 
protein leading to  a 40-kDa product (U 1-70k CL), w as used to  m onitor apoptosis. (A) The H isRS protein w as detected by an anti-Jo-1 positive 
patient serum  in lysates from  untreated and anisom ycin-treated Jurkat cells (for 8 h). The detection of p-actin w as included as a loading control. 
(B) Anti-Jo-1 antibod ies were used to  detect H isRS in lysates from  Jurka t and HEp-2 ce lls treated fo r 8 hours with va rious concentrations of 
cam ptothecin (CPT). The positions of m olecular we ight m arkers are indicated on the  left.
was operated in the data-dependent mode to 
automatically switch between MS and MS/MS, 
without dynamic exclusion to allow accurate spectral 
counting. Raw MS data were converted to peak lists 
using Bioworks Browser software, version 3.1.1., 
and search against the IPI human (v3.36) database 
with a precursor mass tolerance of 10 ppm and a 
product mass tolerance of 0.9 Da. In several separate 
searches, various oxidative protein modifications 
were included as variable modifications, oxidation of 
M, Y, F, W, H, L, P, R, D and N; double oxidation of 
M and W, triple oxidation of W  (see supplementary 
information), chlorination of Y and nitration of Y. To 
obtain quantitative information, spectral counting was 
performed after a final search including only oxidation 
o f M, D, F, Y and W, double oxidation o f M and W  and 
triple oxidation of W  as variable modifications. The 
minimum Mascot score accepted for identification 
o f an oxidized peptide was 30, the minimum Mascot 
score for identified spectra included in the spectral 
count was 20.
In vitro aminoacylation assay 
Healthy and H2O2-treated (2 h) Jurkat cells were 
harvested by centrifugation, 1,000 g for 5 min at 
room temperature, resuspended in MilliQ water 
supplemented with 1 mM DTT and lysed by 5 
30-second pulses in an ice-cold sonication waterbath 
(Bioruptor). The protein suspensions were cleared by 
centrifugation at 21,000 g for 30 min at 4 °C. Twenty 
million Jurkat cell equivalents were used in a 50 j l  
aminoacylation mixture, containing 100 mM KCl, 1 
mM MgCl2, 1 mM DTT, 1 mM ATP, 20 mM Tris-HCl, 
pH 7.4, 15 jM  [14C]histidine (Amersham), and 2.5 U /jl 
RNasin (Promega), and incubated for 1.5 hours at 37 
°C. Prior to RNA separation on a 6.5% polyacrylamide,
0.1 mM NaOAc, pH 5.0, 7.5 M urea gel system, the
RNA was isolated from the aminoacylation mixture 
using TRizol [23]. After electrophoresis, RNA was 
transferred to Hybond-N membranes (Amersham) 
and visualized by phosphorimaging. Total tRNAHis 
and 5.8S rRNA were visualized by northern blot 
hybridization using [32P]-radiolabeled antisense 
probes as described [24]. The hybridization with 
the antisense tRNAHis or 5.8S rRNA probes was 
performed overnight at 65 °C, in hybridization buffer 
(6x SSC, 1x Denhardt's, 0.2% SDS, and 0.1 mg/ 
ml herring sperm DNA). Subsequently, membranes 
were washed twice with buffer containing 2x SSC 
and 0.1% SDS. The hybridization of probes was 
visualized by phosphorimaging and the signals were 
quantified by Quantity One software v4.6.9 (BioRad).
Results
HisRS modifications in apoptotic/necrotic human cell 
lines
Jurkat cells were cultured in the presence of 
anisomycin to induce apoptosis and in the presence 
o f H2O2 to trigger necrosis (see Materials and 
methods). Cell lysates were separated by SDS-PAGE 
and analyzed by immunoblotting with autoimmune 
patient sera containing autoantibodies against U1- 
70k and topoisomerase I (Topo I), as biochemical 
markers of apoptosis and necrosis, respectively [25­
27]. The appearance of the characteristic cleavage 
products of these proteins (Fig. 1A and 2A) confirm 
the induction of apoptosis and necrosis, respectively. 
No change in the electrophoretic mobility o f the 
HisRS protein, which may be indicative of protein 
modification, was observed in material from apoptotic 
Jurkat cells (Fig. 1A). Also after induction o f apoptosis 
in Jurkat or HEp-2 cells by camptothecin no changes 
in HisRS mobility were detected (Fig. 1B). In the
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Fig . 2 Hydrogen peroxide induces H isRS modification.
(A) Ju rka t ce lls were cultured in the  presence o f 0.1% H2O 2 fo r the  indicated periods of time. Cell lysates were analyzed by im munoblotting 
using antibod ies to  Topoisom erase I (Topo I) to  m onitor the  induction o f necrosis, which is indicated by the appearance o f a 45-kDa cleavage 
product (Topo I CL). H isRS w as detected by anti-Jo-1 antibod ies and eIF2a served as a loading control. The position o f H isRS in the  lysates from  
H2O 2-treated cells is indicated by HisRS*. (B) The ce lls were cultured for 0 -  120 min w ith 0.1% H2O2, before they were lysed and analyzed by 
im m unoblotting w ith anti-Jo-1 antibodies. (C) Im m unoblotting analysis o f normal (0 h) and H2O 2-tre a te d  (2 h) Jurkat cell lysates using antibod ies to 
o ther autoantigen ic am inoacyl-tRN A synthetases (AlaRS, G lyRS, ThrRS) as well as to  non-autoantigen ic (G luProRS and MetRS) am inoacyl-tRNA 
synthetases.
necrotic cell extracts we observed a reduction of 
the electrophoretic mobility of the HisRS protein 
(HisRS*) that already could be detected 30 minutes 
after adding H2O2, which is several hours before the 
first detection o f Topo I cleavage (Fig. 2A, B). Eight 
hours after the induction of necrosis the intensity of 
the HisRS signals decreased, which is most likely 
due to cell death and resulting in the leakage of 
4 6  intracellular content, or to accelerated degradation 
o f the modified HisRS protein. The loss o f cytosolic 
porteins as a result o f cell death is supported by a 
similar reduction in the intensity o f the signals of the 
translation initiation factor eIF2a, which served as 
a loading control (Fig. 2A). The analysis of lysates 
from other cell lines such as 3T3, a mouse fibroblast, 
COS-1, an African green monkey kidney fibroblast, 
HEp-2, a human epithelial cell line, TE671, a human 
rhabdomyosarcoma cell line, C2, a mouse myoblast, 
and HSMM, a human skeletal muscle myoblast 
showed a similar change in electrophoretic mobility 
o f HisRS upon H2O2 treatment (data not shown). An 
altered migration pattern was also detected for other 
autoantigenic aaRS (glycyl- (EJ), threonyl- (PL7) 
and alanyl-tRNA synthetase (PL12)) and for the 
non-autoantigenic glutamyl-prolyl-tRNA synthetase 
(GluProRS) and methionyl-tRNA synthetase (MetRS, 
Fig. 2C), although for the latter synthetases the 
efficiency of modification appeared to be much lower 
than that of the autoantigenic aaRS. Other necrosis- 
inducing methods such as exposure to 0.2 mM HgCl2, 
freezing-thawing, and the exposure to 10% ethanol, 
as well as anisomycin-induced secondary necrosis 
(all with Jurkat cells) did not result in changes in
HisRS migration in SDS-PAGE gels (data not shown).
Affinity purification and characterization of modified 
HisRS
Hydrogen peroxide is a powerful oxidizing agent 
that can be converted to hydroxyl radicals with an 
even higher reactivity. This implies that the observed 
changes in HisRS migration might be caused by 
oxidative modification of specific amino acid side 
chains. To identify such amino acids the modified 
protein was isolated, proteolytically cleaved and 
analyzed by liquid chromatography followed by 
tandem mass spectrometry (LC-MS/MS). Affinity- 
purified patient anti-Jo-1 autoantibodies were 
immobilized by covalent coupling to Sepharose and 
used to isolate the HisRS protein from the lysates of 
mock-treated as well as oxidatively stressed Jurkat 
cells. In parallel, bacterially expressed recombinant 
human HisRS protein (recHisRS) was subjected to 
oxidative conditions by generating hydroxyl radicals 
in solution by the Fenton reaction (see Materials 
and methods). HisRS from healthy Jurkat and 
necrotic Jurkat cells, and the untreated and oxidized 
recHisRS were separated by SDS-PAGE and stained 
using colloidal Coomassie prior to in-gel digestion 
with trypsin. The tryptic digests were then subjected 
to high resolution LC-MS/MS on an LTQ-FTICR mass 
spectrometer and the resulting mass spectra were 
searched against all human proteins, to identify any 
peptides containing oxidized amino acids. The total 
sequence coverage of HisRS was 72-76% for the 
protein isolated from the Jurkat cells and 81-84% for 
the recHisRS protein.
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Fig . 3 Identification o f oxidized residues in H isRS from  H2O 2-tre a te d  cells.
(A) Am ino acid sequence of the  H isRS protein, with the  residues found to be oxidized in H isRS* highlighted by b lack boxes. Parts o f the sequence 
covered by the M S/MS analysis are indicated in bold. (B) Q uantita tive  com parison o f the  degree o f oxidation o f the  seven oxidized H isRS residues 
from  e ither untreated (M) or ^ O 2-tre a te d  (H) cells. The graph shows the  num ber o f identified m ass spectra corresponding to  peptides containing 
the  non-modified form  of the  am ino acid (in grey) and o f spectra corresponding to  an oxidized form  of the indicated am ino acid (in black). Numbers 
above the  bars indicate the actual num ber o f spectra  identified.
A large number o f distinct oxidative amino acid 
modifications were considered in several rounds 
o f database searching, resulting in the confident 
identification (Mascot score >30) of oxidation sites 
across all samples. Oxidized methionine (M), 
tryptophan (W), and phenylalanine residues were 
identified. Seven oxidized residues (M141, M185, 
M195, M220, M253, M369 and W432; Fig. 3A) 
were observed in the HisRS protein from oxidatively 
stressed Jurkat cells and each o f these was also 
found in the oxidized recHisRS protein (recHisRS*; 
data not shown). Representative spectra identifying 
the different peptides with oxidized residues are 
supplied in Fig. S1. The (untreated) recombinant 
protein contained additional oxidized residues, which 
were not detected in HisRS from unstressed or 
H2O2-stressed Jurkat cells and which suggests that 
additional amino acid oxidations occurred in vitro, 
e.g. during purification of recHisRS. As oxidative 
modifications can also occur on proteins not exposed 
to excessive oxidative stress and can be generated 
during sample preparation [28,29], we quantitatively 
assessed the occurrence o f the oxidized residues in 
HisRS* as compared to HisRS isolated from mock- 
treated cells. By using spectral counting, several 
o f the oxidation sites (especially M141, M220 and 
M253) were found to be significantly more present 
in HisRS*, whereas other residues were found to be
oxidized to the same extent in both samples (Fig. 3B). 
The oxidized methionine residues were only reliably 
identified in their single oxidized form (methionine 
sulphoxide) and not as the double oxidized methionine 
sulphone, whereas different oxidized forms o f W432 
in the HisRS* protein were found (Fig. S2).
Aminoacylation activity upon oxidative modification of 
HisRS
Protein modifications most likely affect not only 
structural but also functional properties o f proteins. 
To investigate the consequences of the oxidative 
modifications on the activity o f HisRS, we determined 
the aminoacylation o f histidyl-tRNA using extracts from 
healthy and H2O2-treated Jurkat cells. Radiolabeled 
([14C]) histidine was added to these extracts and 
after incubation the conjugation o f [14C]histidine to 
its cognate tRNA was determined by the isolation of 
RNAs from the reaction mixture and analysis of the 
reaction products by denaturing gel electrophoresis 
followed by phosphorimaging. The results showed 
that under these conditions the endogenous 
histidyl-tRNA was indeed aminoacylated and, more 
importantly, that the oxidative modification of HisRS 
did not abolish its activity. Interestingly, the histidyl- 
tRNA synthetase activity in H2O2-treated Jurkat 
cells appeared to be 1.7-fold higher as compared to 
mock treated cells (Fig. 4), which varied from 1.5- to
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E xtracts from mock-treated (M ock) o r H2O 2-treated (H2O 2) Jurkat 
ce lls w ere used in a tR N A  am inoacylation assay (see Materials 
and methods). Am inoacyla tion w as monitored by the conjugation 
o f [14C ]histidine to tR N A His. A s  a contro l the reaction w as perform ed 
in the presence of a 1,000-fold excess o f unlabeled histidine (Ctrl). 
Reaction products w ere analyzed by denaturing gel e lectrophoresis 
and phosphorim aging. The tR N A His and 5.8S rRNA w ere detected by 
northern blot hybridization using [32P]-labeled probes. Upper panel: 
[14C] signals; m iddle and lower panels: northern blot s igna ls fo r tR N A His 
and 5.8S rRNA, respectively.
1.9-fold higher levels between three independent 
experiments. As a control, an excess of non-labeled 
histidine was added to the reaction and this indeed 
interfered with the conjugation of radiolabeled 
histidine. The presence of (non-)conjugated histidyl- 
tRNA in each of the reaction products was monitored 
by northern blot hybridization using an in vitro 
transcribed antisense probe. The results showed that 
the total amount of histidyl-tRNA did not significantly 
differ between these samples.
Recognition of HisRS* by autoantibodies in myositis 
patient sera
As a first approach to investigate the reactivity of 
patient anti-Jo-1 autoantibodies with the modified 
protein, synthetic peptides were generated based 
upon the histidyl-tRNA synthetase sequence and 
containing either methionine or methionine sulphoxide 
at the positions identified by mass spectrometry. 
The recognition of these 13-residue peptides 
corresponding to oxidation sites M141, M220, and 
M253 by patient antibodies was determined by 
ELISA. None of these peptides appeared to be 
reactive with 26 myositis sera, irrespective of the 
methionine oxidation state (results not shown). 
Because the lack of reactivity with the synthetic 
peptides might be due to conformational limitations, 
we next analyzed the recognition of the complete 
(modified) HisRS protein on western blots by patient 
sera. Both oxidized as well as control HisRS protein 
was detected by patient antibodies. To be able to 
detect antibodies specifically targeting epitopes
Fig . 5 A utoantibody reactivity in patient sera to HisRS modified in 
^ O 2-tre a te d  Jurkat cells.
A  diluted anti-Jo-1 positive patient serum w as pre-incubated w ith an 
increasing am ount o f recom binant protein (recHisRS; lanes 1-2: no 
recH isRS added; lanes 3-4; 0.1 ng recHiRS added; lanes 5-6; 1 ng 
recH isRS added; lanes 7-8; 10 ng recHisRS added; lanes 9-10; 100 
ng recH isRS added). W estern blots containing lysates from mock- (M) 
and ^ O 2-tre a te d  (H) Jurkat ce lls w ere subsequently incubated with 
these serum samples. Bound antibod ies w ere v isualized by secondary 
antibody conjugates.
generated by the oxidative modifications, the sera 
were depleted of autoantibodies directed to the non­
modified HisRS protein prior to their incubation with 
the western blots by adding increasing amounts of 
purified recHisRS protein. Western blots containing 
extracts from healthy and H2O2-treated Jurkat cells 
were incubated in parallel with normal and depleted 
myositis sera containing anti-Jo-1 antibody. The 
results in Fig. 5 illustrate that when a relatively 
small amount of serum is used together with an 
increasing amount of recHisRS a gradual depletion 
of autoantibodies was observed. Thirty-five anti-Jo-1 
positive myositis sera, 9 sera from very early myositis 
patients, as well as 16 anti-Jo-1 negative myositis 
sera were screened for the presence of specific 
autoantibodies directed to HisRS* by this approach, 
but in none of these cases a signal that was resistant 
to depletion with recHisRS remained. Therefore, this 
approach did not lead to the detection of modification- 
specific anti-Jo-1 autoantibodies.
Discussion
Myositis is a relatively rare disease that severely 
impairs the patients' muscular system. Skeletal 
muscle dysfunction associated with mononuclear cell 
infiltration is commonly found in myositis patients. 
These local infiltrates are capable of generating high 
amounts of reactive oxygen/nitrogen species (e.g. 
during a respiratory burst), thereby inducing cell death 
mechanisms (e.g. apoptosis or necrosis) in healthy 
muscle tissue. Inflammation-induced cell death may 
result in post-translational modifications that could 
break immunological tolerance. However, continued 
stimulation of the immune system is needed for the 
development of autoantibodies and autoimmunity. 
Recently, Casciola-Rosen and collaborators found 
that regenerating myocytes in myositis patients 
express higher levels of autoantigenic proteins
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LVSELW DAGIK (W 432 double oxidized), Mascot score 58
LVSELW DAGIK (W 432 trip le  oxidized), M ascot score 52
i,.y
(including Jo-1/HisRS) compared to tissue from 
healthy controls. They suggested that this process
S u p p le m e n ta ry  F ig. 1 Identification o f all oxidation events in H isRS 
from  H2O 2-treated Jurkat cells.
M S/MS spectra obtained w ith H isRS isolated from  H2O 2-treated Jurkat 
cells, which allowed the unequivocal identification o f oxidation events 
on m ethionines M141, M185, M195, M220, M253, M368, and on 
tryptophan W 432. Indicated are the  peaks used fo r identification and 
the  Mascot score w ith which th is peptide w as identified.
might perpetuate the chronic inflammatory cycle [30]. 
Up to now only a few HisRS modifications have 
been described in literature. Ramirez-Sandoval and 
colleagues described the appearance o f a HisRS 
cleavage product o f 53 kDa upon campothecin- 
mediated induction o f apoptosis in HEp-2 cells [31]. 
We did not observe a similar cleavage product upon 
the induction o f apoptosis, neither in Jurkat nor in HEp-
2 cells treated with camptothecin or with anisomycin 
(Fig. 1A, B). In addition, HisRS has been reported to 
be cleaved by Granzyme B, which is one o f the serine 
proteases that are present in the granules o f cytotoxic 
T-cells and natural killer cells [32]. These HisRS 
fragments are able to recruit mononuclear cells in 
vitro, but whether this represents the situation at the 
damaged site and results in the initiation of innate 
and adaptive immune responses associated with the 
development of myositis still has to be investigated 
[33].
Our results demonstrate that HisRS and probably 
also other autoantigenic and non-autoantigenic aaRS 
are oxidatively modified in cell lines treated with 
H2O2. Hydrogen peroxide has been used by several 
researchers to study necrosis and this showed a 
certain cell death specificity [27]. Apoptotic pathways 
were activated by low levels of H2O2, whereas 
necrotic characteristics were observed in cells that 
were exposed to relatively high levels of H2O2. In 
addition to being an established necrosis-inducing 
compound H2O2 leads to the formation o f radicals 
that are also produced by infiltrating immune cells 
and during tissue damage in the microenvironment 
found in myositis patients’ muscles [16]. The hydroxyl
49
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S u p p le m e n ta ry  Fig. 2 O xidative m odification o f tryptophan.
Schem atic re p resen ta tion  o f the  oxidative  modification o f tryptophan 
(left-m ost structure) to  its oxidized form  (which is 16 Da heavier), to 
form ylkynuren ine (32 Da heavier) and to  kynuren ine (4 Da heavier).
radical is among the most potent oxidizing agents that 
are generated from H2O2, and can also be released 
by inflammatory cells infiltrating (muscle) tissues 
[34,35]. Resting skeletal muscle cells have been 
shown to release low amounts of superoxide anion 
and H2O 2 to the extracellular environment. These 
amounts may increase considerably with enhanced 
muscle activity [36,37]. Studies of Kerkweg and 
colleagues showed increased superoxide release 
immediately after myocyte damage [17], suggesting 
an important role of ROS in signaling mechanisms 
during tissue trauma. In order to discriminate between 
oxidative stress-mediated or necrosis-induced 
modifications, Jurkat cells were subjected to other 
necrotizing stimuli, like ethanol, freezing-thawing, 
HgCl2 , and anisomycin-induced secondary necrosis. 
None of the alternative necrosis-inducing methods 
resulted in a similar retarded HisRS migration as 
5 0  observed with ^ O 2-treated cells, suggesting that 
the observed HisRS modifications are the result 
of oxidative stress. The modification of HisRS 
appeared to be virtually complete two hours after the 
addition of H2O2, whereas at that time-point hardly 
any necrosis-specific cleavage of Topoisomerase 
I could be detected. These results suggest that the 
detected HisRS modifications are not a general 
necrotic phenomenon but might be a specific result of 
oxidative stress-induced necrosis.
High resolution LC-MS/MS analysis of the purified 
modified protein allowed the identification of several 
oxidation sites (M141, M185, M195, M220, M253, 
M369, and W432). The highest complexity of 
oxidation products was observed for W432 in both 
HisRS* and recHisRS* (Fig. S1). The oxidation of 
tryptophan is known to consist o f three sequential 
steps resulting in the formation of oxidized tryptophan, 
N’-formylkynurenine, and kynurenine, respectively 
[38] (Fig. S2). The presence of (formyl)kynurenine 
has been described in mitochondrial proteins, but 
has so far never been linked to an autoantigen or to 
autoimmunity [39]. The oxidative HisRS modifications 
might generate epitopes recognized by the immune 
system. Several epitope mapping reports determined
autoantibody activities directed against specific 
regions of the HisRS protein. Martin and colleagues 
described reactivities of anti-Jo-1 positive myositis 
sera against two amino acid stretches, namely 2-44 
and 286-509, in a HisRS fragment study covering 
the full-length HisRS amino acid sequence [40]. Two 
oxidation sites (M369, W432) found in our study 
might be related to epitopes found in the latter protein 
fragment and might hint to the origin of autoantibody 
reactivity that has been described before. Oxidatively 
modified proteins have already been implicated in the 
development of autoimmune diseases like systemic 
sclerosis (Topoisomerase I) and type 1 diabetes 
(GAD65) [41,42]. Our analyses with established 
myositis patient sera did not reveal autoantibodies 
specifically targeting HisRS epitopes generated by 
the oxidative modifications. Since such antibodies are 
hypothesized to be among the first that are produced 
upon the induction of autoimmunity, we also analyzed 
whether the modified HisRS protein is recognized by 
very early and/or ‘pre-disease’ sera. However, in 9 very 
early anti-Jo-1 positive myositis sera such antibodies 
could not be detected. Our results thus indicate that 
the oxidative modifications of HisRS are not directly 
linked to the B-cell response in myositis. Alternatively, 
the procedures applied to detect modification- 
dependent antibody reactivities might not be optimal. 
A disadvantage of synthetic peptides is that they are 
largely unstructured and will not allow the detection 
of antibodies targeting discontinuous epitopes. 
The immunoblot procedure in combination with the 
depletion of antibodies binding to the bacterially 
expressed recombinant protein may not be suitable 
for the detection of reactivity to discontinuous and/ 
or conformational epitopes, because the refolding 
of the immobilized protein on the blot might be far 
from optimal. In addition, the recombinant protein 
used for the depletion may not be completely devoid 
of oxidative modifications, which could lead to the 
depletion of modification-specific anti-Jo-1 antibodies. 
To confirm that indeed oxidative modification are 
not recognized by autoantibodies directed to HisRS 
further studies using other procedures and materials, 
e.g. sandwich ELISA, and very early or ‘pre-disease’ 
patient samples will be required. Alternatively, 
immunoprecipitation from  radiolabeled cell extracts 
or in combination with immunoblotting may provide 
opportunities to determine whether specific anti- 
HisRS* autoantibodies do exist or not. The latter 
immunoprecipitation approach with patient sera is, 
however, not possible, because the immunoglobulin 
heavy chains comigrate with HisRS in SDS-PAGE. In 
addition, also in immunoprecipitation the reactivity of 
the polyclonal patient sera with HisRS epitopes that
C hapter 4 Effect of oxidative stress-induced modifications on HisRS
are not modified under oxidative conditions would 
have to be blocked to allow the specific detection of 
reactivity with the modified epitopes. The addition of 
the recombinant HisRS protein to achieve this is not 
possible, because this would lead to co-precipitation 
o f the recombinant protein.
Oxidation of amino acids can have several 
consequences for the function o f the protein [43,44].
Surprisingly, oxidative modification o f HisRS did 
not detectably impair its aminoacylation activity.
Instead, the efficiency by which histidyl-tRNA was 
aminoacylated appeared to be slightly increased.
Pairwise alignment o f the human HisRS amino acid 
sequence with that o f histidyl-tRNA synthetases from 
other organisms, for which structural information is 
available in the PDB database, revealed that M141,
M220 and M253 do not seem to be located in regions 
that are critically important for the activity o f the 
enzyme. The enhanced activity might be explained 
by stabilization of the enzymatically active form or by 
an increased affinity for substrate molecules.
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Abstract
The aminoacyl-tRNA synthetases are conserved throughout all forms of life and catalyze the aminoacylation 
o f tRNAs, a critical step in the translation of genetic information. The aminoacyl-tRNA synthetases can be 
divided in two classes, depending on sequence phylogeny, conserved sequence motifs, and aminoacylation 
activities. Recently, oxidative stress has been implicated in the regulation o f the function of several intracellular 
proteins, and to affect aminoacylation activities. Here, we show that a covalent bond is formed between the 
two monomers of the dimeric histidyl-tRNA synthetase (HisRS) in oxidatively stressed cells. The covalent 
dimerization appeared to be sensitive to reducing agents, suggesting the involvement of disulfide bonds. The 
isolation of the crosslinked dimer followed by its analysis by mass spectrometry allowed the identification of 
four cysteines involved in disulfide bond formation. In combination with the results obtained with amino acid 
substitution mutants, two intermolecular disulfide bonds were mapped in the C-termini o f both monomers. 
In spite of the oxidative modifications of HisRS, the histidyl-tRNA aminoacylation activity in extracts from 
oxidatively stressed cells was not abolished.
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Introduction
The aminoacyl-tRNA synthetases (aaRSs) are 
found in all living organisms and catalyze the 
aminoacylation o f tRNAs. The coupling o f a particular 
amino acid to its cognate tRNA is an important step 
in translation. Eukaryotic cells contain an aaRS for 
each individual amino acid, except for the bifunctional 
glutamyl-prolyl-tRNA synthetase that takes care of 
coupling two amino acids to the corresponding tRNAs 
[1]. In addition, both cytosolic and mitochondrial 
forms of each aaRS are present in mammals [2]. 
The aminoacylation of tRNAs proceeds in a two step 
reaction: (1) the amino acid is adenylated via a reaction 
with ATP, which results in aminoacyladenylate and 
pyrophosphate, and (2) the adenylate is replaced by 
the terminal adenosine residue o f the tRNA acceptor 
stem. These so-called charged tRNAs deliver the 
attached amino acid in a codon-dependent manner 
to the ribosome associated with the mRNA to be 
translated. The aaRSs are divided into two classes 
and three sub-classes based on their sequences, 
conserved sequence motifs, and aminoacylation 
activities. The catalytic domain o f Class I aaRSs 
contains a Rossmann fold and two highly conserved 
sequence motifs whereas Class II aaRSs are 
characterized by an anti-parallel U-sheet surrounded 
by a-helices and three conserved sequence motifs 
[3]. Additionally, Class I enzymes mainly form 
monomeric and dimeric complexes and aminoacylate 
the 2'-OH group o f the terminal ribose o f tRNA, after 
which the aminoacyl group is transferred to the 3'- 
OH by a transesterification reaction. Class II aaRS 
usually form dimeric and tetrameric structures and 
aminoacylate the 3'-OH group of the terminal ribose. 
All individual aaRSs, except lysyl-tRNA synthetase 
(LysRS), belong to either Class I or Class II throughout 
all forms o f life. This high level o f conservation of 
structural and functional characteristics emphasizes 
the importance of these enzymes in translation. 
However, during evolution many individual aaRSs 
developed distinct structural features, additional 
domains, and new biological functions in addition to 
their canonical activities [4]. The additional domains 
are suggested to facilitate the formation of a so- 
called multisynthetase complex, which can be found 
in higher eukaryotes and is thought to promote 
protein synthesis, proofreading activity, and serve as 
a reservoir o f regulatory molecules that are involved 
in functions other than aminoacylation [5-7]. Recent 
investigations report a potential redox-dependent 
regulation of several aaRSs. The studies show how 
oxidative stress-induced modifications of critical 
cysteines in prokaryotic glutamyl-tRNA synthetase
(GluRS) and threonyl-tRNA synthetase (ThrRS), are 
able to impair the aminoacylation activity [8,9]. On the 
other hand, Wakasugi and co-workers reported the 
importance o f an N-terminal extension in mammalian 
tryptophan-tRNA synthetase (TrpRS), which is crucial 
for the interaction with oxidized GAPDH and the 
upregulation o f its aminoacylation activity [10]. The 
N-terminal extension shares amino acid sequence 
homology with several otherwise non-homologous 
aaRSs. This so-called WHEP (TrpRS, HisRS, Glu/
ProRS, and MetRS) domain mediates various 
(non-)canonical functions, including the assembly 
o f a multisynthetase complex, tRNA binding and 
enzymatic activities [11-14]. We wondered whether 
human WHEP domain containing aaRSs are also 
regulated in a redox-dependent way. Histidyl-tRNA 
synthetase (HisRS) is a Class Ila aaRS containing 
three conserved domains as well as an N-terminal 
WHEP domain [15]. The conserved domains are 
involved in its catalytic activity, tRNA anticodon 
binding, tRNA acceptor stem interactions, and 
histidine adenylation [16-18]. Here, we describe 
the oxidative stress-induced formation o f disulfide 
bonds in HisRS homodimers. Mass spectrometry, 
computational modeling and mutagenesis studies 
provided insight in the structural aspects of the 
dimerization and revealed the residues involved.
Materials and methods
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Cell culture
Human T cell leukemia cells (Jurkat) were grown in 
RPMI 1640 GlutamaxTM-I medium supplemented 
with 1 mM sodium pyruvate, 1 mM penicillin, 1 mM 
streptomycin (Gibco) and 10% heat-inactivated fetal 
ca lf serum (PAA Laboratories GmbH). Cells were 
cultured in a humidified incubator at 37 °C with 5%
C 0 2.
Induction of oxidative stress and cell lysate 
preparation
Jurkat cells were maintained at a concentration of 106 
cells/ml. Oxidative stress was induced by exposing 
cells for various periods to 0.1% H20 2 at 37 °C. Cell 
suspensions were harvested by centrifugation at 
1,000g for 5 min, and washed with PBS. Cell pellets 
were resuspended in ice-cold lysis buffer containing 
50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM EDTA,
1% Nonidet-P40 (NP-40), with or without 1 mM DTT 
and lysed by sonication on ice. Insoluble material was 
removed by centrifugation at 21,000g for 30 min at 4 
°C. Cleared cell lysates were used immediately.
Protein digestion for LC-MS/MS 
Recombinant HisRS was separated by non-reducing 
10% SDS-PAGE and stained using colloidal 
Coomassie Brilliant Blue staining (0.08% CBB G250, 
1.6% ortho-phosphoric acid, 8% ammonium sulfate 
and 20% methanol). The band corresponding to 
dimerized HisRS was excised from the gel and 
washed with MilliQ water. To be able to determine 
cysteine residues involved in disulfide bridges, the 
protein was either reduced with 1,4-dithiothreitol 
(6.5 mM) and alkylated with iodoacetamide (54 mM) 
or directly alkylated with iodoacetamide. Following 
alkylation, the protein was in-gel digested with either 
trypsin or chymotrypsin (3 ng/|jl) for 16 h at 37 °C. The 
supernatant o f the digest was collected and the gel 
pieces were washed with 5% formic acid for 15 min at 
room temperature, after which the supernatants were 
combined and stored at -20 ° C.
Nano LC-MS/MS
All LC-MS/MS analyses were performed on a nanoLC 
LTQ-Orbitrap Velos (Thermo, San Jose, CA) mass 
spectrometer at a resolution of 60,000 at 400 m/z. 
For nanoLC, an Agilent 1200 series LC system was 
equipped with a 25 mm Aqua C18 (Phenomenex, 
Torrance, CA) trapping column (packed in-house,
i.d., 100 jm ; resin, 5 jm )  and 400 mm ReproSil-Pur 
C18-AQ (Dr. Maisch GmbH, Ammerbuch, Germany) 
analytical column (packed in-house, i.d., 50 jm ; resin, 
5 8  3 jm ). Solvents used where 0.6% HAc (buffer A) and 
0.6% HAc/80% acetonitrile (ACN) (buffer B). Trapping 
was performed at 5 jL /m in  for 10 min, and elution was 
achieved with a gradient o f 13-32% B in 30 minutes, 
32-40% B in 5 minutes, 40-100% B in 2 minutes and 
100%B for 2 minutes. The flow rate was passively 
split from 0.6 mL/min to 100 nL/min. Nanospray was 
achieved using in-house made distally coated fused 
silica emitters (o.d., 375 jm ; i.d., 20 jm )  biased to 1.8 
kV. The mass spectrometer was operated in the data 
dependent mode to automatically switch between 
MS and MS/MS. Survey full scan MS spectra were 
acquired from m/z 350 to m/z 1500 and the two most 
intense ions were fragmented using CID, ETD (in the 
LTQ) and HCD (in the Orbitrap). The target ion setting 
was 5e5 for the Orbitrap, with a maximum fill time of 
250 ms. Fragment ion spectra were acquired with a 
target ion setting o f 5e3 and a maximum fill time of 
100 ms in the LTQ and a target ion setting o f 3e5 and 
a maximum fill time of 500 ms in the Orbitrap. The 
normalized collision energy was set to 35% for both 
CID and HCD. Supplemental activation was enabled 
for ETD. Dynamic exclusion for selected precursor 
ions was set at 30 seconds.
LC-MS/MS data processing and analysis 
Raw MS data were converted to peak lists using 
Proteome Discoverer (v1.2). For protein and peptide 
identification, MS/MS data were searched against 
all human proteins in the Swissprot database, using 
Mascot v2.2 (Matrix Science) with the appropriate 
enzyme, allowing up to 2 miss cleavages. 
Carbamidomethylation of cysteine was set as a 
fixed modification and oxidation o f methinione and 
tryptophan, double oxidation of methinione and 
tryptophan and triple oxidation of tryptophan were 
included as variable modifications. Precursor mass 
tolerance was set at 15 ppm and fragment ion mass 
tolerance was set at 0.9 Da for CID, 1.1 Da for ETD 
and 0.05 Da for HCD. All peptide identifications were 
combined using Scaffold and analyzed at a protein 
probability o f 99% and a peptide probability of 95% as 
specified by the Peptide Prophet algorithm [19]. For 
the identification of disulfide linked peptides, the peak 
lists were also searched using the MassMatrix search 
engine [20] against the HisRS protein sequence. 
Identification o f disulfide linkages was accepted at 
a minimum o f 2 spectra (from any fragmentation 
method), with at least one of them having a minimum 
MassMatrix score o f 15. All MassMatrix identified 
disulfide linked peptides are listed in Supplementary 
Fig. 1.
Construction of HisRS mutants 
Mammalian expression plasmids containing the 
wild-type HisRS (HisRSwt) coding sequence or a 
deletion mutant that lacked the C-terminal cysteines 
at position 507 and 509 (ACIC) were generated 
using the previously described prokaryotic HisRS 
expression plasmid [21]. Primer 1 was used in 
combination with primer 2 or primer 3 (Supplementary 
Table 1) to generate PCR amplicons corresponding 
to HisRSwt or HisRSACIC, respectively. The 50 
j l  PCR reaction mixture contained 10 mM dNTPs 
(Promega, Madison), 10 pM forward primer, 10 pM 
reverse primer, 1x cloned Pfu reaction buffer, 0.5 
U Pfu Hot start polymerase (Stratagene), and 10 
ng plasmid DNA. PCR cycles were as following: 
denaturation at 95 °C for 1 min, primer annealing at 
52 °C for 1 min, and extension at 72 °C for 2 min for 
35 cycles. Both the PCR products and the pEGFP-C1 
plasmid (Clontech) were digested with BglII (New 
England Biolabs (NEB), Ipswich) and NotI (HisRSwt 
and pEGFP-C1) or BglII and PstI (HisRS-ACIC and 
pEGFP-C1) and subsequently ligated in order to 
construct the pEGFP-HisRSwt or pEGFP-HisRS- 
ACIC, respectively. Cysteine-to-alanine mutants of 
HisRS were generated using the QuikChange site- 
directed mutagenesis approach (Stratagene). The
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substituted cysteines are C83 (primers 4 and 5), 
C174 (primers 6 and 7), C191 (primers 8 and 9), 
C196 (primers 10 and 11), C224 (primers 12 and 
13), C235 (primers 14 and 15), C379 (primers 16 and 
17), and C455 (primers 18 and 19) (Supplementary 
Table 1). Also these amino acid substitution mutants 
were cloned into the pEGFP-C1 vector. The integrity 
o f all constructs was verified by a Sanger-based 
sequencing method supported by Big Dye Terminator 
version 3 of Applied Biosystems.
Expression and in vitro oxidation of recombinant 
human HisRS
Recombinant HisRS protein production was induced 
by adding 1 mM isopropyl U-D-1-thiogalactopyranoside 
(IPTG, MP Biomedicals) to an overnight E. coli 
BL21(DE3)pLysS culture transformed with pET-3d- 
HisRS and the cells were cultured for an additional 4 
hours [22]. Subsequently, bacteria were harvested by 
centrifugation and resuspended in buffer containing 
50 mM Tris-HCl pH 7.4, 100 mM KCl, 1 mM EDTA, 
0.1% NP-40, and 1 mM DTT. The bacteria were lysed 
by 10 min 30-second pulses in an ice-cold sonication 
waterbath (Bioruptor). Recombinant human HisRS 
was purified by two consecutive anion exchange 
chromatography steps. First, the cleared bacterial 
lysate, containing recombinant HisRS, was loaded 
on a DEAE sepharose (Pharmacia Biotech) column 
in buffer A (25 mM Tris/Bis, pH 6.8, 2 mM EDTA, 0.5 
mM DTT) and bound material was eluted with a linear
0 -  1 M NaCl gradient in buffer A. The recombinant 
HisRS containing fractions were desalted using 
HiPrep™1 26/10 (Pharmacia Biotech) and loaded 
onto a Source Q15 column. The bound proteins were 
eluted by a linear 0 -  500 mM NaCl gradient in buffer 
A. The recombinant HisRS containing fractions were 
analyzed by SDS-PAGE and Coomassie Brilliant 
Blue staining, which showed that the purity was > 
95%. Prior to the in vitro oxidation, the purified HisRS 
was desalted using a Thermo ZebaTM Desalt spin 
column, and subsequently subjected to the Fenton 
reaction in a 20 j l  reaction mixture containing 0.1 mM 
Fe(II)SO4 and 1.7 mM ascorbic acid for various time 
periods. The in vitro oxidation reaction was stopped 
by the addition o f 10 mM EDTA.
Jurkat cell electroporation
Jurkat cells were transfected with the pEGFP-HisRS 
constructs using electroporation. Ten million Jurkat 
cells were washed with PBS and resuspended 
in 1 ml RPMI 1640 GlutamaxTM-I without any 
supplements prior to electroporation. Ten jg  o f DNA 
was transferred into 4 mm electroporation cuvettes 
(Cell Projects; EP-104) and mixed gently with 300 j l
Jurkat cell suspension. The electroporation settings 
(960 |j F and 250V) were optimized for Jurkat cells 
using GenepulserR II and resulted in a time constant 
o f approximately 35 ms. After electroporation cell 
suspensions were gently resuspended in 10 ml RPMI 
1640 GlutamaxTM-I medium supplemented with 1 
mM sodium pyruvate, and 10% heat-inactivated fetal 
ca lf serum (PAA Laboratories GmbH). Forty eight 
hours post transfection the cells were harvested by 
centrifugation at 1,000g for 5 min, and washed with 
PBS. Cell lysates were made as described above.
SDS-polyacrylamide gel electrophoresis and 
immunoblotting
Prior to protein separation by SDS-PAGE, (non-) 
reducing sample buffer, containing 62.5 mM 
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, (5% 
ß-mercaptoethanol,) and 0.005% Bromophenol 
Blue, was added to an equal volume of cell lysate.
After heating at 95°C for 5 min, 0.75*106 Jurkat cell 
equivalents were loaded per lane on 10% SDS- 
polyacrylamide gels and after electrophoresis 
transferred to nitrocellulose membranes by semi­
dry western blotting. Protein transfer was checked 
by Ponceau S (Sigma-Aldrich) staining of the 
membrane. All further immunoblotting steps were 
performed under agitation at room temperature. 
Membranes were blocked with 3% non-fat dried 
milk in PBS in order to prevent non-specific binding.
Patient sera, containing anti-HisRS antibodies, in a 59
2,500-fold dilution and monoclonal antibody in a 100­
fold dilution in MPBST (3% non-fat dried milk, PBS,
0.05% Tween-20 (Fluka BioChemika)) were added 
and, after incubation for 1 hour at room temperature, 
bound antibodies were detected with IRDye-labeled 
goat anti-human antibodies or goat anti-mouse (LI­
COR), 2,500-fold diluted in MPBST, followed by near- 
infrared detection and quantification with Odyssey
2.1 equipment and software.
In vitro aminoacylation
Normal and H2O2-treated (2 h) Jurkat cells were 
harvested by centrifugation, 1,000g for 5 minutes 
at room temperature, resuspended in 100 mM 
KCl, 1 mM MgCl2, 20 mM Tris-HCl, pH 7.4, and
2.5 U /jl RNasin (Promega), 1 mM DTT and lysed 
by 5 30-second pulses in an ice-cold sonication 
waterbath (Bioruptor). The cell lysates were cleared 
by centrifugation at 21,000g for 30 min at 4 °C. The 
50 j l  aminoacylation reaction mixtures contained 
100 mM KCl, 1 mM MgCl2, 1 mM DTT, 1 mM ATP,
20 mM Tris-HCl, pH 7.4, 14C-histidine (Amersham),
2.5 U /jl RNasin and 107 Jurkat cell equivalents. After 
incubation for 1.5 hours at 37 °C, TRizol was used to
Fig . 1 ROS-induced covalent coupling o f hum an HisRS dimers. Ju rka t cells w ere  exposed to  0.1%  H2O 2 fo r the  indicated periods o f tim e and cell 
lysates were prepared under reducing (A) or non-reducing conditions (B) and analyzed by im munoblotting. H isRS prote ins (HisRS, H isRS* and 
H isRS**) were visualized w ith patient serum, containing anti-H isRS autoantibodies, and fluorescently labeled secondary antibodies. The positions 
o f m olecular w e igh t m arkers are indicated on the  left and those o f (m odified) H isRS on the right. (C) Purified recom binant human HisRS was 
oxidative ly modified in vitro fo r 3 m inutes using the  Fenton reaction. M ock treated (Ctrl) and oxidized (Fenton) recom binant H isRS w as separated 
by SDS-PAG E and prote ins were detected by C oom assie  B rilliant B lue staining. The positions o f m olecular we ight m arkers are indicated on the left.
isolate total RNA, which was subsequently separated 
by electrophoresis in 6.5% polyacrylamide, 0.1 
M NaOAc, pH 5.0, 7.5 M urea gels [23]. RNA was 
transferred to Hybond-N membranes (Amersham) 
and 14C-labeled molecules were visualized by 
phosphorimaging. An antisense 32P-labeled tRNAHis 
probe was synthesized and used in northern blot 
hybridization as described previously [24]. Hybridized 
60 probes were visualized by phosphorimaging.
Results
Oxidative stress-induced covalent HisRS dimerization 
Since oxidative stress may severely affect the redox 
status in the cytoplasm, HisRS from oxidatively 
stressed cells was analyzed by SDS-PAGE under 
both reducing and non-reducing conditions. Jurkat 
cells were treated with H2O2 for up to 4 hours, lysed 
either in the presence or absence o f DTT and analyzed 
by SDS-PAGE after sample preparation either in the 
presence or in the absence of p-mercaptoethanol. 
A fter reducing sample preparation, mainly monomeric 
HisRS (54 kDa) was observed. During longer 
incubations an extra HisRS band (HisRS*) with 
decreased mobility could be seen (Fig. 1A), which is 
an oxidized form of HisRS [25]. In addition, a very 
weak signal was observed at approximately 110 kDa, 
which did not change as a result o f the treatment with 
H2O2, although a similar slight migration shift was also 
observed for this polypeptide. The analysis under 
non-reducing conditions, however, showed a gradual 
decrease o f the 54 kDa species of HisRS with a 
concomitant increase in the amount of a 110 kDa
species (HisRS**, Fig. 1B). During the first two hours 
o f treatment almost all 54 kDa molecules seem to be 
converted to the 110 kDa form. A comparison of the 
data in Fig. 1A and 1B shows that sample preparation 
in the presence of reducing agents almost completely 
converts the 110 kDa species to the 54 kDa form, 
which suggests that the 110 kDa form is generated by 
disulfide bond formation between HisRS and another 
polypeptide. Because HisRS is known to assemble 
into a homodimer and the apparent molecular mass 
is approximately twice that o f monomeric HisRS, 
the 110 kDa species might represent a HisRS 
homodimer, in which both subunits are linked via at 
least one disulfide bond. The availability o f purified 
recombinant human HisRS allowed us to investigate 
whether in vitro oxidation o f the recombinant protein 
led to the same phenomenon. Indeed, the exposure 
o f the recombinant HisRS to oxidative conditions 
generated by the Fenton reaction resulted in the 
conversion o f the 54 kDa polypeptide to a 110 kDa 
form, when analyzed under non-reducing conditions 
(Fig. 1C). Taken together, these results indicate that 
oxidative conditions both in vivo and in vitro result 
in the formation of disulfide bonds between the two 
subunits o f the HisRS homodimer.
Computational modeling of the human HisRS 
structure
To obtain an impression o f the cysteines in the human 
HisRS protein that might be involved in disulfide 
bond formation, we generated a model for the three 
dimensional structure o f the protein. Besides the 
N-terminal WHEP domain o f the human HisRS, no
Fig . 2 S tructura l model o f the  human H isRS dimer. The quaternary 
s tructure  o f the human HisRS dim er w as generated by com putational 
modeling. (A) S ubunit A is depicted in grey (catalytic domain), ye llow  
(anticodon binding dom ain), green (insertion domain), and m agenta 
(W HEP dom ain). S ubunit B is shown com plete ly in brown. (B) 
H isRS subunits A and B are shown in grey and brown, respectively, 
whereas all cyste ines in both subunits are  depicted in m agenta and 
green, respectively. The W H EP dom ain w as om itted from  the  model. 
(C) Enlarged v ie w  of the  H isRS flexib le  C -term inal ta il with cysteines 
(Cys507 and Cys509) involved in d isulfide bond form ation indicated in 
m agenta and green.
structural data are available for this protein (Protein 
DataBank (PDB) accession number: 1X59), but 
several crystal structures of bacterial HisRS proteins 
have been published [26-29]. Recently, also the 
first crystal structures of eukaryotic HisRSs were 
published, namely that o f Trypanosoma brucei and 
Trypanosoma cruzi HisRS [30]. Using the available 
HisRS structural data a model for the tertiary and 
quaternary structure of the human HisRS was built 
using YASARA software (www.yasara.org) The 
YASARA software selected pdb structure 1WU7, 
from Thermoplasma acidophilum, with an identity 
score o f 25% as the structure that would fit best to 
the human HisRS structure (Supplementary Fig.
2). The result o f computational modeling o f the 
full-length dimeric human HisRS protein, based 
on the Thermoplasma acidophilum HisRS and the 
human WHEP domain structures, is presented in 
Figure 2A. The human WHEP domain had to be fit 
manually into the structure, because the software 
was unable to combine this part with the rest o f the
protein. Therefore, the positioning o f this domain is 
speculative. As a consequence and in view o f the 
absence of cysteines in this domain, we omitted this 
domain from the structures used for disulfide bond 
analysis (Fig. 2B). In the resulting dimeric structure 
all cysteines were highlighted in yellow (subunit 
A) or green (subunit B) (Fig. 2B). The distance
between most cysteine residues does not support the 
formation o f disulfide bonds, except for two cysteine 
residues located close to the C-terminus o f the 
polypeptide (Cys507 and Cys509). The C-terminal 
tail o f HisRS seems to be rather unstructured and 
flexible, which may facilitate disulfide bond formation 
between these cysteine residues (Fig. 2C). In view of 
the putative structural flexibility o f this region either 
one or two disulfide bonds between the two subunits 
can be envisaged.
Mapping of disulfide bonds in HisRS 
To identify the cysteines involved in disulfide bond 
formation, we subjected the 110 kDa species of in 
vitro oxidized recombinant HisRS (Fig. 1B) to in-gel 
digestion using two different enzymes (trypsin and 
chymotrypsin) and analyzed the products by high 
resolution LC-MS/MS. Three different fragmentation 
techniques were applied to maximize coverage of 
the protein sequence. To facilitate the identification 
of residues involved in disulfide bonds, the protein 
was either only alkylated or reduced with DTT and 
subsequently alkylated prior to digestion. The 
sequence coverage of the human HisRS sequence 
is shown in Figure 3. When the protein was reduced 
prior to alkylation, the resulting sequences covered 
96% o f the protein, which included all cysteine 
residues except Cys83 and Cys191 (Fig. 3A). When 
the protein was not reduced before digestion, the total 
62  sequence coverage dropped to 81% and peptides 
containing Cys174, Cys196, Cys507 and Cys509 
were not found, which may suggest that these 
residues are involved in disulfide bond formation in 
the dimer.
Because the Mascot search engine does not allow 
the identification of crosslinked peptides, we also 
analyzed all MS/MS spectra using the MassMatrix 
search engine [31], allowing the specific identification 
of both intermolecular and intramolecular disulfide 
containing peptides. This resulted in the identification 
of 4 unique disulfide containing fragments (identified 
with at least 2 spectra) of the recombinant HisRS 
dimer, which are listed in Table 1. One o f these 
peptides corresponded to a disulfide bond between 
Cys83 and Cys235. However, three different peptides 
(corresponding to a total o f 18 spectra) were identified 
that contained two disulfide bonds between Cys507 
and Cys509, strongly supporting the notion that these 
two residues are involved in the interchain disulfide 
bonds covalently crosslinking the HisRS subunits in 
the dimer, as predicted by the structural model. 
Interestingly, the double disulfide bridge between 
the cysteines close to the C-terminus o f the two 
subunits suggests that two different configurations
A
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Fig. 3 Sequence coverage of H isRS by LC-M S/M S data. Sequences 
tha t were found in peptides identified by mass spectrom etric analysis 
of the  (oxidative ly modified) recom binant H isRS are m arked by gray 
shading, both for the  data obtained w ith the  reduced protein (panel 
A) and for data obtained w ith the  non-reduced protein (panel B). All 
cysteine residues in the  sequence are boxed.
of the linkage are possible, namely a parallel 
(Cys507-Cys507 and Cys509-Cys509) and an anti­
parallel linkage (twice Cys507-Cys509). Because 
the peptides resulting from these two configurations 
would have significantly different structures, we 
hypothesized that these might be separable by C18 
reversed phase column chromatography. In addition, 
specific reporter ions in the resulting MS/MS spectra 
resulting from at least two fragmentation events in 
the peptide might reveal the relative orientation of 
C-terminal elements in the covalent dimer. In Figure 
4A, extracted ion chromatograms of the precursor 
mass o f one o f these peptides (MH+ 1663.73; m/z 
832.372+) are shown for the tryptic digests of HisRS. 
These chromatograms show two distinct peaks in 
the non-reduced (-DTT) sample, which are both 
abolished upon reduction (+DTT), suggesting the 
presence o f both orientations o f the two bonds in 
the HisRS sample. To discriminate between the two 
configurations, we manually annotated the HCD 
generated MS/MS spectra o f this disulfide containing 
peptide (Fig. 4B), and used specific reporter fragment 
ions to show that the first eluting peak originated from 
the parallel configuration and the second peak from 
the anti-parallel configuration (Fig. 4A, lower panels) 
o f the two peptide chains.
Confirmation of intermolecular disulfide bond 
formation by C-terminal cysteines in vivo 
To confirm the involvement o f the two cysteines 
close to the C-terminus o f HisRS in intermolecular 
disulfide bond formation and to demonstrate that this 
also occurs in vivo, we investigated the effects of
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Fig. 4  Detailed LC-MS/MS analysis o f in term olecu larly crosslinked 
C-term inal peptide. (A) LC-MS/MS chrom atogram s o f the tryp tic digest 
o f reduced (top 2 traces) and non-reduced HisRS (bottom 4 traces). 
The top trace (gray) shows the  base peak chrom atogram  (BPC) with 
all observed peptide peaks. In black, the  extracted ion chromatogram 
trace o f the  hom odim er of peptide TG Q PLCIC  (m /z 832.37) is shown for 
the  reduced (+DTT) and non-reduced (-D TT) H isRS protein, showing 
the  presence o f tw o  iso form s o f this peptide in the  non-reduced HisRS. 
The hypothesized structure o f the  two isoform s is inserted in the  left 
part o f the  chrom atogram . The colored traces show the presence of 
specific  reporter fragm ent ions in the  HCD fragm entation spectra of 
the  peptide w ith m/z 832.37. In red, the  trace o f the y5/y5 fragm ent 
is shown, which is  present in both iso form s o f the peptide. The green 
(y2/y2) and blue (y2/y1) traces show fragm ents specific fo r the first 
eluting isoform o f the peptide, and the purple (b6/y2) and orange 
(b6/y1) trace correspond to fragm ents tha t can only be generated by 
fragm entation o f the second isoform. (B ) An HCD MS2 spectrum o f the 
peptide with m/z 832.37, averaged over both isoforms, w ith all identified 
fragm ent ions marked. Fragm ents generated from  a single cleavage 
are indicated by the normal nom enclature and fragm ents generated 
from  double cleavage are indicated w ith the iden tifie r o f both resulting, 
d isulfide linked, fragm ents. The structure o f the four m ost intense ions 
is depicted to the right o f the spectrum.
amino acid substitutions on the ability of ectopically 
expressed HisRS to form covalent dimers upon the 
induction of oxidative stress in Jurkat cells. Jurkat 
cells transfected with constructs encoding the EGFP- 
tagged wild-type or mutant HisRS were treated with 
0.1% H2O2 for 1 hour, to generate the oxidative 
conditions that stimulate disulfide bond formation 
in HisRS. Subsequently, cell lysates were analyzed 
by immunoblotting using antibodies to HisRS 
and EGFP. The EGFP-HisRS fusion protein can 
dimerize both with another EGFP-HisRS molecule 
or with endogenous HisRS, resulting in covalent 
dimers with distinct electrophoretic mobilities. The 
relative amounts of these dimers will depend on 
the relative concentrations of these molecules in 
the transfected cells. The major anti-EGFP reactive 
dimer band most likely represents the EGFP-HisRS 
homodimer, because the concentration of newly 
synthesized EGFP-HisRS (in transfected cells) will 
be significantly higher than that of newly synthesized 
endogenous HisRS. Therefore, the chance for an 
EGFP-HisRS molecule to encounter another EGFP- 
HisRS molecule will be much higher compared to a 
non-tagged HisRS partner. The results showed that 
all cysteine substitution mutants were able to form 
covalent HisRS dimers, with the exception of the 
C-terminal deletion mutant (ACIC), which lacks the
3 most C-terminal residues, including Cys507 and 
Cys509 (Fig. 5). These data strongly suggest that 
intermolecular bonds between the HisRS subunits, 
formed under oxidative conditions, are only formed 
between the C-terminal cysteines and that no other 
disulfide bonds contribute to the covalent linkage 
between the subunits of the dimer.
Oxidative modifications o f HisRS do not abrogate its 
tRNA aminoacylation activity
To investigate whether the oxidative modifications, 
including the formation of disulfide bonds, of HisRS 
affect its capacity to catalyze the aminoacylation 
of histidyl-tRNA, in vitro aminoacylation reactions 
were performed using 14C-histidine and lysates from 
either normal or oxidatively stressed Jurkat cells. The 
conjugation of radiolabeled histidine to tRNAHis was 
monitored by autoradiography. RNA was isolated
Table 1. List of peptides containing disulfide bonds in dimerized recombinant HisRS.
Peptide sequence5 MH+ A A  involved Intra /in ter chain #  peptides
TIC ($)S S VD KLD K  + C($)FKR 1758.88 C83, C235 Inter o r Intra 2
RTG Q PLC($)IC ($) + RTGQ PLC($)IC ($) 1975.93 C507, C509 Inter 4
RTG Q PLC($)IC ($) + TG Q PLC($)IC($) 1819.83 C507, C509 Inter 7
TG Q PLC($)IC ($) + TG Q PLC($)IC($) 1663.73 C507, C509 Inter 7
63
Dollar s igns indicate the  position(s) o f crosslinking
wt 83 174 191 196 224 235 379 455 ACIC
H A
-E -H isR S ** 
-H isR S ** 
-E -H isR S
-H isR S
-E-H isR S **
-E -H isR S
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Fig . 5 E ffect o f cyste ine substitu tions on d isulfide bond form ation  in H isRS dimers. Extracts o f Ju rka t cells, transfected w ith constructs encoding 
EGFP-tagged HisRS mutants and treated with 0.1%  H2O 2 fo r 1 hour (+ lanes) or untreated (- lanes), w ere  ana lyzed fo r the  presence o f covalent 
H isRS d im ers by non-reducing SDS-PAG E and im m unoblotting using anti-H isRS and anti-EG FP antibodies. The upper panels show  the  signals 
obtained w ith anti-H isRS autoantibodies. M onom eric H isRS (H isRS) and crosslinked H isRS (H isRS**) signa ls w ere  detected a t 54 kDa and 110 
kDa, respectively. In addition, s ignals tha t correspond to  (crosslinked) EGFP-tagged HisRS were detected a t approxim ately 80 kDa (E -H isR S ): 
and 160 kDa (E-H isRS**). The  lower panel shows the  results obtained w ith a monoclonal anti-EG FP antibody, which confirm s the  positions o f the 
EGFP-tagged (m utant) H isRS molecules. Jurkat cells were transfected w ith constructs encoding EGFP-tagged: wt: w ild  type HisRS; 83: HisRS- 
C83A; 174: H isRS-C174A, 191: H isRS-C191A; 196: H isRS-C196A; 224: H isRS-C224A; 235: H isRS-C235A; 379: H isRS-C379A; 455: H isRS- 
C455A; ACIC: HisRS-ACIC; or m ock transfected (-). Ce lls w ere  harvested 48 hours post-transfection.
from aminoacylation reaction mixtures, separated by 
denaturating gel electrophoresis and transferred to 
Hybond-N membranes. The aminoacylated tRNAHis 
signals were visualized via direct phosphorimaging, 
whereas 32P-labeled antisense probes were used 
to detect total (histidyl-)tRNAHis by northern blot 
hybridization (Fig. 6). The results of the northern 
64  blot showed that tRNAHis levels were comparable 
between the individual samples. Surprisingly, the 
aminoacylation o f tRNAHis was not diminished in 
lysates from the H2O2-treated cells; the signals 
obtained were reproducibly stronger (approximately 
1.6-fold, as quantified by phosphorimaging) than
His-tRNAHis
His-tRNAHis
tRNAHi*
1 2 3
Fig . 6 H isRS am inoacylation activity. Jurkat cells were m ock-treated 
or H2O 2-treated, prior to the  am inoacylation assay. The control 
am inoacylation assay sam ples (Ctrl) were supplem ented with a 
1,000-fold excess o f unlabeled-histidine. The  conjugated 14C-histidyl- 
tR N A His w as analyzed v ia  RNA isolation followed by denaturing gel 
e lectrophoresis, a fter which radiolabeled RNAs were visualized 
by phosphorim aging. Total tR N A His w as detected by northern blot 
hybridization using a 32P-labeled antisense probe.
those in the untreated cells. (Fig. 6).
Discussion
The formation o f intermolecular or intramolecular 
disulfide bridges in hetero- or homo-multimeric 
complexes might fine-tune protein activity or 
regulate protein rigidness that is needed for specific 
conformational structures. In this study we identified 
oxidative stress induced disulfide bridges in 
homodimeric HisRS.
The aaRSs fulfill an essential role in protein synthesis, 
and mischarging o f tRNAs and/or dysregulation of the 
aminoacylation activity of aaRSs can severely impair 
the production of proteins. Aminoacylation o f tRNAs 
thus can be a rate-limiting step in protein synthesis 
and optimal aaRS activity has to be ensured for 
proper translation. We previously showed that 
HisRS is oxidatively modified upon H2O2-induced 
stress which resulted in several oxidized amino 
acids in endogenous as well as recombinant HisRS 
[25]. Protein oxidation is often associated with the 
inhibition o f protein activity and/or function and can 
result in degradation by the proteosome. However, 
an increasing number o f proteins functioning in 
different cellular processes have been reported to be 
regulated in a redox-dependent manner [32-35]. The 
redox-regulated protein activity is associated with the 
oxidation and/or disulfide bond formation o f cysteine 
residues in the emerging oxidative environment. A 
variable intracellular redox-state might be involved in 
the regulation o f several different cellular processes
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S upp lem entary  Table 1. Primer sequences.
P rim er Sequence (5’ - 3 ’)
1 GG GG AG ATC TATG G CAG AG CG TG CG G CG 3
2 G G G G G CG G CCG CTCAG CAG ATG CAG AG G a
3 G G G G CTG CAG TCAG AG G G G CTG G C CTG TTCa
4 TAATCATCCG TG CCTTCAAG CG CC
5 GGCGCTTG AAG G CACG GATG ATTA
6 GAATTCTACCAGGCCGATTTTGACATTG
7 CAATGTCAAAATCGGCCTGGTAGAATTC
8 CTGATG CAGAG G CCCTG AAGATCATG
9 CATGATCTTCAG GG CCTCTG CATCAG
10 CTG AAG ATCATG G CCG AGATCCTGAG TTC
11 GAACTCAGGATCTCG G CCATG ATCTTCAG
12 GATGTTTGCTATCGCCG GTGTTTCTG AC
13 GTCAGAAACACCG G CG ATAG CAAACATC
14 GTTCCGTACCATCG CCTCCTCAG TAGACAAG
15 CTTG TCTACTGAG G AG G CG ATGG TACG G AAC
16 G CG CAAG G TG CCAG CCG TG G GG CTC AG CATTG
17 CAATGCTG AG CCC CACG G C TG G CACC TTG CG C
18 CCAG TTACAGTACG CCGAG G AG G CAG GCATC
19 GATGCCTG CCTCCTCG GCGTACTGTAACTG G
a BglII, Notl, and PstI restriction sites are underlined in prim ers 1, 2,
and 3, respectively
as a response to specific (patho-)physiological 
signals. Protein synthesis has been suggested to 
be sensitive to oxidative stress [36,37]. The data 
obtained in this study suggest that HisRS activity 
might be modulated by redox-fluctuations as well. To 
explain this at the molecular level, we have generated 
the first structural model for the human HisRS (Fig. 2) 
based upon an existing prokaryotic HisRS structure, 
which gives insight into the oxidative-stress induced 
disulfide bridge formation.
Most o f the cysteines in the human HisRS model 
are located at distances that are not suitable for 
disulfide bond formation. Only two cysteines near 
the C-terminal end of HisRS Cys507 and Cys509), 
appeared to be potentially involved in disulfide bond 
formation. The combined results o f mass spectrometry 
and MassMatrix analysis suggested that C83, C174, 
C196, C235, C507, and C509 might be involved in 
crosslinking HisRS dimers via disulfide bonds. The 
HisRS derived peptides containing C174, C196, 
C507, and C509 were not detectable in mass spectra 
obtained with non-reduced samples, in contrast 
to those obtained with reduced HisRS samples. 
This might have been caused by a shift in the m/z 
values o f the respective peptides, e.g. as a result of 
disulfide formation. Alternatively, oxidative conditions 
might affect redox-sensitive protease cleavage sites, 
although this possibility is not very likely, because two
proteases with distinct specificities were used. The 
MassMatrix search engine suggested the potential 
involvement of residues C83 and C235 in disulfide 
bond formation, although the probability was low 
(Table 1). Cysteine-to-alanine mutagenesis o f these 
residues showed no effect on the covalent HisRS 
dimerization, indicating that these cysteines are not 
involved in intermolecular disulfide bonds. However, 
an intramolecular crosslink between C83 and C235 
might still be formed, although this does not seem to be 
very likely based upon their positions in the structural 
model for HisRS. In contrast, the formation o f two 
intermolecular disulfide bonds by C507 and C509, 
as predicted by the structural model, was supported 
by both the MassMatrix and mutagenesis results. A 
detailed analysis o f the LC-MS/MS data revealed that 
these residues can lead to two distinct crosslinked 
configurations, one in which C507 and C509 of one 
subunit are coupled to the same residues of the other 
subunit, and a second in which C507 of one subunit 
is coupled to C509 of the other and vice versa. The 
occurrence of both configurations is consistent with 
the putative flexible nature of the C-terminal part of 
HisRS as predicted by the structural model.
The results of the experiments in which the 
aminoacylation o f tRNAHis was investigated in lysates 
from either mock-treated or oxidatively stressed cells 
indicate that the oxidative modification o f HisRS does 
not abrogate its enzymatic activity. Instead, a slight 
increase of tRNAHis aminoacylation was reproducibly 65  
observed. In contrast to these observations, 
pyrophosphate exchange and aminoacylation activity 
were reported to be abolished by the modification 
o f sulfhydryl groups of a prokaryotic HisRS. It was 
suggested that these modifications induced structural 
changes that affect aminoacyl activation instead of 
being directly involved in substrate binding of catalytic 
processes [38,39]. Why would HisRS become 
more active as a result o f these modifications?
Francklyn and Arnez comprehensively described the 
structural domains o f HisRS, as well as substrate 
binding interactions and the mechanism o f tRNA 
aminoacylation [40]. In addition, they developed a 
model in which conformational changes in the dimeric 
HisRS are important for proper tRNA aminoacylation.
An obvious effect o f the formation o f disulfide bonds 
between the two subunits o f the dimer is stabilization 
o f the dimer. It is well established that dimerization 
o f HisRS is required for its enzymatic acitivity, and a 
large fraction o f the HisRS pool appears to exist as 
dimers in HeLa cells [41]. If both subunits o f the dimer 
dissociate as a result o f the reaction they catalyze, 
e.g. to facilitate the release o f the charged tRNA, then 
the dimer may be more easily restored when both
MassMatrix identified disulfide linked peptides from non-reduced HisRS
Index scar.* charge score
1205 245 +4 11 Í
PP2 PPcag MH(obs) HH delta mis
3.2 2.6 401.4511 1602.7827 1602.7866 -0.0039
1326
1327
1328
1329
1330
1331
1256
1259
1265
1266
18 9.9 6.7 
14 9.8 4.1
5.8 910.4189 1819.8305 1819.8322 -0.0017
6.0 607.2819 1819.8310 1819.8322 -0.0011
2.0 607.2823 1819.8323 1819.8322 0.0001 
2.7 607.2826 1819.8332 1819.8322 0.0010
3.9 607.2828 1819.8338 1819.8322 0.0016 
4.6 607.2828 1819.8338 1819.8322 0.0016
2 2.6 416.6870 832.3668 832.3692 -0.0024
'-8 555.2485 1663.7309 1663.7311 -0.0002
.6 832.3697 1663.7321 1663.7311 0.0010
832.3704 1663.7334 1663.7311 0.0024
<.0 832.3706 1663.7339 1663.7311 0.0029
462.2340 2768.3675 2768.3892 -0.0217
Unique sequence + modifications [start:end]
1 * TIC ($1) SSVDKTIBK C($1)FST [A233:243 A83:85]
2 x TIC($1)SSVDKLD C($1)FKR
« TIC(S1)SSVDKLD ' C($1)PF® [A233:243 A83:86]
1 x RTGQPLC(Sx)IC($x) T PLC($x)IC(Sx)
1 * RTGQPLC(Sx)IC($X) T PLC($X)IC(Sx)
x RTO PLC($x)IC($X) TGQPLC ($X)IC(Sx)
X RTGQPLC ($x)IC($x) TGQPLC ($X)1C($X)
X RTGQPLC(Sx)ic(Sx) T .PLC(Sx)IC(Sx)
X RGQPLC(Sx)IC(Sx) TG.PLC(Sx)IC(Sx) [A501:509 3502:509)
0 X TG.P LC(SI)IC(SI) [A502:509]
0 V TGQPtC($x)IC(Sx) T .PLC(Sx)IC(Sx)
\ T .PLC($x) IC ($x) TGQPLC($x) IC(Sx)
% T . PLC (Sx) IC (Sx) T PLC ($x) IC(Sx)
V T .PLC (Sx) IC ($x) T PLC ($x) IC (Sx) [¿>502:509 B502:509]
1 V VEEIKEBTGQPLC($1)IC A C($1)GVSDSKF [A495:509 «222:231
CID
Index scan» charge score
1372 614 +3 14 1
1373 612 +4 13 2
1374 707 +4 10 1
1375 712 +3 18 1
1256 952 +3 12 S
1260 911 +2 10 2
1266 931 +2 10 C
PP2 ppta5 »/* MW (o6s) km delta mis.
7.1 5.0 659.3151 1975.9306 1975.9333 -0.0027
7.3 4.2 494.7382 1975.9308 1975.9333 -0.002S
6.1 1.6 494.7394 1975.9357 1975.9333 0.0024
8.3 6.8 659.3172 1975.9370 1975.9333 0.0038
9.6 14.6 555.2485 1663.7309 1663.7311 -0.0002
5.6 2.2 832.3699 1663.7325 1663.7311 0.0014 
5.9 2.2 832.3706 1663.7339 1663.7311 0.0029
Unique sequence + modifications [start:end)
2 V R .PLC(5x)IC(Sx) R ,PLC(5x)IC(Sx)
2 \ f  RTG : LC($x) IC($x) RTG3t%C<$x) IC($x)
V RTGQPLC(Sx)IC(Sx) RTGQPLC(Sx)IC(Sx)
V RTGQPLC(Sx)IC($x) RTGQPLC(Sx)IC(Sx) [A501:509 5501:509]
0 V TGQPLC(Sx)IC($x) TGQPLC($x)IC(Sx)
1 'J T QP C($x)IC(Sx) T QP C($x)IC(Sx)
I V T QP C ($x)IC($x) T QP C($x)IC(Sx) [A502:509 B502:509]
ETD
Index scant charge score pp pp2 PPtag m/i MW(obs) MH delta miss Unique sequence ♦ modifications [start:end]
1239 802 +2 15 32.5 18.8 4.8 910.4189 1819.8305 1819.8322 -0.0017 1 'I RTGQPLC(Sx)IC(Sx) TGQPLC($x)IC($x) [A501:509 B502:509 HCD
66
MassMatrix identified disulfide linked peptides from reduced HisRS
1369
1326
1310 1007
I [it
41 5.3 8.9 8.1 645.9677 1935.8884 1935.8908 -0.0024
22 2.4 7.5 3.0 607.2827 1819.8334 1819.8322 0.0012
10 1.8 5.0 3-0 832.3694 1663.7316 1663.7311 0.0005 
28 2.0 6.5 .0 890.3972 1779.7870 1779.7896 -0.0026
11 3.9 9.7 3.4 394.1341 787.2609 787.2605 0.0004
RT jPLCI ($1) TOQPLCIC(Sl) + CW4C(7}+ CAMC(17) [AS01:509 BS02:S09] 
RTG.PLC(Sx)1C($X) T .PLC(Sx)ZC(Sx) (A501:509 3502:509) 
TGQPtC($X)IC($X) T>,PLC($X) 1C (Sx) [A502:509 B502:509]
T PLCI (Si) T jPLCI (SI) + CAKC(6) + CAMC(16) (AS02:509 3502:509] 
Cl (SD CIC(Sl) + CAMC(1) + CAMC(6) [A507:509 3507:509]
CID
Index scant charge score pp pp2 PPtag m/z MW(obs) MW delta miss Unique sequence + modifications [start:end)
1348 855 *3 12 23.5 22.1 «45.9677 1935.8884 1935.8908 -0.0024 1 , RTOQPLCI (Si) TOQPLCI (51) * CAMC(7)* CM4C(17) [A501:509 BS02:509 I- ^  ^  ^
S u p p le m e n ta ry  Fig. 1 D isu lfide linked peptides identified by MassMatrix.
The M S/MS spectra o f non-reduced and reduced HisRS sam ples w ere  analyzed fo r crosslinked peptides using the  MassMatrix search engine. 
(A) Four intra- and/or in term olecu lar peptide crosslinks w ith a M assM atrix score o f a t least 15 in e ither o f the  fragm entation methods (trypsin and 
chym otrypsin) and a t least 2 spectra m atches w ere detected in peak lists o f the  non-reduced HisRS sample. (B) No intra- or in term olecu lar peptide 
crosslinks tha t meet these criteria were found in the  reduced HisRS spectra.
subunits remain covalently attached to each other via 
the flexible C-terminal tail. Alternatively, the disulfide 
bonds may affect the induced-fit mechanisms 
involved in structuring the histidine-binding pocket. 
Moreover, it should be stressed that the oxidative 
conditions also induce the oxidation o f 4 methionine 
and 1 tryptophan residue of HisRS (Van Dooren et 
al. 2011), as well as modifications o f many other 
cellular components. Obviously, also these changes 
may affect the aminoacylation activity in cell lysates. 
Further studies will be required to shed more light on 
this issue.
In conclusion, the generation o f the first structural 
model o f human HisRS helped to explain the 
formation o f disulfide bonds between the subunits
o f the HisRS homodimer, which are generated 
under oxidative conditions. Two cysteine residues 
in the flexible C-terminal region are involved in the 
covalent linkage between these subunits, which may, 
in combination with other oxidative modifications, 
slightly enhance the catalytic activity o f HisRS in 
tRNAHis aminoacylation.
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S u p p le m e n ta ry  F ig. 2 Multip le sequence a lignm ent o f HisRS.
C lusta lW  w as used to  align the  sequences o f H isRS from  H.s.: Homo sapiens, T.b.: Trypanosoma brucei, T a .: Thermoplasma acidophilum, and 
E.c.: Escherichia coli (K12). Pairw ise and multiple a lignm ent settings were set a t default. Pairw ise sequence a lignm ent identity scores o f the  human 
H isRS com pared to  the  other H isRSs are depicted in the  grey box. Identical and sim ilar am ino acids w ere highlighted by Ja lv iew  v.2.4. The  amino 
acids tha t form  the  W H EP domain, insertion domain, cata lytic dom ain motifs, and anticodon binding dom ain are indicated w ith a horizontal black 
line. Asterisk: cysteine residue involved in d isulfide bond formation.
embedded in the Netherlands Genomics Initiative.
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Abstract
The histidyl-tRNA synthetase, also known as the Jo-1 autoantigen, is one o f the main targets of the immune 
system in myositis, which is characterized by chronic inflammation of the skeletal muscles. Autoantibodies 
are found in up to 80% o f polymyositis/dermatomyositis patients and antibodies to HisRS are the most 
prevalent myositis-specific autoantibodies. Post-translational modifications have been suggested to initiate 
the loss of immunological tolerance and result in the production o f autoantibodies in a number o f autoimmune 
diseases. Since infiltrating lymphocytes and necrotic loci are found in skeletal muscle tissue o f most myositis 
patients, free radicals associated with oxidative or nitrosative stress have been implicated as important 
modifying agents. To investigate whether HisRS is modified in oxidatively/nitrosatively stressed cells, Jurkat 
cells were subjected to agents producing intracellular reactive oxygen/nitrogen species (ROS/RNS). The 
HisRS polypeptides, which are known to assemble into homodimers, appeared to be crosslinked under 
these conditions. The covalent homodimerization was resistant to reducing agents indicating that disulfide 
bonds were not involved. Superoxide and peroxynitrite scavengers inhibited the formation the covalent bonds 
substantiating the involvement of ROS/RNS. The results o f mutagenesis experiments showed that the covalent 
homodimerization of HisRS involves cysteines in the C-terminal tail o f the protein. Neither cell death nor 
alterations in the tRNA aminoacylation activity o f HisRS were detected in SIN-1-treated Jurkat cells, although 
cell growth and translation were inhibited. Autoantibodies in myositis patient sera that specifically target the 
crosslinked HisRS dimer were not detected.
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Introduction
Myositis or idiopathic inflammatory myopathies (IIM) 
can be subdivided into 3 main disorders, polymyositis 
(PM), dermatomyositis (DM) and inclusion-body 
myositis (IBM), all with their own distinct serological 
and histological features [1,2]. In up to 80% of PM 
and DM patients myositis-associated autoantibodies 
(MAA) or myositis-specific autoantibodies (MSA) can 
be found, directed against a variety o f ubiquitously 
expressed cellular components [3,4]. Myositis-specific 
autoantibodies against the main autoantigen, histidyl- 
tRNA synthetase (HisRS; anti-Jo-1 antibodies) are 
found in 20% to 30% o f PM/DM patients. Although 
the exact etiology of myositis remains unknown, the 
large number of inflammatory cells and the presence 
o f autoantibodies found in these patients suggest that 
autoimmune processes are involved. The generation 
o f neo-epitopes as a result o f modifications o f self­
proteins has been suggested to initiate an immune 
response and autoimmunity. In addition, multiple 
factors including environmental, genetic, and 
hormonal factors and defects in the clearance of cell 
remnants may contribute to the loss of immunological 
tolerance.
The levels o f reactive oxygen and reactive nitrogen 
species (ROS/RNS) are increased in autoimmune 
diseases like rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE) [5]. The direct detection 
o f ROS in vivo is difficult due to their high reactivity 
with biomolecules such as nucleic acids, lipids 
and proteins. Moreover, ROS and RNS contain 
different reactive moieties that result in distinct 
protein modifications that affect protein activity, 
folding, processing, and antigenicity. Such activities 
may facilitate the measurement o f ROS/RNS end 
products and the determination of intracellular levels 
o f radicals. Studies on synovial fluid (SF), tissue and 
sera from RA patients showed oxidized low-density- 
lipoproteins, elevated levels of protein carbonylation 
and increased recognition o f 3-nitrotyrosine by IgGs 
isolated from SF [6-8]. In SLE anti-nitrotyrosine 
antibodies have been reported that crossreact with 
single-stranded DNA, and in experimental animals 
elevated immunogenicity of RNS-modified DNA 
compared to native DNA was observed, as well 
as increased serum levels of 3-nitrotyrosine and 
protein carbonylation [9-11]. These studies suggest 
the generation o f neo-epitopes by the exposure to 
ROS/RNS, through post-translational modifications 
o f biomolecules, which are able to stimulate 
autoreactive T-cells and B-cells. Interestingly, De 
Paepe and colleagues reported elevated levels of 
inducible nitric oxide synthase (iNOS) expression in
endomysial infiltrates o f PM patients, which suggests 
the increased production o f nitric oxide (NO) and 
other reactive nitrogen intermediates in the myositis 
muscle [12]. In addition, skeletal muscle tissue 
is known to produce ROS/RNS in rest, and upon 
exercise or tissue damage the ROS/RNS levels 
increase significantly [13]. The elevated levels of 
ROS/RNS may damage the surrounding tissues 
and modify extracellular and/or intracellular proteins.
The production of equimolar amounts of NO^ and 
O2"  (superoxide anion) may lead to the generation 
o f readily diffusible peroxynitrite (ONOO-) molecules 
in the muscle tissue microenvironment. Peroxynitrite 
has been associated with protein modifications which 
are found in cytotoxicity and several autoimmune 
diseases.
In this study we investigate the effects o f ROS/RNS 
on the major myositis-specific autoantigen, HisRS, 
using the metabolite SIN-1 to stimulate the formation 
o f intracellular ONOO- . We observed covalent 
crosslinking o f the HisRS protein in SIN-1 treated 
Jurkat cells. Insight into the chemical nature o f the 
covalent linkage is provided and the possibility that 
this altered structure plays a role in the recognition by 
myositis antibodies is investigated.
Materials and methods
Cell culture, electroporation and metabolic labeling 
Jurkat T-lymphoma cells were cultured in RPMI 1640 71 
GlutamaxTM-I medium supplemented with 1 mM 
sodium pyruvate, 1 mM penicillin, 1 mM streptomycin 
(Gibco) and 10% heat-inactivated fetal calf serum 
(PAA Laboratories GmbH). Cells were maintained 
at a maximum density of 106 cells/ml in a humidified 
incubator at 37 °C with 5% CO2. Jurkat cells were 
transfected with plasmid DNA by electroporation.
Ten million cells per transfection were washed 
with PBS and resuspended in 1 ml culture medium 
without supplements. Subsequently, 10 |jg DNA 
was gently mixed with 300 j l  Jurkat cell suspension 
in 4 mm electroporation cuvettes (Cell Projects).
The electroporation settings (960 jF  and 250V) 
were optimized for Jurkat cells using GenepulserR
II and resulted in a time constant of approximately 
35 ms. After electroporation cell suspensions were 
gently mixed and resuspended in 10 ml RPMI 1640 
GlutamaxTM-I medium supplemented with 1 mM 
sodium pyruvate and 10% heat-inactivated fetal 
ca lf serum (PAA Laboratories GmbH). Forty-eight 
hours post-transfection the cells were harvested 
by centrifugation at 1,000xg for 5 min, and washed 
with PBS. For metabolic labeling logarithmically 
growing Jurkat cells were exposed for 6 hours to 0.4
Table 1. Prim er sequences
P rim ers S eq u en ce  (5 ’ - 3 ’)
1 GTGCTCAAAACCCCCGCCGGCACAAGAGAC
2 GTCTCTTGTGCCGGCGGGGGTTTTGAGCAC
3 AAGGGCACAAGAGCCTATAGTCCCCGG
4 CCGGGGACTATAGGCTCTTGTGCCCTT
5 GATACACCTGTATTTGCCCTAAAGGAAACACTGATGG
6 CCATCAGTGTTTCCTTTAGGGCAAATACAGGTGTATC
7 GTATGGGGAAGACTCCGCCCTTATCTATGACCTG
8 CAGGTCATAGATAAGGGCGGAGTCTTCCCCATAC
9 GAAGACTCCAAGCTTATCGCTGACCTGAAGGACCAGGGC
10 GCCCTGGTCCTTCAGGTCAGCGATAAGCTTGGAGTCTTC
11 GCGCAAGGTGCCAGCCGTGGGGCTCAGCATTG
12 CAATGCTGAGCCCCACGGCTGGCACCTTGCGC
13 CCAGTTACAGTACGCCGAGGAGGCAGGCATC
14 GATGCCTGCCTCCTCGGCGTACTGTAACTGG
15 GGGGAGATCTATGGCAGAGCGTGCGGCG
16 GGGGCTGCAGTCAGAGGGGCTGGCCTGTTC
mM SIN-1 or buffer as a control, after which 9 |jM 
(concentration; 11 mCi/ml, specific activity; >1000 
Ci/mmol) [35S]methionine (PerkinElmer) was added. 
Cells were cultured for another 4 hours and at the 
indicated time points, 2*106 cells were collected. Cell 
lysates were prepared according to the procedures 
described below. For cell growth experiments Jurkat 
cells were mock- or SIN-1 (0.4 mM) treated and every 
72  24 hours another dose o f 0.4 mM SIN-1 was added. 
Cell numbers were determined in triplicate with a 
Coulter A c^ T 8 (Coulter Series Analyzer, Miami, US) 
at 0, 8, 24, 48, and 72 hours after adding the first 
dose of SIN-1.
Induction of ROS/RNS stress and cell lysate 
preparation
The cells were exposed to either 0.4 mM SIN-1 
(Enzo Life Sciences; Plymouth Meeting, PA) for the 
indicated time periods or incubated with various 
SIN-1 concentrations for 8 hours at 37 °C. Cell 
suspensions were harvested by centrifugation at 
1,000xg for 5 min, and washed with PBS. Cell pellets 
were resuspended in ice-cold lysis buffer containing 
50 mM Tris-HCl, pH 7.4, 100 mM KCl, 1 mM EDTA, 
0.1% Nonidet-P40 (NP-40), and 1 mM DTT and lysed 
by sonication on ice. Insoluble material was removed 
by centrifugation at 21,000xg for 30 min at 4 °C and 
supernatants were used immediately.
Gelelectrophoresis and immunoblotting 
Prior to protein separation by SDS-PAGE, reducing 
sample buffer, containing 62.5 mM Tris-HCl, pH 6.8, 
2% SDS, 10% glycerol, 5% p-mercapto-ethanol,
and 0.005% Bromophenol Blue, was added to an 
equal volume of cell lysate. After heating for 5 min 
at 95 °C, 0.75*106 Jurkat cell equivalents per lane 
were separated by electrophoresis in 10% SDS- 
polyacrylamide gels and subsequently transferred 
to nitrocellulose membranes by semi-dry western 
blotting. Protein transfer was checked by Ponceau S 
(Sigma-Aldrich) staining. All further immunoblotting 
steps were performed under agitation at room 
temperature. Membranes were blocked with 3% 
non-fat dried milk in PBS. Patient serum in a 2,500- 
fold dilution and monoclonal antibody in a 100-fold 
dilution in PBS containing 0.05% Tween-20 (Fluka 
BioChemika; MPBST) was added and bound 
antibodies were detected with IRDye-labeled goat 
anti-human antibodies or goat anti-mouse antibodies 
(LI-COR), respectively, 2,500-fold diluted in MPBST, 
followed by near-infrared detection and quantification 
with Odyssey 2.1 software (LI-COR).
Site-directed mutagenesis
The coding sequence of HisRS was isolated from a 
previously described prokaryotic HisRS expression 
plasmid by PCR (50 j l  reaction mixture containing 
10 mM dNTPs, 10 pM forward primer, 10 pM reverse 
primer, 1x cloned Pfu reaction buffer, 0.5 U Pfu Hot 
start polymerase (Stratagene), and 10 ng plasmid 
DNA) [14]. PCR cycles were as follows: denaturation 
at 95 °C for 1 min, primer annealing at 52 °C for 1 
min, and extension at 72 °C for 2 min for 35 cycles. In 
parallel a C-terminal truncation mutant (ACIC; primer 
15 and 16) was generated that lacked the cysteines 
at position 507 and 509. The resulting cDNAs 
were inserted in the pEGFP-C1 vector (Clontech). 
Using the QuickChange site-directed mutagenesis 
approach (Stratagene) amino acid substitution 
mutants K60A (primers 1 and 2), D64A (primers 3 and 
4), E98A (primers 5 and 6), K112A (primers 7 and 8), 
Y115A (primers 9 and 10), C379A (primers 11 and 
12), and C455A (primers 13 and 14) were generated. 
See Table 1 for primer sequences.
In vitro aminoacylation assay 
Mock and SIN-1-treated (8 h) Jurkat cells were 
harvested by centrifugation (1,000xg for 5 minutes 
at room temperature), resuspended in 100 mM 
KCl, 1 mM MgCl2, 20 mM Tris-HCl, pH 7.4, 2.5 U/ 
j l  RNasin (Promega), and 1 mM DTT and lysed by 
five 30-s pulses in an ice-cold sonication waterbath 
(Bioruptor). The resulting homogenates were cleared 
by centrifugation at 21,000xg for 30 min at 4 °C. To 
study tRNA aminoacylation lysates (10x106 Jurkat cell 
equivalents) were incubated for 1.5 hours at 37 °C in 
50 j l  reactions containing 100 mM KCl, 1 mM MgCl2,
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1 mM DTT, 1 mM ATP, 20 mM Tris-HCl, pH 7.4, [14C] 
histidine (Amersham), and 2.5 U/|jl RNasin. TRIzol 
was used to isolate total RNA from the aminoacylation 
reaction mixtures and the RNA was separated in 
6.5% polyacrylamide 0.1 M NaOAc, pH 5.0, 7.5 M 
urea gels [15]. Subsequently, RNA was transferred to 
Hybond-N membranes (Amersham) and [14C]-labeled 
RNA was visualized by phosphorimaging. Anti-sense 
[32P]labeled-tRNAHis and [32P]labeled-5.8S rRNA 
probes were synthesized as described previously 
and used in northern blot hybridization [16]. The 
membranes were blocked for 1 hour at 65 °C with 
hybridization mix containing 1x Denhardt's solution, 
0.1 mg/ml herring sperm DNA, 0.2% SDS, and 6x 
SSC. Subsequently, membranes were incubated 
overnight with [32P]labeled anti-sense tRNAHis or 5.8S 
rRNA at 65 °C. The membranes were washed twice 
with 2x SSC and 0.1% SDS before hybridized probes 
were visualized by phosphorimaging. Signals were 
quantified by Quantity One software v4.6.9 (Bio-Rad).
Detection of autoantibodies to crosslinked HisRS 
Patient sera with antibodies reactive with the 
bacterially expressed recombinant human HisRS 
[14] protein were incubated with 0.1, 1, 10, or 100 ng 
purified recombinant HisRS per 100 j l  serum diluted 
400 to 50,000-fold in PBS. After 30 min incubation at 
room temperature, sera were centrifuged at 16,000xg 
for 30 min at 4 °C. The anti-Jo-1 depleted and control 
anti-Jo-1 sera were used for immunoblotting as 
described above.
Results
HisRS crosslinking upon SIN-1 treatment of Jurkat 
cells
To investigate whether HisRS is post-translationally 
modified under ROS/RNS conditions, Jurkat cells 
were cultured in the presence o f SIN-1 to generate 
ONOO-. SIN-1 is a metabolite o f molsidomine 
and decomposes spontaneously in solution in the 
presence of O2, releasing NO^ and O2"  that can react 
and form ONOO-.
Cultured Jurkat cells were subjected to 0.4 mM SIN- 
1 for several time periods. Subsequently, Jurkat cell 
lysates were separated by SDS-PAGE and transferred 
to nitrocellulose membranes for immunoblotting. The 
formation of a high molecular weight HisRS isoform 
(HisRS*) was observed in SIN-1-treated Jurkat cells 
(Fig. 1A). This polypeptide was detected both with 
an anti-Jo-1 positive patient serum and with a single 
chain antibody (scFv) directed to HisRS [17]. Since 
HisRS is known to form homodimers in vivo and the 
molecular mass (100 -  110 kDa) o f HisRS* appeared
to correspond to that o f a HisRS homodimer, the 
high molecular weight species might correspond to 
a crosslinked homodimer. The formation o f HisRS* 
appeared to be relatively efficient leading to an 
approximately 1:1 ratio between HisRS and HisRS* 
after 8 hours. Because the sample preparation was 
performed under reducing and denaturing conditions, 
the putative linkage between the HisRS polypeptides 
cannot be due to disulfide bond formation (Fig. 1A).
Cell death- and cell type-independent HisRS 
crosslinking upon SIN-1 treatment 
It has been shown that peroxynitrite can elicit either 
apoptosis or necrosis, depending on its intracellular 
concentration [18]. To investigate whether HisRS 
crosslinking is associated with the induction of cell 
death, we determined the induction of apoptosis or 
necrosis by SIN-1. Neither morphological changes 
that are characteristic for cell death nor prototypical 
molecular alterations for apoptosis (U1-70k 
cleavage) or necrosis (topoisomerase I cleavage)
[19] were observed in Jurkat cells treated with SIN- 
1 (Supplementary Fig. 1). Even with the highest 
concentrations of SIN-1 that were used (1.6 mM; 
see Fig. 1B) no detectable induction o f cell death 
was observed in cells exposed for 8 hours. Note 
that the highest concentrations of SIN-1 (0.8 mM 
and 1.6 mM) led to a slight retardation of crosslinked 
HisRS in SDS-PAGE (indicated by HisRS**). Similar 
experiments with other cell lines (HEp-2 and HeLa, 73  
two epithelial cell lines, Molt-4, a lymphoblast line, 
and TE671, rhabdomyosarcoma cells) demonstrated 
that the observed crosslinking of HisRS upon SIN- 
1 treatment is not a unique feature of Jurkat cells, 
because the same phenomenon was observed in 
the other cell lines (data not shown). To investigate 
whether other Class II aminoacyl-tRNA synthetases 
and other autoantigenic proteins showed similar 
changes after SIN-1 treatment, lysates from Jurkat 
cells treated with 0.4 mM SIN-1 for 8 hours were 
analyzed by immunoblotting using antibodies specific 
for alanyl-tRNA synthetase (PL12), threonyl-tRNA 
synthetase (PL7), phenylalanyl-tRNA synthetase 
(Zo), U1A, a U1 snRNP associated protein, and 
Rrp40, a core exosome protein. For none of these 
proteins changes in the electrophoretic mobility 
in SDS-PAGE comparable to that o f HisRS were 
observed (Fig. 1C and data not shown).
ROS/RNS scavengers inhibit HisRS crosslinking 
As described above SIN-1 decomposition forms 
O2"  and NO^ and leads to the generation of 
ONOO-. We hypothesized that at least one of these 
compounds contributed directly to the generation of
0 0.4 mM SIN-1
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Fig. 1 M odification o f H isRS in S IN -1-treated Jurka t cells.
Extracts o f m ock and S IN -1-treated Jurka t ce lls w ere  separated by SDS-PAG E and transferred to 
n itrocellu lose membranes. H isR S and o the r tR N A  synthetases w ere  v isualized by im m unoblotting using 
m onospecific  auto im m une patient sera. The  e lF2a  protein, w hich w as used as a  contro l, w a s  visualized 
using a  m onoclonal antibody. The  positions o f S IN -1-induced high m olecular w e igh t H isRS species are 
marked by asterisks. The  positions o f m olecular w e igh t m arkers a re  indicated on the  left o f each panel. 
(A ) Extracts from  Jurka t ce lls  treated w ith  0 .4  mM SIN-1 fo r the  indicated periods o f tim e. (B ) Extracts from  
Jurka t ce lls treated fo r 8  hours w ith  increasing SIN-1 concentrations (0 - 1 . 6  mM) as indicated. (C) Extracts 
o f ce lls  tha t w ere  treated fo r 8  hours w ith  0 .4  mM SIN-1 w e re  used fo r the  ana lys is  o f o ther autoantigen ic 
am inoacyl-tR N A  synthetases. Zo: phenyla lanyl-tRNA synthetase, PL7: threonyl-tR N A  synthetase, PL12: 
a lanyi-tR N A  synthetase.
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the crosslinked HisRS dimer. To shed more light on 
this, scavengers for superoxide and peroxynitrite 
were added to the Jurkat cultures during SIN-1 
treatment. The cells were treated with SIN-1 in the 
presence o f Tiron (a superoxide scavenger) [20] or 
uric acid (a peroxynitrite scavenger) [21] (Fig. 2). 
Jurkat cells treated with either 1000 |jM Tiron or 
100 j M uric acid alone showed no effects on cell 
morphology or cell survival (Supplementary Fig. 2). 
The exposure o f the cells to these compounds also 
did not lead to detectable changes o f HisRS, whereas 
SIN-1 alone as before stimulated the crosslinking of 
HisRS. The crosslinking o f HisRS appeared to be 
repressed in a concentration dependent manner by 
both scavengers, although the repression by Tiron 
was more pronounced than that in the presence of 
uric acid (Fig. 2). These results are consistent with 
the involvement o f superoxides in the generation of 
the HisRS crosslinks.
Covalent crosslinking of homodimeric HisRS 
The aminoacyl-tRNA synthetases have been 
grouped into two different classes depending on 
their conformation, conserved domains, and activity 
[22]. Crystal structure analysis and native gel 
electrophoresis confirmed that the HisRS protein is 
a Class II aminoacyl-tRNA synthetase and is able 
to form dimers [23,24]. To investigate whether the 
SIN-1-induced HisRS species indeed represents 
a crosslinked homodimer, an EGFP-HisRS fusion 
protein was expressed in Jurkat cells. The expression 
o f the fusion protein was confirmed by western blotting 
using both anti-EGFP and anti-Jo-1 antibodies (Fig. 
3). Like the endogenous HisRS protein also the
EGFP-tagged HisRS appeared to be crosslinked 
upon SIN-1 treatment. Interestingly, when the 
material from SIN-1 treated cells was probed with the 
anti-Jo-1 antibody an additional crosslinking species 
was observed, which may represent a crosslinked 
dimer composed of non-tagged HisRS and EGFP- 
HisRS. These data strongly support the hypothesis 
that the crosslinked HisRS species formed during 
SIN-1 treatment represent crosslinked HisRS dimers.
Identification of the amino acids involved in HisRS 
crosslinking
The formation of peroxynitrite upon SIN-1 treatment 
elicits both oxidative and nitrosative stress resulting 
in the crosslinking of HisRS dimers. To obtain 
more insight into the amino acids that are involved 
in crosslinking, several residues selected based 
upon structural data (personal communication Prof. 
Dr. P. Schimmel; [25]) were replaced by alanine. 
In addition, a C-terminal truncation mutant was 
generated. The EGFP-tagged HisRS mutants K60A, 
D64A, E98A, K112A, Y115A, C379A, and C455A 
were all able to form crosslinked dimers after SIN-
1 treatment, although the efficiency of dimerization 
seems to be affected by some of these mutations, 
which is substantiated by the differences in the ratio 
between crosslinked EGFP-HisRS homodimer and 
crosslinked EGFP-HisRS -  endogenous HisRS 
heterodimer. In contrast, crosslinking of the HisRS 
fusion protein was totally abolished by the deletion 
of the three most C-terminal amino acids (ACIC) (Fig. 
4A). The exact position of the mutated residues and 
their side chains are depicted in the structural model 
for the human HisRS protein (lacking the N-terminal
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Fig . 2 E ffects o f ROS/RNS scavengers on S IN -1-induced HisRS 
crosslinking.
Jurkat cells were treated fo r 8 hours w ith 0.4 mM SIN-1 in the presence 
o f d ifferent concentrations o f Tiron (lanes 3-6) o r uric acid (lanes 10-13) 
as indicated, o r only with e ither 1000 jM  Tiron (lane 1), 100 jM  uric 
acid (lane 8), 0.4 mM SIN-1 (lanes 7, 14) or buffer (lanes 2, 9). Extracts 
o f treated cells were analyzed by im m unoblotting using a m onospecific 
anti-Jo-1 patient serum  or a patient serum  reactive w ith the S m -B /B : 
proteins, which was used as a control. The positions o f m olecular 
we ight markers are indicated on the left.
60 amino acids), which was generated by the 
YASARA program (Fig. 4B,C). These results indicate 
that the C-terminal residues -C-I-C are essential for 
the formation of the crosslinked HisRS dimer.
Effects of SIN-1 treatment on cell growth and 
translation
To study the effects of SIN-1-induced crosslinking of 
HisRS on its function, cell growth rates, the efficiency 
of translation, and the aminoacylation o f tRNAHis were 
determined. Jurkat cells were cultured in the presence 
of 0.4 mM SIN-1 and at different time points (up to 72 
hours) the number of cells was determined. The results 
showed that cell growth was indeed impaired by the 
exposure to SIN-1 (Fig. 5A). The reduced cell growth 
rates m ight be due to the inhibition of translation as 
a result of the impairment of the function of HisRS 
and/or other factors involved in protein synthesis. To 
investigate the effects on the efficiency o f translation, 
the incorporation of [35S]methionine in proteins 
in (SIN-1 treated) Jurkat cells was determined. 
The results showed that protein synthesis during 
a period of 2 or 4 hours after culturing the cells for 
6 hours in the presence of SIN-1 was reduced by 
approximately 40% (Fig. 5B). The next question we 
tried to answer was whether crosslinking of HisRS 
dimers would result in decreased aminoacylation of 
tRNAHis. Lysates from mock and SIN-1-treated Jurkat 
cells were used in in vitro aminoacylation reactions. 
Reaction products were analyzed by denaturing gel 
electrophoresis and autoradiography or northern
F ig . 3 C rosslinking o f EG FP-H isRS in S IN -1-treated Jurkat cells.
Jurkat cells were transfected with cDNA constructs encoding EGFP- 
H isRS by electroporation. Fourty-eight hours post-transfection the 
cells were exposed to 0.4 mM SIN-1 (+) or buffer ( - )  fo r 8 hours and 
extracts were analyzed by im m unoblotting. The blots were stained with 
e ither mouse monoclonal anti-EG FP antibod ies (lanes 1, 2) or anti-Jo-1 
antibodies (lanes 3, 4). High m olecular w e ight s ignals (approxim ately 
135 kDa and 160 kDa) in material from  SIN-1 treated cells are indicated 
with arrowheads.
blot hybridization. The total amounts of tRNAHis and 
5.8S rRNA, which was analyzed as a control, did not 
significantly differ between mock and SIN-1 treated 
Jurkat cells. More importantly, the HisRS activity was 
not or hardly altered as a result o f the SIN-1-induced 
crosslinking (Fig. 5C). As an additional control the 
aminoacylation reaction with lysate from mock- 
treated cells was incubated with a 1,000-fold excess 
of unlabelled histidine (Ctrl), which, as expected, 
completely abolished the aminoacylation o f tRNAHis. 
These results suggest that the aminoacylation of 
tRNAHis remains unaffected and thus cannot explain 
the impaired growth and inhibition of translation 
detected after SIN-1 treatment.
Autoantibodies specifically targeting the crosslinked 
HisRS dimer are not detectable 
Dimerization, oligomerization and crosslinking of 
proteins may contribute to the formation of pathogenic 
structures [26-28]. Such structures may generate 
neo-epitopes and initiate an autoimmune response. 
To address the question whether autoantibodies 
specifically directed against the crosslinked HisRS 
dimer are present in myositis sera, a longitudinal series 
o f serum samples from an anti-Jo-1-positive patient, 
collected during a period o f 13 years, was used. First, 
the reactivity of these samples with HisRS from both 
mock and SIN-1 treated Jurkat cells was assessed 
by immunoblotting. The ratio between the signals 
for HisRS and HisRS* did not detectably change 
during the course of the disease (Supplementary 
Fig. 3A). To rule out the possibility that crosslinked 
dimer specific antibody signals are masked by 
other anti-Jo-1 antibody signals, the autoantibody 
reactivities were determined using a competition 
assay as described in Materials and methods. The 
purified, bacterially expressed recombinant human 
HisRS protein efficiently competed for the binding
75
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Fig . 4  S IN -1-induced crosslinking o f H isRS mutants.
(A) Ju rka t ce lls were transfected w ith cDNA constructs encoding the  EGFP-tagged w ild-type (wt), K60A, D64A, E98A, K112A, Y115A, C379A, 
C455A single am ino acid substitution mutants, or the  C -term ina lly truncated (ACIC) EGFP-H isRS protein and 48 hours post-transfection the  cells 
w ere  m ock ( - )  or S IN -1-treated (+) for 8 hours. Cell extracts were analyzed by im m unoblotting using a m onospecific anti-Jo-1 patient serum. The 
HisRS fusion pro te ins are indicated w ith EGFP-HisRS, w hereas endogenous H isRS and crosslinked H isRS are labelled w ith H isRS and HisRS*, 
respectively. The crosslinked EGFP-H isRS species are indicated w ith arrowheads. (B) Structural model o f the  hom odim eric H isRS protein (lacking 
the  N-term inal 60 am ino acids), w ith subunits A and B in grey and brown, respectively. The positions o f the  mutated am ino acids are indicated in 
m agenta (one subunit) and green (other subunit). Note tha t K60 is not included in th is  model. (C) Enlargem ent o f the  C -term ina l region o f both 
subunits w ith  the  truncated cysteines and the ir side chains in m agenta and green.
o f anti-Jo-1 antibodies to HisRS from Jurkat cells, 
and the competition for the binding to HisRS* was 
efficient as for the binding to HisRS (Supplementary 
Fig. 3B). Using this approach, thirty-five anti-Jo-1 
sera o f established myositis patients were analyzed. 
However, in none of the tested sera specific reactivity 
to the crosslinked HisRS dimer was detected 
(results not shown). Taken together, these results 
do not provide evidence for the existence of specific 
autoantibodies to the crosslinked HisRS dimer in 
established myositis patients.
Discussion
Aminoacyl-tRNA synthetases fulfill an important role 
in protein synthesis by conjugating the tRNAs to their 
cognate amino acids via an esterification reaction. As 
a consequence, translation can be impaired severely 
if tRNAs are mischarged or their aminoacylation 
activity is dysregulated in some way. Here, we show 
that elevated levels of reactive oxygen/nitrogen 
species lead to a covalent linkage between HisRS 
molecules. The homodimers are resistant to reducing 
agents and their association depends on the three 
most C-terminal residues (CIC) of HisRS. The tRNA
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Fig . 5 The effects o f SIN-1 treatm ent on cell growth, translation, and 
tR N A His aminoacylation.
(A) Logarithm ically grow ing Jurkat cells were exposed to  SIN-1 (0.4 
mM) or buffer (mock) fo r 0 -  72 hours and a t several tim e points 
the  num ber o f cells w as determ ined. The  graphs show  the mean 
and standard deviation of experim ents perform ed in trip licate. (B) 
Cells were m ock or SIN-1 treated fo r 6 hours prior to  the  addition 
o f [35S]-m ethionine. Ce lls  were harvested a fter 2 hours and 4 hours 
and cell lysates were fractionated by SDS-PAG E and transferred to 
n itrocellulose m embranes. The  tota l ^ 5S]-m eth ion ine signa ls were 
quantified using phosphorim aging. Finally, p-actin was visualized by 
incubating the  blots with a monoclonal anti- p-actin antibody. The  [35S]- 
m ethionine signa ls w ere  norm alized based upon tota l p-actin signals. 
(C) Cell lysates from  m ock and SIN-1 (0.4 mM) treated Jurkat cells 
w ere  used in an in vitro am inoacylation assay containing 14C-histidine. 
As a contro l (Ctrl) extract o f mock-treated ce lls w as supplem ented 
w ith a 1,000-fold excess of unlabelled h istidine. The 14C signals 
w ere  visualized by phosphorim aging. Total tRNAHis w as visualized by 
northern blot hybridization using a p P ]-lab e led  antisense tR N A His probe 
and phosphorim aging.
aminoacylation activity o f HisRS did not seem to be 
affected by this crosslink.
Cells have to cope with all kinds of endo- and 
exogenous stress factors, and this may lead to cell 
death when defense mechanisms are inadequate or
failing. Under such conditions, elevated levels o f ROS/ 
RNS may be generated. Also during an inflammation 
a respiratory burst will lead to enhanced oxidative/ 
nitrosative stress. The formation of ROS/RNS in cells 
or tissues has been implicated in a number of (patho) 
physiological processes. Low levels of radicals have 
been suggested to act as messenger molecules and 
to regulate cellular processes, whereas excessive 
amounts can overload the antioxidant mechanisms 
and result in the modification of macromolecules. 
Inflammatory cells that infiltrate endomysial tissue 
in PM and DM patients were shown to produce 
increased nitric oxide synthase (NOS) levels [12], 
which may lead to higher NO concentrations. We 
recently observed that HisRS is oxidatively modified 
in Jurkat cells upon H2O2-induced stress. In addition 
we showed that H2O2-induced stress leads to the 
formation of disulfide bonds linking the C-termini of 
both subunits of the HisRS dimer (Van Dooren et al., 
manuscript submitted for publication). In the present 
study we have shown that the same cysteines at 
the C-termini are involved in subunit crosslinking 
as a result of the exposure to another ROS/RNS 
generator, SIN-1. In contrast to the H2O2-induced 
crosslinks, the SIN-1-induced crosslinks appear to 
be resistant to reducing agents. The inhibition o f SIN- 
1-induced crosslinking by both a superoxide and a 
peroxynitrite scavenger suggests that peroxynitrite, 
which can be formed by the reaction of NO with O2", 
plays an important role. Peroxynitrite is in equilibrium 
with peroxynitrous acid (ONOOH) and either one 
can undergo direct reactions with biomolecules, 
including thiols associated with these biomolecules. 
Alternatively, in biological systems peroxynitrite 
can rapidly react with carbon dioxide, which is in 
equilibrium with the bicarbonate anion, leading to 
the formation of nitrogen dioxide and carbonate 
radicals. Currently, it is unknown whether these 
radicals or direct peroxynitrite reaction products can 
result in the formation of covalent bonds between 
the C-terminal cysteines of HisRS. Besides linkages 
formed between the side chains of two cysteines, 
covalent bonds between one cysteine and another 
amino acid in the other subunit might be possible as 
well. Indeed, cysteine-tyrosine thioether crosslinks 
and cysteine-dehydroalanine (dehydroalanine may 
result from the oxidation of serine) crosslinks have 
been reported [29-32]. However, the involvement 
of the latter linkages in the HisRS crosslinks is very 
unlikely, because the deletion of the C-terminal 
CIC amino acids not only abrogated the EGFP- 
HisRSACIC -  EGFP-HisRSACIC crosslink, but 
also the EGFP-HisRSACIC -  endogenous HisRS 
crosslink. If such linkages would be involved in
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•>-- r n M  S IN - 1  S u p p le m e n ta ry  F ig . 1 Detection 
o f cell death markers in SIN-1 
treated Jurkat cell lysates.
Protein extracts o f m ock and 
SIN-1 treated Jurkat cells were 
fractionated by SDS-PAGE and 
analyzed via  immunoblotting. 
Topoisomerase I (Topo I) and 
U1-70k w ere  visualized by 
im m unoblotting using patient 
sera containing antibodies 
aga inst these proteins. (A) Cells 
were  treated w ith 0.4 mM SIN-1 
fo r the indicated periods o f time. 
(B) Jurkat cells were  treated 
fo r 8 hours w ith d ifferent SIN-1 
concentrations as indicated.
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dimeric Jo-1 crosslinking, the formation of the latter 
would be expected to be unaffected by the deletion 
of the C-terminal CIC element in the EGFP-tagged 
protein. Further studies will be required to unravel the 
chemical nature of the SIN-1-induced bond between 
the HisRS subunits. It should be noted that our 
results do not completely rule out the possibility that 
one or more non-HisRS protein(s) are crosslinked 
with the EGFP-HisRS protein. To unambiguously 
proof that the SIN-1-induced crosslinked HisRS 
species represent HisRS homodimers, the molecular 
composition of these molecules has to be elucidated, 
e.g. by mass spectrometry.
None of the other tested (autoantigenic) proteins 
78 showed a similar effect upon treatment of the cells with 
SIN-1, which suggests that the crosslink is specific for 
HisRS, which is consistent with the presence of the 
two cysteines in the flexible C-terminal tail of HisRS. 
In contrast to the previously reported SIN-1-induced 
cell death [18], the Jurkat cells used in our studies 
did not display the typical features of apoptosis 
or necrosis, like U1-70k and topoisomerase I 
cleavage [19]. Nevertheless, the cells appeared 
to be stressed, since both cell growth and protein 
translation were affected by the SIN-1 treatment. The 
tRNA aminoacylation activity of HisRS from treated 
cells was comparable to that of control cells, which 
suggests that the retarded cell growth and decreased 
rate of protein synthesis were not due to disturbed 
tRNAHis aminoacylation.
Oxidatively modified proteins have been proposed 
to initiate an immune response when they are 
exposed to the immune system. Since ROS/RNS 
often are associated with necrotic loci and infiltrating 
inflammatory cells are commonly found in skeletal 
muscle tissue of myositis patients this might be a 
feasible mechanism for the generation of myositis- 
associated autoimmunity. Indeed, the ROS/RNS- 
induced HisRS modification described here may result
in the generation of a neo-epitope and thus facilitate 
the generation of an autoimmune response. To study 
whether autoantibodies specifically recognizing neo­
epitopes in the crosslinked HisRS dimer are present 
in patient sera, it is necessary to analyze predisease 
sera, since such autoantibodies are expected to be 
produced early in the disease. However, we were 
unable to obtain such sera, because most individuals 
are visiting the clinic only when clinical symptoms 
become manifest.
In conclusion, our data reveal a novel peroxynitrite 
or peroxynitrite-derived radical-induced crosslink in 
homodimeric HisRS that depends on the C-terminal 
cysteines and raise new questions on the chemical 
nature and physiological role of this crosslink. 
Although HisRS crosslinking does not appear to 
affect the tRNAHis aminoacylation, it may play a role in 
the preservation of enzyme activity during stress by 
preventing the dissociation of the HisRS dimer.
S u p p le m e n ta ry  F ig . 2 Detection o f cell death m arkers in ROS/RNS 
scavenger treated Jurkat cells.
Jurkat cells were treated fo r 8 hours w ith 0.4 mM SIN-1 in the presence 
o f d ifferent concentrations o f e ithe r Tiron o r uric acid as indicated. As 
a control cells were treated w ith 0.4 mM SIN-1 (lanes 7, 14), 1000 pM 
Tiron (lane 1) or 100 pM uric acid (lane 8) alone. Topoisomerase I (Topo 
I) and U1-70k were  visualized by im m unoblotting using patient sera.
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S u p p le m e n ta ry  Fig. 3 Reactivity o f patient sera w ith crosslinked HisRS.
(A) Extracts from  m ock ( - )  and 0.4 mM S IN -1-treated (+) Ju rka t cells were analyzed by SDS- 
PAGE and immunoblotting. S trips containing m ock and S IN -1-treated extract were incubated 
w ith a spanning collection o f serum  sam ples from  an anti-Jo-1 positive patient taken over 
a period o f 13 years. S ignal in tensities of the  endogenous H isRS (H isRS) and crosslinked 
HisRS (H isRS*) w ere  quantified w ith  O dyssey software and used to  determ ine the  ratio of 
anti-Jo-1 and anti-Jo-1*. (B) Th irty-five  anti-Jo-1 positive m yositis patient sera were analyzed 
by im m unoblotting fo r reactivities with prote ins o f m ock or SIN-1 treated Jurkat cells. The 
blots were incubated with sera tha t were depleted fo r anti-Jo-1 antibod ies by pre-incubation 
w ith 100 ng o f recom binant H isRS (+ recHisRS) or tha t w ere treated in the  sam e w ay w ithout 
recom binant H isRS ( -  recHisRS). The figure  shows the  data fo r only one o f these patient 
sera; all o ther sera showed s im ilar results. The endogenous H isRS and crosslinked H isRS are 
indicated as H isRS and HisRS*, respective ly
recHisRS
•HisRS*
■HisRS
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Abstract
O bjective
Inclusion body myositis (IBM) is the most common acquired muscle disease in people over 45. Both degenerative 
and autoimmune features are involved in its pathogenesis. Specific antigens to which the autoimmune 
response in IBM is directed have not been described so far. To better understand IBM pathophysiology and to 
facilitate the diagnosis of this disease human muscle tissue was used to identify IBM-specific or -associated 
autoantigens.
M ethods
Western blots were prepared with extracts from human hamstring muscle or from cultured cell lines. The 
reactivity o f IBM patient and control sera with this material was assessed by immunoblotting.
R esults
A mature skeletal muscle antigen of 44 kDa, Mup44, was identified as an autoantibody target in IBM. Mup44 
was recognized by 23% o f IBM patient sera. Only a limited number o f sera from other myositis subclasses, 
polymyositis and dermatomyositis, was reactive with Mup44 (2% and 0% reactivity, respectively). In addition, 
sera from most other autoimmune diseases tested and sera from healthy individuals showed no reactivity 
with Mup44, although anti-Mup44 reactivity was detected in some systemic lupus erythematosus (SLE) and 
Sjogren's syndrome (SjS) sera (9% and 7%, respectively).
In te rp re ta tion
For the first time, an IBM-associated autoantigen, designated Mup44, was identified. Mup44 is expressed in 
human skeletal muscle, but not in Jurkat, human T lymphocyte cells nor in C2C12, mouse myoblast cells. 
Anti-Mup44 antibodies are found with a relatively high frequency in IBM sera and in some sera o f SLE and SjS 
patients. Mup44 may facilitate the diagnosis o f IBM.
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Introduction
Sporadic Inclusion Body Myositis (IBM) is the most 
common muscle disease in people over 45. It is 
clinically characterized by insidious onset of muscle 
weakness, without evidence of extramuscular 
manifestations, finally causing serious disability 
[1-3]. IBM belongs to the idiopathic inflammatory 
myopathies (IIM), collectively called myositis, which 
are defined by an acquired muscle weakness and the 
presence o f inflammatory infiltrates in skeletal muscle 
tissue in the absence of a clear cause. Myositis is 
classified into dermatomyositis (DM), polymyositis 
(PM) and IBM [4-8].
PM and DM are considered to be autoimmune 
diseases. The presence o f inflammatory cell infiltrates 
in the affected muscles, the frequent occurrence 
o f autoantibodies and the association with other 
autoimmune diseases suggest that their generation 
is immune mediated with an important role for both 
CD4+ and CD8+ T lymphocytes [7-9]. High-titer 
autoantibodies are detected in the sera of 60-80% of 
PM and DM patients. They are classified in myositis- 
specific autoantibodies (MSA) such as anti-Jo-1, 
anti-Mi-2 and anti-SRP antibodies, which are highly 
specific for myositis and not or only sporadically 
occurring in other rheumatic diseases, and in 
myositis-associated antibodies (MAA), which are 
also frequently found in several other autoimmune 
diseases [7,10-13]. The most common MSA is anti- 
Jo-1, which is found in 20-30% of PM and DM patients 
and its production may precede the symptoms of 
myositis (reviewed in [7]). The presence of specific 
autoantibodies in PM and DM is correlated with 
specific clinical phenotypes, e.g. anti-Jo-1 is a marker 
for the anti-synthetase syndrome, consisting o f PM or 
DM in combination with extramuscular manifestations 
like Raynaud's phenomenon, interstitial lung disease 
and polyarthritis [7].
IBM on the other hand is hypothesized to be a primarily 
degenerative disease with secondary immune 
components [1,14]. Cytoplasmic accumulation of 
several aggregate-prone proteins (e.g. p-amyloid, 
aB-crystallin, TAR DNA binding protein-43) 
including some which are typically associated with 
neurodegenerative diseases such as Alzheimer's 
disease, has been reported as a characteristic 
feature of IBM muscle [14-18]. Endoplasmic 
reticulum (ER) stress, proteasome inhibition, 
mitochondrial abnormalities and oxidative stress are 
seen as major determinants for the development of 
the disease [1,14,19,20]. At the same time IBM is a 
muscle-specific autoimmune disease in which clonal 
expansion of T- and B-cells plays a part [1,2,9,20,21].
Although MAA such as anti-Ro52 and anti-La have 
been reported in IBM, no IBM-specific autoantibodies 
have been identified so far. In addition, known MSAs 
such anti-Jo-1 and anti-Mi-2 are only occasionally 
found in IBM [10,11,22,23]. It was proposed that 
autoantibodies are less frequently found in IBM than 
in PM and DM and that the presence o f a MSA (anti- 
Jo-1 autoantibody) may even exclude the diagnosis 
o f IBM [7,11,24].
Based upon the hypothesis that the autoimmune 
response in IBM is directed towards muscle-specific 
antigens, we investigated in this study the reactivity 
o f IBM patient sera with human skeletal muscle tissue 
extracts. A muscle-specific polypeptide of 44 kDa 
appeared to be recognized by 23% o f IBM sera and 
autoantibodies to this protein display a rather high 
level o f disease-specificity.
Methods
Serum samples
Serum samples from a group o f well-characterized 
inflammatory myopathy patients described by Abdo et 
al. [25] (31 IBM, 48 PM and 24 DM patients; diagnosed 
according to established international criteria [25,26]) 
were used in this study. Serum samples were stored 
at -80 °C for long term storage; at the time of analysis 
NaN3 was added (final concentration 0.02%) to 50 |jl 
serum aliquots, which were stored at 4 °C. Separate 
groups of serum samples from IBM patients from the 83  
study of Hengstman et al. [11] and from Dr. Badrising 
(Department of Rheumatology, Leiden University 
Medical Center, Leiden, The Netherlands) were also 
studied.
To assess the disease specificity o f the detected 
antibodies, sera from patients with systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), 
scleroderma (Scl), PM-scleroderma overlap (PM-Scl) 
and primary Sjogren's syndrome (SjS) [27,28] as well 
as serum from healthy individuals obtained from the 
Sanquin Blood Supply Foundation (Nijmegen, The 
Netherlands) were analyzed.
Muscle extracts
Human healthy hamstring muscle obtained from 
reconstructive surgery (a kind gift o f Dr. Snoeck, 
Canisius-Wilhelmina Hospital, Nijmegen, The 
Netherlands) was frozen in liquid nitrogen and stored 
at -80 °C. Small pieces o f frozen muscle tissue were 
pulverized with a Microdismembrator (Braun Biotech 
International, Melsungen, Germany), resuspended 
in 10 volumes of RIPA buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1%
SDS, 10 mM DTT, 0.5 mM PMSF and Protease
Table 1. Prevalence of anti-Mup44 autoantibodies 
in myositis patient sera
# o f sera 
tested
# of sera
recognizing
Mup44
% of sera
recognizing
Mup44
IBMa 31 9 29
DMa 24 0 0
PMa 47 1 2
IBMb 28 4 14
IBMc 32 8 25
aM yositis serum  cohort 1 [25]; bIBM serum  cohort 2 [11]; cIBM serum 
cohort 3 [Dr. Badrising, Leiden University Medical Center, Leiden, 
The Netherlands]
Inhibitor Cocktail (Roche, Mannheim, Germany)) 
at 4 °C and centrifuged for 15 minutes at 21,000 g. 
The supernatant was used for SDS-PAGE followed 
by western blot analysis. Protein concentration o f the 
muscle extracts was determined by the BCA assay 
(Pierce, Rockford, USA).
Jurkat and C2C12 cell lysates 
Human Jurkat T-lymphocyte and mouse C2C12 
myoblast cells were cultured according to standard 
procedures. C2C12 cells were grown to confluency 
and cultured for 5 days with DMEM containing 2% 
horse serum for differentiation into myotubes. Jurkat 
cells were pelleted by centrifugation, washed with 
8 4  PBS, lysed by sonication in lysis buffer (50 mM Hepes- 
KOH, pH 7.4, 100 mM KCl, 10 mM MgCl2, 0.05% NP- 
40, 0.5 mM PMSF and Protease Inhibitor Cocktail) 
and centrifuged at 21,000 g. C2C12 myotubes were 
washed with PBS, scraped in lysis buffer, followed 
by sonication and centrifugation. The resulting 
supernatants were used for SDS-PAGE followed by 
western blot analysis. Protein concentration o f the 
lysates was determined by the BCA assay.
Western blot analysis
200-300 jg  o f human muscle extract or 100-200 
jg  o f Jurkat or C2C12 cell lysate was separated by 
electrophoresis in mini-Protean 12% SDS-PAGE gels 
(Bio-Rad, Hertfordshire, United Kingdom), using the 
full width of the gels, and blotted to nitrocellulose 
membranes. Membranes were cut into strips of 3-4 
mm wide, blocked with 5% milk powder in PBS-0.1% 
Tween-20 (PBS-T) and incubated with human patient 
serum, diluted 1:1000 in 5% milk-PBS-T. Bound 
antibodies were visualized using goat-anti-human- 
IRDye800 labeled secondary antibody (Rockland, 
Gilbertsville, USA) and scanned with the Odyssey 
system (LI-COR Biosciences, Lincoln, USA).
Table 2. Prevalence of anti-Mup44 autoantibodies 
in autoimmune patient sera
# o f sera 
tested
# of sera
recognizing
Mup44
% of sera
recognizing
Mup44
IBMa 91 21 23
DMa 24 0 0
PM 47 1 2
PM-Scl 22 0 0
Scl 16 0 0
RA 22 0 0
SLE 43 4 9
SjS 28 2 7
NHSb 32 0 0
aTotal of all tested IBM sera; bSera from  healthy individuals.
Serological data
Ro52, Ro60, La and Jo-1 autoantibody reactivity has 
been analyzed by ELISA as described [10,11].
Results
Identification of Mup44 in skeletal muscle extracts 
To investigate the presence o f (IBM-specific) 
autoantibody targets in human skeletal muscle 
tissue, human hamstring extracts were separated by 
SDS-PAGE, blotted to nitrocellulose and incubated 
with serum from IBM patients. As shown in Figure 1A 
several muscle polypeptides were recognized by the 
antibodies in these patient sera. Although different 
sera were reactive with different muscle antigens, one 
prominent band appeared to be commonly detected
Table 3. Co-occurrence o f anti-Mup44 
autoantibodies with anti-Ro52, anti-Ro60, anti-La 
and anti-Jo-1 autoantibodies in IBM patient sera
IBM
seraa
Anti-Mup44
positive
Anti-Mup44
negative
# o f sera 58 11 47
Anti- 10 2 (18%) 8 (17%)
Ro52 (17%)
Anti- 9 1 (9%) 8 (17%)
Ro60 (16%)
Anti-La 6 1 (9%) 5 (11%)
(10%)
Anti-Jo-1 1 (2%) 0 (0%) 1 (2%)
aIBM sera from  cohort 1 [11] and cohort 3 (Dr. Badrising, Leiden 
University Medical Center, Leiden, The Netherlands) fo r which 
Ro52, Ro60, La and Jo-1 autoantibody data were obtained.
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Fig . 1 Human skeleta l m uscle conta ins a novel IBM autoantigen.
(A ) A human skeleta l m uscle tissue  extract w as separated by SDS-PAG E and blotted to  n itrocellulose m embranes. The  b lot s trips w ere incubated 
w ith IBM patient sera (A-I) and a healthy contro l serum  (NHS), followed by detection o f the  bound antibod ies by incubation w ith an IRDye800- 
labeled anti-hum an secondary antibody. Bound antibod ies were visualized w ith the  O dyssey infrared im aging system. A rrows indicate the  Mup44 
m uscle antigen detected by IBM sera. (B-C) Human Jurkat cell lysate (B) and m ouse C2C12 myotube cell lysate (C) w ere  analyzed in the  same 
w ay as in panel A. Asterisks and arrowheads in panels A, B and C indicate putatively identical antigens. The positions of m olecular w e ight markers 
are indicated on the  left o f each panel.
by several IBM sera (Fig. 1A, arrow). Four out o f 9 
IBM sera were reactive with this polypeptide with a 
molecular weight of 44 kDa.
Interestingly, while some antigens detected in muscle 
extracts by IBM sera were also identified using lysates 
from cultured human cell lines such as Jurkat cells 
(Fig. 1B), the prominent 44 kDa polypeptide appeared 
to be detectable only in the material from skeletal 
muscles. Western blotting with differentiated mouse 
C2C12 myotube cell lysates and mouse skeletal 
muscle extracts indicated that the antigen recognized 
by the IBM sera is specifically present in skeletal 
muscle samples, since it could not be detected in 
the myotube cell culture lysates (Fig. 1C), whereas 
it was detected in mouse skeletal muscle extracts 
(data not shown). Immunoblotting using adjacent blot 
strips confirmed that the 44 kDa antigen detected by 
different IBM patient sera (Fig. 2) showed exactly the 
same electrophoretic mobility in SDS-PAGE gels, 
strongly suggesting that a common antigenic protein, 
hereafter indicated by Mup44 (Muscle protein of 44 
kDa), is recognized by these sera.
Association of anti-Mup44 autoantibodies with IBM in 
myositis sera
To investigate whether anti-Mup44 antibodies are 
only present in IBM sera or are also found in other 
myositis sera, sera from DM and PM patients were 
analyzed by immunoblotting as described above. 
For these analyses, the sera of the myositis cohort 
recently characterized by Abdo et al. was used [25]. 
As shown in Table 1, 29% o f the IBM sera in this
cohort contain autoantibodies to Mup44. Although 
DM and PM sera were reactive with several antigenic 
proteins in muscle extracts (Fig. 2 and data not 
shown), none o f the DM and only one o f the PM 
sera appeared to show reactivity with Mup44, 
indicating a strong specificity for IBM. The relatively 
high frequency o f autoantibodies directed to Mup44 
in IBM sera was confirmed in two independent IBM 
cohorts, in which 14% and 25% o f reactive sera were 
observed, respectively (Table 1). A combination o f the 
data from the three IBM cohorts results in an overall 
anti-Mup44 reactivity in 23% of IBM sera (21 of 91 
serum samples) (Table 2).
Prevalence of autoantibodies to Mup44 in other 
autoimmune patient sera
To further explore the disease-specificity of the 
autoantibodies directed to Mup44, sera from patients 
with several autoimmune diseases, PM-Scl, Scl, 
RA, SLE and SjS as well as serum from healthy 
individuals, were analyzed by immunoblotting. As 
shown in Table 2, none o f the healthy controls, PM- 
Scl, Scl and RA patient sera contained autoantibodies 
directed to Mup44. In contrast, anti-Mup44 reactivity 
was detected in 9% o f SLE sera and 7% o f SjS sera.
Co-occurrence of MAA and anti-Jo-1 with anti-Mup44 
autoantibodies
Although in IBM no disease-specific autoantibodies 
have been described, MAA such as anti-Ro52, anti- 
Ro60 and anti-La have been reported to be present
[10,11,22,23]. To investigate whether the presence
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Fig . 2 IBM sera identify a com m on 44 kDa m uscle protein.
Human ske leta l muscle extract w as separated by SDS-PAG E and 
blotted to  n itrocellulose m em branes. The b lo t strips w ere  incubated 
w ith IBM patient sera (lanes 1-12), PM sera (lanes 13-14) and healthy 
contro l serum  (NHS; lane 15), fo llow ed by detection o f the  bound 
antibod ies by incubation w ith an IRDye800-labeled anti-human 
secondary antibody. Bound antibod ies were visualized w ith the 
O dyssey infrared im aging system. The arrow  marks the  position of 
Mup44. The positions o f m olecular we ight m arkers are indicated on 
the  left; asterisks m ark non-specific bands resulting from  the  reactivity 
o f the  secondary (anti-human) antibody w ith  m uscle extract proteins.
o f these and anti-Jo-1 antibodies correlated with 
the anti-Mup44 reactivity, available serological 
data for two o f the three IBM cohorts (Hengstman 
and Badrising cohorts) were compared. Analysis 
o f the co-occurrence revealed no difference in the 
prevalence of these antibodies in anti-Mup44-positive 
and anti-Mup44-negative patients (Table 3). Thus, 
there appears to be no preference for a combined 
presence of IBM-associated Mup44 and MAA in IBM 
serum samples.
Discussion
In this study we revealed for the first time the 
presence o f IBM-associated autoantibodies. By 
using human skeletal muscle proteins as substrates 
in immunoblotting we were able to identify a 44 
kDa muscle autoantigen, named Mup44, which 
is recognized by 23% of IBM sera, whereas it is 
hardly or not reactive with other myositis sera. The 
frequency of anti-Mup44 reactivity in IBM sera is 
indeed relatively high when compared with other 
autoantibody reactivities in myositis. It is similar to
that o f the most frequently detected MSA anti-Jo-1, 
which is targeted by 20%-30% o f PM and DM patients
[7,8,10,23]. The specific association o f anti-Mup44 
with IBM in comparison with PM and DM implies that 
these Mup44 autoantibodies may be used as an IBM- 
biomarker in myositis patients.
Although control groups o f autoimmune sera from 
PM-Scl, Scl and RA patients, as well as sera from 
healthy individuals showed no reactivity with Mup44, 
some SjS and SLE patient sera did recognize the 
Mup44 antigen (7% and 9%, respectively). On the 
other hand, the possibility o f (developing) overlap 
syndromes exists as well. It has been reported that 
SjS can be found in combination with IBM [22,29,30]. 
The onset of SjS mostly precedes the onset of 
IBM, raising the possibility that the two anti-Mup44 
positive SjS patients in our study may develop or 
have developed IBM as well. Similar cases of SLE 
and IBM overlap have also been reported [30,31], 
which may explain why some SLE patients contain 
autoantibodies to Mup44.
We cannot exclude the possibility that anti-Mup44 
autoantibodies may rather be myositis-associated 
than myositis-specific. Interestingly, while myositis- 
specific Jo-1 autoantibodies are common in DM 
and PM and appeared to be negatively associated 
with IBM [32], anti-Mup44 antibodies showed an 
opposite distribution. Also, MAA found so far can all 
be detected in both PM and DM patients and often 
also in IBM [10,11,13,23], which is in contrast to the 
distribution o f the anti-Mup44 autoantibodies. 
Previously, it was common practice to use cultured 
cell lines such as HeLa cells for the identification 
o f autoantigens in autoimmune diseases (for 
examples see [33-35]). As a result o f the apparent 
absence of Mup44 expression in such cell lines the 
patient antibodies to this protein may have escaped 
detection so far. Interestingly, Dalakas et al. noted in 
1997 the recognition by IBM patient sera of various 
human muscle antigens ranging in size from 35 to 
145 kDa, an observation which was, however, not 
explored in more detail [36]. Notably, most of the 
previously identified autoantibodies in myositis target 
ubiquitously expressed molecules [13]. The use 
o f cultured cell lines as antigen source may have 
contributed to the idea that autoantibodies are less 
frequently produced in IBM than for instance in PM 
and DM [7,10].
The presence o f specific autoantibodies in PM and 
DM is correlated with specific clinical phenotypes, 
e.g. anti-Jo-1 is a marker for the anti-synthetase 
syndrome, while anti-SRP antibodies are markers for 
a necrotising myopathy [7,37]. It will therefore be very 
interesting to compare the clinical symptoms and
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prognosis of IBM patients with the presence o f anti- 
Mup44 autoantibodies in their sera to determine the 
value of these novel autoantibodies as biomarkers 
for specific phenotypes. In a preliminary investigation 
with a limited number o f patients we found no obvious 
differences in clinical features, but this study has to 
be extended to obtain conclusive results.
The molecular identity o f the Mup44 antigen is not 
resolved yet and is currently under investigation. The 
identification of the Mup44 corresponding gene, its 
expression and the analysis o f its immunoreactivity 
will further clarify the disease-specificity of the anti- 
Mup44 antibodies. The molecular identity of Mup44 
will also shed light on the target(s) o f the immune 
system in IBM and may aid the understanding of IBM 
pathophysiology.
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Polymyositis (PM), dermatomyositis (DM) and 
inclusion-body myositis (IBM) form the main 
disorders in the group o f idiopathic inflammatory 
myopathies, which are seen with a frequency o f 1 to 
6 per 100,000 individuals. Diagnostics and efficient 
treatment are improving due to the development 
o f techniques with enhanced specificity and 
sensitivity, although the etiology remains elusive. 
The presence o f autoantibodies in patients' sera 
and inflammatory loci in patients' muscle biopsies 
emphasize the immunological nature of myositis. 
To elucidate whether these phenomena contribute 
to the development of the disease, would be of 
great importance for future treatment strategies for 
this relatively unknown disease. Post-translational 
modification o f biomolecules induced by a number 
o f endo- or exogenous factors are known to be 
associated with functional effects as well as the loss 
o f immunological tolerance and the development 
o f autoantibodies against neo-epitopes in several 
autoimmune diseases. The research described in 
this thesis was focused on the autoantigenic and 
functional effects o f post-translational modifications 
o f the Jo-1 (or histidyl-tRNA synthetase) protein, 
which is amongst the most frequently targeted 
autoantigenic proteins by autoantibodies in PM/DM 
patients.
Myositis classification facilitates 
disease prognosis and treatment
As described in Chapter 2, more advanced and less 
invasive imaging techniques will further improve the 
differentiation between myositis subtypes. However, 
to date the diagnosis cannot solely be based on non­
invasive imaging procedures yet, which stresses the 
importance of specific serum biomarkers. In recent 
years several novel myositis-specific autoantibodies 
(MSA) have been described, which can be correlated 
to distinct clinical phenotypes and may predict 
disease progression and/or prognosis (for an 
overview see Chapter 2). Nevertheless, at least 10% 
o f myositis patients are completely devoid o f known 
autoantibodies, which might be due to different 
pathological mechanisms underlying the disease and/ 
or technical limitations of the currently used detection 
methods. This emphasizes the need o f multiplex 
assays that allow the simultaneous detection of 
multiple autoantibody reactivities and can lead to the 
identification of biomarker (autoantibody) profiles. 
Moreover, the development o f protein arrays will 
facilitate the screening of tissue specific proteomes 
(described in the next paragraphs). Although these 
techniques show great potential, further investigation
is needed to improve the current sensitivity and 
specificity o f these approaches as well as their 
implementation in the clinic. The currently described 
autoantibody profiles are used to subtype the different 
myositis entities but may also reveal whether different 
mechanisms underlie the development of clinically 
distinct symptoms and autoantibodies. In addition, 
these patient specific autoantibody profiles may 
be applicable to develop personalized therapeutic 
programs that stop or inhibit disease progression. The 
subclassification of myositis patients already proved 
its significance for treatment, since in general IBM 
patients do not respond to immunosuppressive drugs 
and therefore their treatment can be adapted early in 
the disease process, which eliminates unnecessary 
negative side effects and improves the quality o f life.
Tilting the balance from immunological 
tolerance to autoimmunity
Studies on autoimmune disorders using familial 
history and mono- and dizygotic tw ins suggest that 
the development of autoimmune diseases generally 
depends on a combination o f genetic predispositions 
and environmental factors. The concordance rates 
indicate that environmental agents account for 
approximately 70% o f the risk of developing an 
autoimmune disease whereas the remaining 30% 
are of genetic influence. Several genetic risk or 
protective factors have already been described 93  
for myositis and a number o f predispositions that 
correlate with autoantibodies, human leukocyte 
antigen (HLA), or latitudinal differences are 
summarized in Table 1. Many o f these genes regulate 
responses to environmental agents such as HLA 
and immunoglobulin gamma heavy chain genes. A 
number of polymorphic loci in these genes are found 
to be risk factors for the major myositis types (Table 
1). In addition, in the TNFa gene that encodes the 
proinflammatory tumor necrosis factor a protein, 
homozygous polymorphisms are found at position 
238A and 308A that are associated with distinct 
clinical manifestions or increased TNFa levels. A 
missense single nucleotide polymorphism is reported 
in the minor T allele of protein tyrosine phosphatase, 
non-receptor type 22 (PTPN22), which causes an 
amino acid substition (R620W) that is believed to be 
a risk factor for idiopathic inflammatory myopathies in 
general. A latitudinal gradient in the frequency of the 
R620W substitution is reported as well. For further 
reading about the genetic implications in myositis, 
the reader is referred to recent reviews by Chinoy 
et al., O'Hanlon and Miller, and Rider and Miller [1­
3]. Hormones as well as a number of environmental
Table 1. Genetic factors that are associated with myositis
Genetic polymorphism3 Phenotype References
HLA DRB1*0301b PMb, DM, JDM, IBM, anti-synthetase [1,2,61]
HLA DRB1*0701 Anti-Mi-2, anti-Jo-1 [2,61]
HLA DRB1*0302 Anti-Mi-2 [61]
HLA DQA*0301 JDM, anti-p155 [2,62]
TNFa-238A JDM [63]
TNFa-308A PM, DM, JDM, anti-Jo-1 [1,63,64]
Gm 3 23 5 PM, DM, JDM, IBM, anti-synthetase [64]
Gm 13 JDM [64]
PTPN22 R620W PM, JDM, anti-Jo-1, anti-p155/140, 
latitudinal gradient in Europe
[65,66]
a P olym orphism s described above have not been subdivided into protective or risk factors nor linked to  e thnic differences. b Abbreviations: 
HLA: human leukocyte antigen, PM: polym yositis, DM: derm atom yositis, JDM: juven ile  DM, IBM: inclusion body myositis, TNFa: tum or 
necrotsis facto r a, Gm: im m unoglobulin gam m a heavy chain, PTPN22: protein tyrosine phosphatase, nonreceptor type  22.
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factors such as toxins or viruses are suggested to 
increase the risk for the development o f autoimmunity 
in genetically susceptible individuals.
Several hypotheses for the mechanisms involved 
in the loss of immunological tolerance have been 
proposed, three o f which will be discussed briefly in 
this paragraph. First, the so-called molecular mimicry 
model suggests that autoantibodies in patients 
initially are generated against epitopes present on 
bacteria or viruses, and can crossreact with self 
proteins (or se lf antigens). Several autoantibodies 
detected in systemic lupus erythematosus (SLE) 
patients, including anti-Sm-B/B', anti-Sm-D, and 
anti-Ro60 have been shown to crossreact with 
the Epstein-Barr virus nuclear antigen-1 (EBNA- 
1) [4]. Since an epitope on Ro60 was reported to 
be recognized by predisease SLE serum samples, 
which crossreact with a peptide o f EBNA-1, it was 
suggested that Epstein-Barr virus (EBV) might initiate 
the development o f SLE. In addition, SLE patients 
appeared to be infected by EBV more frequently than 
healthy controls, which emphasizes the potential role 
o f infectious pathogens in the loss o f immunological 
tolerance [5]. A similar association has been 
postulated for the development of other autoimmune 
disorders including Sjogren's syndrome, rheumatoid 
arthritis (RA), and myositis [6-8]. A number o f cases 
have been reported in which myositis-like symptoms 
occur in virus infected individuals, whereas in some 
myositis patients viral particles or viral mRNA was 
detected in the disease' main target tissue (skeletal 
muscle) [6,9,10]. However, no conclusive evidence 
has been reported yet, although a seasonal onset 
and studies using animal models endorse viral 
induction as a potential model to lose immunological 
tolerance [11-14]. The infectious agents that have
been associated with the development o f myositis 
were recently reviewed by Crum-Cianflone [6]. 
Second, the anti-idiotypic antibody model relies on 
specific idiotypes, which are characteristic structures 
within a group of immunoglobulin or T cell receptor 
molecules and are based on the antigenic binding 
specificity of the variable region o f the antibody or 
T-cell receptor. These structures are recognized by 
anti-idiotypic antibodies, which are known to occur in 
autoimmune diseases [15]. Antibodies with a specific 
idiotype are believed to trigger a cascade in which 
the production o f anti-idiotypic antibodies is followed 
by the production o f anti-anti-idiotypic antibodies. The 
resulting network of interacting antibodies has been 
postulated to be involved in both physiological and 
pathological processes [16,17].
Finally, the third hypothesis predicts that distinct 
physiological and pathological circumstances can 
lead to the post-translational modification (PTM) of a 
myriad of se lf antigens, which when presented to the 
immune system might break immunological tolerance 
and result in the production o f autoantibodies. The 
studies and hypotheses formulated in this thesis are 
based on this model. The asset o f this hypothesis 
is that it combines non-immune mediated triggers 
such as endoplasmatic reticulum stress or hypoxia, 
with immune mediated mechanisms such as 
those described above. The following paragraphs 
will elaborate on the established and putative 
protein modifications and mechanisms involved in 
autoimmunity, mainly focusing on myositis.
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Fig . 1 Model fo r breaking im m unolog ica l to lerance by post-translational modifications.
Environm ental triggers or tissue  injury may induce cell death (e.g. apoptosis or necrosis) or lead to  the  production o f ROS/RNS. E ither apoptosis, 
necrosis and/or RO S/RNS stress can induce m odifications (asterisks) o f endogenous proteins, which may lead to  the form ation o f neo-epitopes. 
Antigen presenting ce lls (APC) present modified peptides and proteins, resulting from  cell death or RO S/RNS stress to  the  im mune system  in 
genetica lly susceptible  individuals when clearance m echanism s are defective. Th is  w ill result in the  activation o f autoreactive  T  helper cells (TH) 
and initiation o f an autoim m une response, including the  activation o f B  cells (B), follow ed by the  production o f autoantibod ies (Ab). O ver tim e 
epitope spreading may lead to  autoantibod ies tha t recognize the  sam e antigen in its non-modified state  or even antibod ies to  an associated protein.
Are cell death-induced PTMs involved 
in autoimmunity?
Apoptosis-induced myositis?
A number of mechanisms can lead to cell death (e.g. 
apoptosis or necrosis), each of which involves specific 
(non)enzymatic systems. The initiation o f these 
processes can result from several immunological 
and/or environmental triggers and lead to the post- 
translational modification of self proteins, which may 
generate neo-epitopes and break immunological 
tolerance (Fig. 1). A well known example is found in 
patients suffering from RA, in which frequently anti- 
citrullinated protein antibodies can be detected. The 
peptidylarginine deiminases are believed to play 
a major role in the disease, since these enzymes 
catalyze the conversion o f peptidylarginine to 
peptidylcitrulline and are known to be highly active in 
dying cells. A report that described the immunization 
o f rats with either noncitrullinated or citrullinated rat 
serum albumin emphasized the role o f this modification 
in the development of citrulline-specific antibodies as 
well as the ability to break tolerance to self antigens
[18]. More recently, Hof and coworkers reported the 
preferential recognition of an apoptotically cleaved 
U1-70k protein by autoantibodies in sera o f mixed 
connective tissue disease (MCTD) patients [19]. In 
individuals suffering from PM and DM inflammatory 
cell infiltrates, capable o f inducing cell death, are 
often found, but these patients are devoid of loci that 
show extensive apoptosis in lung and muscle tissues.
Studies on the expression o f pro- and anti-apoptotic 
molecules in myositis patients contradict each other 
[20,21], leaving the question whether apoptotic 
mechanisms are of importance in the initiation and/ 
or progression of myositis unanswered (see also 
Chapters 1 and 4). Nevertheless, it is important to 
note that granzyme B (GrB), which is known to induce 
caspase-dependent as well as caspase-independent 
forms o f apoptosis, might play a role in myositis [22]. 
Moreover, the number of GrB substrates expanded 
in recent years and a GrB susceptible Jo-1 protein 
has been found specifically in lung tissue, which 
suggests that tissue specific modifications (discussed 
in the next paragraph) can underlie different disease 
entities [23].
Necrosis-induced myositis?
Not much is known about the contribution of necrosis 
to the development o f autoimmune disorders. 
However, necrotic loci and the infiltration o f immune 
cells into non-necrotic MHC class I expressing 
muscle fibers have been found in most o f the myositis 
subtypes. These MHC I expressing cells may trigger 
or continuously stimulate the individual's immune 
system by presenting cell death induced neo­
epitopes to autoreactive lymphocytes. Such necrosis- 
specific neo-epitopes may be generated by specific 
cleavages o f autoantigenic proteins, which are distinct 
from the cleavages observed in apoptotic cells [24]. 
The cleavage products may also be different for the 
various necrotic triggers and/or signaling pathways
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that lead to necrosis [25,26]. In Chapters 3 and 4 
compound-specific necrotic modifications on several 
autoantigenic proteins including Jo-1 are described 
(Fig. 1). The autoantigens modified upon the exposure 
o f cells to hydrogen peroxide (H2O2) were altered well 
before the appearance of necrotic markers. Many 
protein modifications fulfill distinct functions during 
cell death processes such as inhibiting or stimulating 
protein activity or introducing pro-inflammatory 
properties. However, since reactive oxygen species 
(ROS) such as H2O2 led to the modification of 
biomolecules and none of the alternative necrosis- 
inducing compounds resulted in a similar modification 
(data not shown), the possibility remains that these 
modifications are not due to the induction o f necrosis, 
but are rather caused by this type of oxidative stress. 
Depending on temporal, spatial and conformational 
differences proteins may become functionally (in) 
active, and/or highly immunogenic as a result o f the 
same modification. We conclude that H2O2-induced 
oxidative modifications can be involved in the 
induction of a distinct necrotic pathway and/or can 
support the generation o f neo-epitopes.
Are reactive oxygen/nitrogen species 
involved in PTM?
In parallel with skeletal muscle fibers (Chapter 1), the 
lung is suggested to be one o f the main target tissues 
9 6  in myositis patients. Interstitial lung disease (ILD) is a 
manifestation that is strongly associated with myositis 
patients in which anti-synthetase antibodies are 
found. The development of ILD is classified based 
upon a number o f causal agents including inhalation 
o f (in)organic substances or infections. In addition, 
oxidative stress has been suggested to contribute 
to the epithelial cell damage in interstitial pneumonia 
[27]. Moreover, since both muscle and lung tissue is 
exposed to high levels o f oxygen, they may provide 
a source o f autoantigens (e.g. Jo-1; Fig. 1) modified 
by reactive oxygen and nitrogen species (ROS/RNS). 
Both the infiltrating immune cells and skeletal 
muscle tissue are able to generate relatively high 
concentrations of ROS/RNS, which may lead to the 
modification o f biomolecules and induce cell death as 
well. ROS/RNS-induced protein modifications and/ 
or tissue damage has already been implicated in the 
pathogenesis of RA, scleroderma and type 1 diabetes 
[28-30]. A similar role in myositis is supported by the 
data presented in this thesis. Along with oxidatively 
modified autoantigens from SLE, scleroderma, and 
PM/Scl overlap disorders also the major autoantigen 
in myositis, Jo-1, was found to be modified in cells 
subjected to oxidative stress. Two of the modified
regions coincided with previously identified Jo-1 
autoepitopes [31]. It will be interesting to investigate 
whether Jo-1 is similarly modified in muscles or lungs 
from myositis patients.
In contrast to the destructive processes of ROS/ 
RNS, a beneficial role for ROS resulting from the 
NADPH oxidase (NOX2) complex in the regulation 
o f autoreactive T lymphocytes and the development 
o f collagen-induced arthritis has been suggested 
[32,33]. The dual role of ROS/RNS (protective and 
destructive) introduces another level o f complexity to 
the biological effects of ROS/RNS. Indeed, protective 
effects, as a result o f ROS, might be observed in 
myositis patients, since exercise programs report 
beneficial effects on disease progression and on the 
number o f inflammatory infiltrates [34]. The controlled 
increase in ROS production, as a result o f exercise, 
might exert protective effects in the local environment 
o f skeletal muscles. However, additional studies that 
compare local ROS concentrations before and after 
exercise have yet to be performed.
The distinct nature o f RNS reactive groups and the 
life span of reactive molecules compared to ROS may 
lead to unique biomolecular modifications. Indeed, 
distinct RNS induced modifications in human and 
mouse models have been described to contribute 
to the pathogenesis o f autoimmune diseases (e.g. 
SLE and RA) [35-37]. The ROS/RNS-induced Jo-1 
modification documented in Chapter 6, the reduction- 
resistant covalent dimerization o f Jo-1 involving the 
C-terminal cysteines, may likewise play a role in 
the pathogenesis of myositis. The results described 
in this chapter strongly suggest that peroxynitrite 
reaction products or radicals, which are able to react 
with peroxynitrite, are involved in the formation o f the 
yet uncharacterized reduction-resistant Jo-1 dimer 
crosslink. Follow-up studies using precipitation and 
mass spectrometry-based identification techniques 
are needed to elucidate the chemical identity of this 
protein crosslink.
Does the autoimmune response 
in myositis target tissue-specific 
antigens?
In contrast to the tissue-specific autoimmune 
diseases, most autoantigenic targets o f systemic 
autoimmune diseases are ubiquitously expressed 
and can be distributed over different subcellular 
compartments. Their broad expression patterns 
suggest that these (modified) autoantigens may elicit 
an autoimmune response whenever neo-epitopes 
are presented to the immune system. However, there 
appears to be cell and/or tissue type specificity in
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the modification and presentation o f autoantigens. 
Studies o f Ulanet et al. and of Levine et al. provide 
evidence for the cell type specific cleavage of the B23 
and Jo-1 autoantigens, respectively, by GrB [23,38]. 
They describe a conformation o f the autoantigen that 
renders the protein susceptible to GrB cleavage, 
which may only occur in certain tissues/cells. The 
presence o f the cleavable Jo-1 protein in the lung may 
suggest that the initiation and propagation o f myositis 
occurs in lung tissue and spreads to skeletal muscle. 
These data also suggest that the formation of neo­
epitopes on autoantigenic proteins not only depends 
on the compound or enzyme that is responsible for 
inducing the modification, but also on the cell type. 
As a consequence, a number of autoantibodies may 
have escaped detection, because cultured cells were 
used to identify and characterize them. In this respect, 
it seems worthwhile to use material from tissues that 
are most strongly affected in autoimmune diseases 
to study disease-specific autoantibodies and their 
targets. The data presented in Chapter 7 support this 
idea and provide evidence for the first IBM-specific 
autoantibodies, which can only be detected by using 
antigens from skeletal muscle tissue. However, one 
has to bear in mind that not always the most strongly 
affected tissue may be the source o f the autoantigen 
that elicits the initial immune response. It will be 
interesting to study the autoantibody profiles o f PM/ 
DM and IBM patients using skeletal muscle as well 
as lung tissue.
Can autoantibodies aid the diagnosis of 
myositis?
In general autoimmune patients enter the clinic when 
the first symptoms pass a certain threshold, which, 
however, can be years after the initial onset o f the 
disease. Reaching a diagnosis may take several 
months. In the pre-disease phase epitope spreading 
may occur and lead to the detection of autoantibody 
reactivities that are directed against multiple epitopes 
o f one or more autoantigens [39,40]. This process may 
result in the disappearance o f autoantibodies that are 
reactive with the initially triggering epitope. Therefore 
it is very important to collect serum samples from the 
time patients enter the clinic and continue with this 
during subsequent visits. Such longitudinal serum 
collections can give insight in how the reactivity to 
a particular autoantigen develops during the course 
o f the disease, as described for U1-70k by Hof and 
collaborators [19]. Studies in which serum samples 
o f individuals suffering from RA or SLE, which were 
collected before the first clinical symptoms appeared 
(pre-disease samples), were analyzed allowed the
detection o f one or more epitope specificities. In 
some cases, the corresponding antibodies could be 
detected in samples taken many years before the first 
visit to the clinic, which emphasizes the predictive 
value of such autoantibody subsets [40-44].
To date extensive information on myositis-specific 
autoantibodies preceding the disease is still lacking.
However, in one case anti-Jo-1 antibodies were found 
in a patient before muscle disease became manifest 
[45]. Increasing evidence shows that autoantibodies 
can be very helpful for the subclassification of myositis 
patients, the prediction o f disease progression, and 
the responsiveness to treatment [46-49]. Several 
correlations between autoantibodies and clinical 
features have been described. Interstitial lung disease 
is frequently observed in patients with myositis 
and is strongly associated with the production of 
aminoacyl-tRNA synthetase autoantibodies [50,51].
The anti-p155/p140 autoantibody has recently been 
described as one o f the most common autoantibodies 
in cancer-associated DM [52,53].
So far, only few studies report on post-translational 
modifications of the Jo-1 autoantigen [23,54] and 
autoantibodies specifically reactive with a modified 
Jo-1 protein have not been found. Anti-Jo-1 antibodies 
are known to undergo affinity maturation and class 
switching [45]. Since the anti-Jo-1 positive patient 
sera used in the experiments described in Chapter
4 and 6 were obtained from established myositis 
patients, epitope spreading may have occurred. 9 7  
This emphasizes the importance to investigate pre­
disease sera for the occurrence o f anti-ROS/RNS- 
modified Jo-1 autoantibodies.
Does ROS/RNS-induced crosslinking 
functionally affect proteins?
As described above, post-translational modifications 
can generate neo-epitopes, which may result 
in the loss of immunological tolerance and the 
initiation o f autoimmunity. However, radical-induced 
modifications are also known to affect functional 
activities. The fluctuations o f the intracellular redox 
status affect many proteins such as aminoacyl- 
tRNA synthetases, transcription factors, and protein 
kinases and can provide a regulatory mechanism for 
metabolic signaling and transcriptional processes 
via the reversible modification of proteins involved 
[55-58]. For instance, gene expression in contractile 
muscle cells is partially regulated by NF-kB, which 
is activated upon the release o f IkB. In addition to 
the phosphorylation dependent release o f IkB, the 
NF-kB/IkB complex can also dissociate upon ROS 
stimulation [59]. The influence o f the redox status
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on factors involved in translation is illustrated by 
the oxidation o f cysteines in prokaryotic glutamyl- 
tRNA synthetase, which results in impaired tRNAGlu 
aminoacylation in vitro [60]. Two isoforms o f the 
tryptophanyl-tRNA synthetase (TrpRS) exist in 
human cells, the major full-length form (TrpRS), and 
a truncated form that lacks the N-terminal extension 
(mini-TrpRS). Both forms are able to aminoacylate 
tRNATrp, but Wakasugi and coworkers observed an 
increased aminoacylation activity of mini-TrpRS but 
not o f TrpRS as a result o f binding to oxidized GAPDH 
[58]. These studies emphasize the role of oxidative 
stress-induced regulation o f cellular processes. 
Increasing evidence suggests that thiols can play 
a key role in the regulation of redox-dependent 
systems. This may also be the case for histidyl-tRNA 
synthetase (Jo-1), because elevated aminoacylation 
activity was observed under conditions that led 
to oxidative changes of the thiols close to the 
C-terminus (Chapters 4 and 5). Since the Jo-1 protein 
is known to function as a homodimeric protein in vivo, 
the disulfide bonds involved in crosslinking the Jo-1 
dimer (Chapter 5) may stabilize the dimer and alter 
the balance between dimeric and monomeric Jo-1, 
which might lead to an increased aminoacylation 
activity (Fig. 2). It would be interesting to investigate 
whether similar crosslinking events occur in other 
di- or multimeric aminoacyl-tRNA synthetases. The 
increased activity o f crosslinked Jo-1, and other tRNA 
synthetases or factors involved in protein synthesis, 
may temporarily elevate protein synthesis in order to 
restore the redox balance.
Concluding remarks and perspectives
Fig. 2 Dim erization and crosslinking o f Jo-1.
Under normal physio logical circum stances Jo-1 resides e ither as a 
m onom er (A) or as a hom odim er (B) in the  cytoplasm . Under oxidative 
conditions crosslinked d im ers can form, e.g. by d isulfide bonds 
between the ir C -term inal cysteine side chains (C, D). The covalent 
bond(s) in the  Jo-1 d im er may sh ift the  equ ilib rium  between B and D 
to  D. Both B and D w ill associa te  w ith histidine and tRNAHis and will 
cata lyze the am inoacylation o f tR N A His (E, F).
upregulated under oxidative stress conditions? Are 
the C-terminal cysteines in the Jo-1 protein involved 
in an intracellular redox-regulated mechanism? What 
is the chemical nature of the cysteine-dependent, 
reduction-resistant Jo-1 crosslink? Does the structural 
Jo-1 model correspond to the endogenous human 
Jo-1 dimer? The data described in this thesis may 
facilitate follow-up studies to elucidate the questions 
above and to obtain further insight in the role of Jo-1 
in (patho)physiological processes.
This thesis provides an overview of myositis-specific 
autoantibodies and their detection methods, and 
discusses their significance for disease classification 
and prognosis. In addition, the research described 
contributed to understanding the role of oxidative/ 
nitrosative stress-induced protein modifications 
in the development of autoantibodies. Especially 
the functional and autoantigenic properties of the 
myositis-specific autoantigen Jo-1 are thoroughly 
investigated. The elucidation of disulfide-dependent 
and independent Jo-1 homodimer crosslinks, 
the apparent oxidative stress-regulated tRNA- 
aminoacylation activity as well as the structural Jo-1 
model open the door to new research questions. Are 
oxidative/nitrosative stress-modified proteins present 
in affected tissues of autoimmune diseases? Do 
autoantibodies to oxidative/nitrosative stress-induced 
modifications exist and, if so, develop early in disease? 
Why is the tRNA-aminoacylation activity of Jo-1
Chapter 8 General discussion
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Curriculum vitae 
List of publicatons
During the last decades the number o f patients 
suffering from an autoimmune disease has gradually 
increased. Currently, these disorders affect 
approximately 2-3% of the world population. One of the 
most pronounced molecular features is the presence 
o f autoantibodies in the sera o f patients. Whether 
these autoantibodies contribute to the development 
o f the disease or are merely an epiphenomenon 
remains unclear. In recent years, however, some of 
the autoantibodies have been reported to be not only 
disease-specific and useful as diagnostic biomarkers, 
but also predictors of disease progression. For 
instance, in patients with rheumatoid arthritis 
citrullinated proteins are targeted by autoantibodies, 
which can be found years prior to the development of 
clinical symptoms. Additionally, citrullination-specific 
autoantibodies are almost exclusively found in these 
patients and their presence predicts the severity of 
disease progression. Therefore they can serve as 
serological and prognostic markers. Besides the 
physiological process of citrullination autoantibody 
targets have been suggested to become citrullinated 
in the extracellular environment by activated 
peptidylarginine deaminase (PAD) enzymes, which 
are released by dying cells. The presentation o f the 
aberrantly modified proteins to the immune system 
is believed to break immunological tolerance and 
10 4  result in the development of autoimmunity. The post- 
translational modifications of proteins as a result 
o f exogenous or endogenous triggers that lead to 
the loss of immunological tolerance is regarded 
as a potential mechanism in the development of 
autoimmune diseases.
Idiopathic inflammatory myopathies, also indicated 
with myositis, represent a group of autoimmune 
disorders in which mainly skeletal muscles are 
affected. Patients suffering from myositis are 
characterized by skeletal muscle weakness, atrophy 
and inflammatory features. Because of distinct 
clinical, serological and histological phenotypes 
the idiopathic inflammatory myopathies are most 
commonly diagnosed as polymyositis (PM), 
dermatomyositis (DM) and inclusion-body myositis 
(IBM), for which specific criteria have been defined. 
The sera of myositis patients often contain disease- 
specific autoantibodies, and inflammatory cell 
infiltrates can be detected in patients' skeletal muscle 
tissue. All o f these characteristics are currently being 
used for diagnostic and prognostic purposes, but in 
spite of intensive study no clear causative agents 
have been identified yet.
Summary Based upon the hypothesis that the unusual post- 
translational modifications o f autoantigens may elicit 
a primary immune response in the early stages of the 
development o f autoimmunity and the fact that skeletal 
muscles are often oxidatively stressed, we decided to 
investigate the effects of oxidative stress on one of 
the main targets of the immune system in myositis, 
the Jo-1 autoantigen. In the studies described in this 
thesis a number of reactive oxygen and nitrogen 
species (ROS/RNS)-induced modifications o f Jo-
1, which is the histidyl-tRNA synthetase (HisRS), 
were identified and characterized. In addition, the 
importance of using autoimmune-associated tissues 
in the detection of novel myositis autoantibodies 
was explored. The goal was to obtain insight in 
autoantibody targets and the role of ROS/RNS- 
induced modifications in the reactivity of myositis- 
associated autoantibodies.
Chapter 1 contains a comprehensive overview of our 
current knowlegde of cell death- and cellular stress- 
associated processes that are believed to be involved 
in the development of myositis. An overview of the 
targets of myositis-specific autoantibodies and their 
biochemical features is presented in Chapter 2. In 
this chapter also the most commonly applied and 
novel autoantibody detection methods are discussed, 
as well as the importance of autoantibodies in 
the diagnosis of myositis, prediction/monitoring of 
disease progression and treatment.
It was investigated whether ROS can induce protein 
modifications that may be involved in the generation 
o f neo-epitopes. Chapters 3 and 4 describe ROS- 
induced modifications in a number o f autoantibody 
targets associated with different autoimmune 
disorders, including systemic lupus erythematosus, 
systemic sclerosis, and myositis. A  similarly retarded 
migration in SDS-PAGE was observed for several 
autoantigens in extracts o f H2O2-treated Jurkat cells, in 
oxidized cell lysates, as well as for the corresponding 
recombinant proteins (recU1A and recHisRS) that 
were expressed in bacteria and oxidized in vitro. 
Further analyses o f the modified HisRS demonstrated 
that several methionines and a single tryptophan 
residue becomes oxidatively modified. Several 
experimental approaches to investigate the presence 
o f autoantibodies to the oxidatively modified HisRS 
so far did not lead to the detection of autoantibodies 
in the tested myositis patient sera.
In addition to the slight migratory retardation o f HisRS 
in SDS-PAGE upon oxidative stress, also a more 
slowly migrating species at a position corresponding
to twice the molecular weight o f HisRS was observed. 
Reduction of the protein prior to gel electrophoresis 
appeared to eliminate the appearance of this putative 
HisRS dimer (Chapter 5). Further analyses showed 
that indeed the formation of one or two disulfide 
bond(s) was responsible for the generation of this 
HisRS isoform. Thus, upon hydrogen peroxide- 
induced stress the HisRS protein is covalently 
crosslinked by the generation o f disulfide bonds, 
which are dependent on two cysteine residues in 
the C-terminal tail o f the HisRS subunits. Since such 
modifications might induce structural and functional 
changes the HisRS activity was analyzed in an in 
vitro aminoacylation assay. The oxidative stress- 
induced HisRS modifications did not abrogate its 
tRNAHis aminoacylation activity, but instead slightly 
enhanced this activity.
In addition to oxidative stress induced by the 
exposure to hydrogen peroxide, Jurkat cells were 
also treated with SIN-1, which is known to lead to 
the production o f both ROS and RNS. In Chapter 6 
we report the formation of another covalent dimer 
o f the HisRS protein in cells treated with SIN-1. In 
contrast to the previously detected dimer, this isoform 
o f HisRS appeared to be resistant to reducing agents, 
indicative o f another chemical bond. Nevertheless, 
mutagenesis studies showed that the same cysteines 
near the C-terminus o f HisRS are involved in the 
induction o f this HisRS dimer. The exact nature o f the 
bonds in this homodimer remains to be determined. 
The HisRS modifications induced by SIN-1 neither 
affected its catalytic activity nor its immunoreactivity 
with antibodies in myositis patient sera.
As mentioned in Chapter 1, the elucidation of 
autoantibody profiles are becoming more important 
in recent years, because of their potentially high 
diagnostic and prognostic relevance. In studies 
that elucidate novel autoantibody reactivities often 
material from cultured cells has been used, in 
spite of the availability of tissues that are most 
strongly affected in the disease. The potential of 
detecting novel autoantibodies in myositis by using 
skeletal muscle material was addressed in the work 
described in Chapter 7. Although this did not lead to 
the identification o f new reactivities associated with 
poly- and/or dermatomyositis, a novel autoantibody 
reactivity was found for inclusion-body myositis. 
Inclusion-body myositis was regarded to be a 
primarily degenerative disease with secondary 
immune components and the detection of certain 
autoantibodies has been suggested to exclude the 
diagnosis o f IBM. However, using human skeletal
muscle tissue extracts autoantibodies to a protein of 
44 kDa (Mup44) were detected in 23% of IBM patient 
sera. Importantly, anti-Mup44 reactivity was specific 
for IBM and almost not detected in sera from PM and 
DM patients. Anti-Mup44 represents the first disease- 
specific autoantibody marker for IBM.
In Chapter 8 the findings described in this thesis 
are discussed in a broader context. The importance 
o f determining genetic and environmental risk or 
protective factors in myositis patients as well as 
how autoantibodies can contribute to diagnosis or 
predict disease development are further elaborated. 
The possibility that the environmental factors 
induce cell death and that the post-translational 
modifications occurring under these conditions play 
a role in breaking immunological tolerance to self­
components is discussed. In this context also tissue- 
specific aspects may be important. More specifically, 
the implications of the dimerization and crosslinking 
o f the histidyl-tRNA synthetase as a result of 
the formation of covalent bonds, as observed in 
oxidatively stressed cells, are addressed.
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Gedurende de laatste decennia is het aantal patiënten 
die aan auto-immuunziekten lijden gestaag gestegen. 
Momenteel lijdt circa 2-3% van de wereldbevolking 
aan dit ziektebeeld. Eén van de meest uitgesproken 
moleculaire kenmerken is de aanwezigheid van 
autoantilichamen in sera van patiënten. Het is 
nog onduidelijk of deze autoantilichamen aan de 
ontwikkeling van de ziekte bijdragen of niet meer als 
een bijverschijnsel van het ziektebeeld zijn. Maar in 
de afgelopen jaren is voor sommige autoantilichamen 
niet alleen beschreven dat ze ziekte-specifiek of 
bruikbaar als diagnostische biomarkers zijn, maar is 
duidelijk geworden dat ze het ziekteverloop kunnen 
verspellen. Bijvoorbeeld in patiënten met reumatoïde 
artritis kunnen al jaren voor de ontwikkeling 
van klinische symptomen, autoantilichamen 
worden gevonden welke gecitrullineerde eiwitten 
herkennen. Tevens worden citmllinatie-specifieke 
autoantilichamen bijna uitsluitend in deze patiënten 
gevonden en voorspeld hun aanwezigheid de 
hevigheid van het ziekteverloop. Hierdoor kunnen 
ze als serologische en prognostische markers 
gebruikt worden. Naast het fysiologische proces 
van citrullinatie wordt gedacht dat peptidylarginine 
deaminase (PAD) enzymen, welke door stervende 
cellen uitgescheiden worden, in het extracellulaire 
milieu autoantilichaam doelwitten citrullineren.
10 6  Men denkt dat de presentatie van ongebruikelijk 
gemodificeerde eiwitten aan het immuun systeem leidt 
tot het doorbreken van de immunologische tolerantie 
en resulteert in de ontwikkeling van autoimmuniteit. 
De post-translationele modificatie van eiwitten, als 
gevolg van exogene o f endogene schakelaars, die 
leiden tot het verlies van immunologische tolerantie, 
wordt als mogelijk mechanisme voor de ontwikkeling 
van auto-immuunziekten gezien.
Idiopathische inflammatoire myopathieën welke 
ook wel myositis genoemd worden, zijn een groep 
auto-immuun stoornissen waar voornamelijk de 
skeletspieren zijn aangetast. Patiënten met myositis 
lijden aan een skeletspier zwakte, atrofie en 
hebben ontstekingskenmerken. Door opmerkelijke 
klinische, serologische en histologische fenotypen 
worden de idiopathische inflammatoire myopathieën 
over het algemeen als polymyositis (PM), 
dermatomyositis (DM) en inclusion-body myositis 
(IBM) gediagnosticeerd, waarvoor speciale criteria 
zijn vastgesteld. De sera van myositis patiënten 
bevatten vaak ziekte-specifieke autoantilichamen en 
ontstekingshaarden, bestaande uit immuun cellen, 
en kunnen vaak in het skelet spierweefsel van
Samenvatting patiënten worden aangetoond. Al deze kenmerken 
worden tegenwoordig voor diagnostische en 
prognostische doeleinden gebruikt. Maar ondanks 
intensief onderzoek is er nog geen oorzaak van de 
ziekte geïdentificeerd.
Van de hypothese uitgaande dat ongebruikelijke post- 
translationele modificaties van autoantigenen, een 
primaire immuun respons tijdens de eerste stappen 
van de ziekte ontwikkeling te weeg kunnen brengen 
en het feit dat skeletspieren vaak oxidatief gestresst 
zijn, hebben we besloten de effecten van oxidatieve 
stress bij het Jo-1 autoantigeen te bestuderen, welke 
een van de hoofddoelwitten van het immuun systeem 
in myositis is. De studies in dit proefschrift beschrijven 
en karakteriseren een aantal reactieve zuurstof 
en stikstof species (ROS/RNS) geïnduceerde 
modificaties van Jo-1, ofwel histidyl-tRNA synthetase 
(HisRS). Tevens wordt het nut van autoimmuun- 
geassocieerde weefsels voor de detectie van nieuwe 
myositis autoantilichamen onderzocht. Het doel was 
om inzicht in autoantilichaam doelwitten te krijgen 
en welke rol ROS/RNS geïnduceerde modificaties 
in de reactiviteit van myositis geassocieerde 
autoantilichamen spelen.
In hoofdstuk 1 wordt een uitgebreide beschrijving 
gegeven van onze huidige kennis over celdood en 
celstress geassocieerde processen, waarvan gedacht 
wordt dat ze betrokken zijn bij de ontwikkeling van 
myositis. hoofdstuk 2 presenteert een overzicht van 
de myositis-specifieke autoantilichaam doelwitten en 
hun biochemische kenmerken. Tevens worden de 
meest gebruikte en nieuwe autoantilichaam detectie 
methoden en de relevantie van autoantilichamen in 
de diagnose van myositis, en voorspelling/monitoring 
van ziektevoortgang en behandeling in dit hoofdstuk 
bediscussieerd.
Er is onderzocht o f ROS eiwit modificaties te weeg 
kunnen brengen die mogelijk betrokken zijn bij 
de vorming van neo-epitopen. Hoofdstukken 3 
en 4 beschrijven ROS-geinduceerde modificaties 
in een aantal autoantilichaam doelwitten, welke 
geassocieerd zijn met verschillende auto- 
immuunstoornissen, waaronder systemic lupus 
erythematosus, systemic sclerosis, en myositis. Voor 
verschillende autoantigenen kon in extracten van 
H2O2 behandelde Jurkat cellen, geoxideerd cellysaat 
en bijbehorende recombinant eiwitten (recU IA  en 
recHisRS), welke in bacteriën tot expressie gebracht 
waren en in vitro geoxideerd, een vergelijkbaar 
vertraagde migratie in SDS-PAGE worden 
vastgesteld. Verdere analyse van het gemodificeerde
HisRS wees uit dat verschillende methionines en 
een enkel tryptofaan residue oxidatief gemodificeerd 
was. Met behulp van verschillende experimentele 
methodes is onderzocht o f autoantilichamen tegen 
de oxidatief gemodificeerd HisRS aanwezig waren, 
maar tot dus ver zijn er geen autoantilichamen in de 
geteste myositis patiënt sera gevonden.
Bovenop de vertraagde migratie van HisRS in SDS- 
PAGE onder oxidatieve stress, is een nog langzamer 
migrerend product zichtbaar, welke overeenkomt 
met twee maal het moleculair gewicht van HisRS. 
Door het eiwit voor gel electroforese te reduceren 
is het mogelijk om de vermoedelijke HisRS dimeer 
te laten verdwijnen (hoofdstuk 5). Verdere analyses 
lieten zien dat inderdaad de vorming van één of twee 
disulfide bindingen verantwoordelijk waren voor de 
vorming van deze HisRS isovorm. Hieruit volgt dat 
onder invloed van waterstof peroxide geïnduceerde 
stress de HisRS eiwitten een covalente binding 
aangaan door de vorming van disulfide bruggen, 
welke afhankelijk zijn van twee cysteine residuen 
in de C-terminale staart van de HisRS subunits. 
Omdat zulke modificaties mogelijk structurele en 
functionele veranderingen te weeg brengen, is de 
HisRS activiteit geanalyseerd met behulp van een 
in vitro aminoacylatie assay. De oxidatieve stress 
geïnduceerde HisRS modificaties heffen de tRNAHis 
aminoacylerings activiteit niet op, maar lijken de 
activiteit licht te verhogen.
Jurkat cellen werden niet alleen blootgesteld 
aan oxidatieve stress, als gevolg van waterstof 
peroxide, maar ook behandeld met SIN-1 wat leidt 
tot de productie van ROS en RNS. In hoofdstuk 6 
beschrijven we de vorming van nog een covalente 
dimeer van het HisRS eiwit welke word gevormd in 
cellen die behandeld zijn met SIN-1. In tegenstelling 
tot de hiervoor beschreven dimeer, blijkt deze 
isovorm van HisRS resistent tegen reducerende 
omstandigheden te zijn, wat de aanwezigheid van een 
andere chemische binding aan geeft. Daarentegen 
wijzen mutagenese studies erop dat dezelfde 
cysteines aan de C-terminus van HisRS betrokken 
zijn bij de vorming van deze HisRS dimeer. De exacte 
aard van de binding in deze homodimeer moet 
nog worden opgehelderd. De SIN-1 geïnduceerde 
HisRS modificaties hebben noch een effect op de 
katalytische activiteit noch op de immunoreactiviteit 
van antilichamen in myositis patiënten sera.
de laatste jaren steeds belangrijker. In de huidige 
studies, die nieuwe autoantilichaam doelwitten 
onderzoeken, wordt vaak materiaal uit cel culturen 
gebruikt, ondanks de beschikbaarheid van weefsels 
die het meest aangedaan zijn in een ziektebeeld. De 
mogelijkheid om nieuwe autoantilichamen in myositis 
te detecteren, door gebruik te maken van skeletspier 
materiaal, wordt in hoofdstuk 7 beschreven. Hoewel 
er geen nieuwe autoantilichamen voor polymyositis 
en/of dermatomyositis geïdentificeerd werden, is een 
nieuw autoantilichaam voor inclusion-body myositis 
gevonden. Inclusion-body myositis werd primair 
als degeneratieve ziekte gezien met secondaire 
immunologische aspecten, waarbij de detectie 
van bepaalde autoantilichamen de IBM diagnose 
leken uit te sluiten. Maar met behulp van humaan 
skeletspierweefsel extracten zijn autoantilichamen in 
23% van IBM patiënten sera ontdekt, die reactief zijn 
met een eiwit van 44 kDa (Mup44). Belangrijk is dat 
de anti-Mup44 reactiviteit specifiek was voor IBM en 
nagenoeg niet detecteerbaar in sera van PM en DM 
patiënten. Anti-Mup44 is de eerste ziekte specifieke 
autoantilichaam marker voor IBM.
Hoofdstuk 8 bediscussieerd de bevindingen die 
in dit proefschrift beschreven zijn in een bredere 
context. Het belang van gedefinieerde genetische 
en omgevingsfactoren in myositis patiënten, die 
een risico vormen o f juist beschermend werken, 
als wel hoe autoantilichamen kunnen bijdragen 
aan de diagnose of het voorspellen van de 
ziekte ontwikkeling, worden verder uitgelegd. De 
mogelijkheid dat omgevingsfactoren celdood kunnen 
induceren en dat post-translationele modificaties 
tijdens deze condities een rol spelen in het verlies van 
immunologische tolerantie tegen self-componenten 
wordt bediscussieerd. Hierbij is het ook mogelijk dat 
weefsel-specifieke aspecten belangrijk zijn. Ofwel 
de dimerizatie en crosslinking van het histidyl-tRNA 
synthetase als gevolg van de vorming van covalente 
bindingen, zoals in oxidatief gestresste cellen, wordt 
beschreven.
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Zoals in hoofdstuk 1 vermeld, wordt door hun 
potentiële diagnostische en prognostische relevantie 
het ophelderen van autoantilichaam profielen in
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